Baxter International (BAX) 10-K 21 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Jan. 31, 2014	Jun. 28, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'BAX	'	'
Entity Registrant Name	'BAXTER INTERNATIONAL INC	'	'
Entity Central Index Key	'0000010456	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	543,187,695	'
Entity Public Float	'	'	$38,000,000,000

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Current assets	'		'
Cash and equivalents	$2,733		$3,270
Accounts and other current receivables, net	2,911		2,425
Inventories	3,499		2,803
Short-term deferred income taxes	393		344
Prepaid expenses and other	468		418
Total current assets	10,004		9,260
Property, Plant and Equipment, Net	7,832		6,098
Other assets	'		'
Goodwill	4,205		2,502
Other intangible assets, net	2,294		814
Other	1,534		1,716
Total other assets	8,033		5,032
Total assets	25,869		20,390
Current liabilities	'		'
Short-term debt	181		27
Current maturities of long-term debt and lease obligations	859	[1]	323	[1]
Accounts payable and accrued liabilities	4,866		4,409
Total current liabilities	5,906		4,759
Long-Term Debt and Lease Obligations	8,126	[1]	5,580	[1]
Other Long-Term Liabilities	3,351		3,073
Commitments and Contingencies	'		'
Equity	'		'
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2013 and 2012	683		683
Common stock in treasury, at cost, 140,456,989 shares in 2013 and 137,281,399 shares in 2012	-7,914		-7,592
Additional contributed capital	5,818		5,769
Retained earnings	11,852		10,888
Accumulated other comprehensive loss	-1,976		-2,810
Total Baxter International Inc. (Baxter) shareholders' equity	8,463		6,938
Noncontrolling interests	23		40
Total equity	8,486		6,978
Total liabilities and equity	$25,869		$20,390
[1]	Book values include any discounts, premiums and adjustments related to hedging instruments.

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Common stock, par value	$1	$1
Common stock, authorized	2,000,000,000	2,000,000,000
Common stock, issued	683,494,944	683,494,944
Treasury stock, shares	140,456,989	137,281,399

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Net sales	$15,259		$14,190		$13,893
Cost of sales	7,664		6,889		6,847
Gross margin	7,595	[1]	7,301	[2]	7,046
Marketing and administrative expenses	3,681		3,324		3,154
Research and development expenses	1,246		1,156		946
Net interest expense	128		87		54
Other (income) expense, net	-9		-155		83
Income before income taxes	2,549		2,889		2,809
Income tax expense	537		563		553
Net income	2,012		2,326		2,256
Less: Net income attributable to noncontrolling interests	'		'		32
Net income attributable to Baxter	$2,012	[1]	$2,326	[2]	$2,224
Net income attributable to Baxter per common share	'		'		'
Basic	$3.70	[1]	$4.22	[2]	$3.91
Diluted	$3.66	[1]	$4.18	[2]	$3.88
Weighted-average number of common shares outstanding	'		'		'
Basic	543		551		569
Diluted	549		556		573
[1]	The first quarter of 2013 included currency-related charges of $28 million related to the Venezuelan currency devaluation in February 2013 and derivative instruments entered into to hedge anticipated foreign currency cash outflows for the planned acquisition of Gambro (Gambro-related derivatives), in addition to charges of $17 million associated with Gambro pre-acquisition costs. The second quarter of 2013 included losses of $55 million for Gambro-related derivatives, charges of $23 million related to Gambro pre-acquisition costs and a net benefit of $2 million related to business optimization activity. The third quarter of 2013 included Gambro acquisition and integration charges of $58 million, tax and legal reserves of $83 million, business development charges of $25 million related to upfront payments for collaboration agreements, and a net gain of $20 million principally associated with Gambro-related derivatives. The fourth quarter of 2013 included business development charges of $78 million related to upfront and milestone payments for collaboration agreements, business optimization charges of $282 million, Gambro acquisition and integration charges of $94 million and product-related charges of $17 million, principally related to remediation efforts for modifications to the SIGMA Spectrum Infusion Pump.
[2]	The first quarter of 2012 included a $53 million gain related to the reduction of a contingent payment liability for certain milestones associated with the 2011 acquisition of Prism and business development charges of $48 million which primarily related to an R&D charge associated with the company's collaboration with Momenta. The second quarter of 2012 included a $38 million gain related to the reduction of a contingent payment liability for certain milestones associated with the 2010 acquisition of ApaTech, business development charges of $30 million which related to an R&D charge associated with the company's collaboration with Chatham and a $23 million net benefit from reserve adjustments which primarily related to an adjustment to the COLLEAGUE infusion pump reserves. The third quarter of 2012 included an R&D charge of $50 million related to the company's agreement with Onconova. The fourth quarter of 2012 included charges of $170 million primarily related to the settlement of certain pension obligations and $150 million related to business optimization initiatives (of which $62 million was recorded in cost of sales).

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net income	$2,012	$2,326	$2,256
Other comprehensive income (loss), net of tax:	'	'	'
Currency translation adjustments, net of tax expense (benefit) of $41 in 2013, $22 in 2012 and ($12) in 2011	236	-98	-205
Pension and other employee benefits, net of tax expense (benefit) of $309 in 2013, ($1) in 2012 and ($151) in 2011	592	-111	-263
Hedging activities, net of tax expense (benefit) of $7 in 2013, ($6) in 2012 and $5 in 2011	15	-7	5
Other, net of tax expense (benefit) of ($3) in 2013, ($2) in 2012 and $1 in 2011	-9	-3	1
Total other comprehensive income (loss), net of tax	834	-219	-462
Comprehensive income	2,846	2,107	1,794
Less: Comprehensive income attributable to noncontrolling interests	'	'	22
Comprehensive income attributable to Baxter	$2,846	$2,107	$1,772

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Income (Parenthetical) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Tax expense (benefit) on currency translation adjustments	$41	$22	($12)
Tax expense(benefit) pension and other employee benefits	309	-1	-151
Tax expense (benefit) on hedging activities	7	-6	5
Tax expense (benefit) on Other	($3)	($2)	$1

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operations	'	'	'
Net income	$2,012	$2,326	$2,256
Adjustments	'	'	'
Depreciation and amortization	823	712	670
Deferred income taxes	-224	-17	172
Stock compensation	150	130	119
Realized excess tax benefits from stock issued under employee benefit plans	-34	-24	-21
Business optimization charges	282	150	192
Asset impairment and other charges	'	'	182
Net periodic pension benefit and OPEB costs	381	477	255
Other	54	-42	32
Changes in balance sheet items	'	'	'
Accounts and other current receivables, net	-36	-41	-229
Inventories	-311	-129	-315
Accounts payable and accrued liabilities	329	18	98
Business optimization and infusion pump payments	-125	-283	-347
Other	-103	-171	-247
Cash flows from operations	3,198	3,106	2,817
Cash Flows from Investing Activities	'	'	'
Capital expenditures (including additions to the pool of equipment placed with or leased to customers of $148 in 2013, $150 in 2012 and $155 in 2011)	-1,525	-1,161	-960
Acquisitions and investments, net of cash acquired	-3,851	-515	-590
Divestitures and other investing activities	14	107	123
Cash flows from investing activities	-5,362	-1,569	-1,427
Cash flows from financing activities	'	'	'
Issuances of debt	3,636	1,037	506
Payments of obligations	-540	-22	-23
(Decrease) increase in debt with original maturities of three months or less, net	'	-250	250
Cash dividends on common stock	-1,023	-804	-709
Proceeds and realized excess tax benefits from stock issued under employee benefit plans	508	512	448
Purchases of treasury stock	-913	-1,480	-1,583
Other	-23	-108	-26
Cash flows from financing activities	1,645	-1,115	-1,137
Effect of Foreign Exchange Rate Changes on Cash and Equivalents	-18	-57	-33
(Decrease) Increase in Cash and Equivalents	-537	365	220
Cash and Equivalents at Beginning of Year	3,270	2,905	2,685
Cash and Equivalents at End of Year	2,733	3,270	2,905
Other supplemental information	'	'	'
Interest paid, net of portion capitalized	200	135	88
Income taxes paid	$648	$415	$357

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Additions to the Investing Activities pool of equipment placed with or leased to customers	$148	$150	$155

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Equity (USD $)	Total		Common Stock	Common Stock Held In Treasury	Additional Contributed Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Shareholders' Equity	Noncontrolling Interest
In Millions, except Share data
Beginning of year at Dec. 31, 2010	'		$683	($5,655)	$5,753	$7,925	($2,139)	'	$229
Beginning of year at Dec. 31, 2010	'		'	103,000,000	'	'	'	'	'
Balance, beginning at Dec. 31, 2010	'		683,000,000	'	'	'	'	'	'
Net income attributable to Baxter	2,224		'	'	'	2,224	'	'	'
Purchases of common stock	-1,600		'	-1,583	'	'	'	'	'
Other comprehensive income (loss) attributable to Baxter	'		'	'	'	'	-452	'	'
Dividends declared on common stock	'		'	'	'	-719	'	'	'
Stock issued under employee benefit plans and other	'		'	519	30	'	'	'	'
Change in noncontrolling interests	'		'	'	'	'	'	'	14
Stock issued under employee benefit plans	'		'	'	'	-1	'	'	'
Purchases of common stock	30,000,000		'	30,000,000	'	'	'	'	'
Stock issued under employee benefit plans and other	'		'	-10,000,000	'	'	'	'	'
End of year at Dec. 31, 2011	6,828		683	-6,719	5,783	9,429	-2,591	6,585	243
End of year at Dec. 31, 2011	'		'	123,000,000	'	'	'	'	'
End of year at Dec. 31, 2011	'		683,000,000	'	'	'	'	'	'
Net income attributable to Baxter	2,326	[1]	'	'	'	2,326	'	'	'
Purchases of common stock	-1,500		'	-1,480	'	'	'	'	'
Elimination of SIGMA noncontrolling ownership interest	'		'	'	'	'	'	'	-159
Other comprehensive income (loss) attributable to Baxter	'		'	'	'	'	-219	'	'
Dividends declared on common stock	'		'	'	'	-866	'	'	'
Stock issued under employee benefit plans and other	'		'	607	17	'	'	'	'
Change in noncontrolling interests	'		'	'	'	'	'	'	-44
Stock issued under employee benefit plans	'		'	'	'	-1	'	'	'
Exercise of SIGMA purchase option	'		'	'	-31	'	'	'	'
Purchases of common stock	25,000,000		'	25,000,000	'	'	'	'	'
Stock issued under employee benefit plans and other	'		'	-11,000,000	'	'	'	'	'
End of year at Dec. 31, 2012	6,978		683	-7,592	5,769	10,888	-2,810	6,938	40
End of year at Dec. 31, 2012	137,281,399		'	137,000,000	'	'	'	'	'
End of year at Dec. 31, 2012	683,494,944		683,000,000	'	'	'	'	'	'
Net income attributable to Baxter	2,012	[2]	'	'	'	2,012	'	'	'
Purchases of common stock	-900		'	-913	'	'	'	'	'
Other comprehensive income (loss) attributable to Baxter	'		'	'	'	'	834	'	'
Dividends declared on common stock	'		'	'	'	-1,048	'	'	'
Stock issued under employee benefit plans and other	'		'	591	45	'	'	'	'
Change in noncontrolling interests	'		'	'	'	'	'	'	-17
Exercise of SIGMA purchase option	'		'	'	4	'	'	'	'
Purchases of common stock	13,000,000		'	13,000,000	'	'	'	'	'
Stock issued under employee benefit plans and other	'		'	-10,000,000	'	'	'	'	'
End of year at Dec. 31, 2013	$8,486		$683	($7,914)	$5,818	$11,852	($1,976)	$8,463	$23
End of year at Dec. 31, 2013	140,456,989		'	140,000,000	'	'	'	'	'
End of year at Dec. 31, 2013	683,494,944		683,000,000	'	'	'	'	'	'
[1]	The first quarter of 2012 included a $53 million gain related to the reduction of a contingent payment liability for certain milestones associated with the 2011 acquisition of Prism and business development charges of $48 million which primarily related to an R&D charge associated with the company's collaboration with Momenta. The second quarter of 2012 included a $38 million gain related to the reduction of a contingent payment liability for certain milestones associated with the 2010 acquisition of ApaTech, business development charges of $30 million which related to an R&D charge associated with the company's collaboration with Chatham and a $23 million net benefit from reserve adjustments which primarily related to an adjustment to the COLLEAGUE infusion pump reserves. The third quarter of 2012 included an R&D charge of $50 million related to the company's agreement with Onconova. The fourth quarter of 2012 included charges of $170 million primarily related to the settlement of certain pension obligations and $150 million related to business optimization initiatives (of which $62 million was recorded in cost of sales).
[2]	The first quarter of 2013 included currency-related charges of $28 million related to the Venezuelan currency devaluation in February 2013 and derivative instruments entered into to hedge anticipated foreign currency cash outflows for the planned acquisition of Gambro (Gambro-related derivatives), in addition to charges of $17 million associated with Gambro pre-acquisition costs. The second quarter of 2013 included losses of $55 million for Gambro-related derivatives, charges of $23 million related to Gambro pre-acquisition costs and a net benefit of $2 million related to business optimization activity. The third quarter of 2013 included Gambro acquisition and integration charges of $58 million, tax and legal reserves of $83 million, business development charges of $25 million related to upfront payments for collaboration agreements, and a net gain of $20 million principally associated with Gambro-related derivatives. The fourth quarter of 2013 included business development charges of $78 million related to upfront and milestone payments for collaboration agreements, business optimization charges of $282 million, Gambro acquisition and integration charges of $94 million and product-related charges of $17 million, principally related to remediation efforts for modifications to the SIGMA Spectrum Infusion Pump.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies	'
	NOTE 1
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Nature of Operations
	Baxter International Inc. (Baxter or the company), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. The company operates in two segments, BioScience and Medical Products, which are described in Note 16.
	Use of Estimates
	The preparation of the financial statements in conformity with generally accepted accounting principles (GAAP) requires the company to make estimates and assumptions that affect reported amounts and related disclosures. Actual results could differ from those estimates.
	Basis of Consolidation
	The consolidated financial statements include the accounts of Baxter and its majority-owned subsidiaries, any minority-owned subsidiaries that Baxter controls, and variable interest entities (VIEs) in which Baxter is the primary beneficiary, after elimination of intercompany transactions. During 2012, the company exercised its option to purchase the remaining equity of Sigma International General Medical Apparatus, LLC (SIGMA), which Baxter previously consolidated as the primary beneficiary of a VIE. The company has not subsequently entered into any new arrangements in which it determined that it was the primary beneficiary of a VIE, and there were no VIEs consolidated by the company as of December 31, 2013. Refer to Note 2 for additional information about the SIGMA option exercise.
	On September 6, 2013, Baxter acquired Indap Holding AB, the holding company for Gambro AB (Gambro), a privately held dialysis product company based in Lund, Sweden, for cash consideration of $3.7 billion. Beginning September 6, 2013, Baxter’s financial statements include the assets, liabilities, and operating results of Gambro. Refer to Note 4 for additional information.
	Certain reclassifications have been made to conform the prior period consolidated financial statements to the current period presentation.
	Revenue Recognition
	The company recognizes revenues from product sales and services when earned. Specifically, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectibility is reasonably assured. For product sales, revenue is not recognized until title and risk of loss have transferred to the customer. The shipping terms for the majority of the company’s revenue arrangements are FOB destination. The recognition of revenue is delayed if there are significant post-delivery obligations, such as training, installation or other services. Provisions for discounts, rebates to customers, chargebacks to wholesalers and returns are provided for at the time the related sales are recorded, and are reflected as a reduction to gross sales to arrive at net sales.
	The company sometimes enters into arrangements in which it commits to delivering multiple products or services to its customers. In these cases, total arrangement consideration is allocated to the deliverables based on their relative selling prices. Then the allocated consideration is recognized as revenue in accordance with the principles described above. Selling prices are determined by applying a selling price hierarchy. Selling prices are determined using vendor specific objective evidence (VSOE), if it exists. Otherwise, selling prices are determined using third party evidence (TPE). If neither VSOE nor TPE is available, the company uses its best estimate of selling prices.
	Accounts Receivable and Allowance for Doubtful Accounts
	In the normal course of business, the company provides credit to its customers, performs credit evaluations of these customers and maintains reserves for potential credit losses. In determining the amount of the allowance for doubtful accounts, the company considers, among other items, historical credit losses, the past-due status of receivables, payment histories and other customer-specific information. Receivables are written off when the company determines they are uncollectible. The allowance for doubtful accounts was $169 million at December 31, 2013 and $127 million at December 31, 2012.
	Product Warranties
	The company provides for the estimated costs relating to product warranties at the time the related revenue is recognized. The cost is determined based on actual company experience for the same or similar products, as well as other relevant information. Product warranty liabilities are adjusted based on changes in estimates.
	Cash and Equivalents
	Cash and equivalents include cash, certificates of deposit and money market funds with an original maturity of three months or less.
	Inventories
	as of December 31 (in millions)	2013			2012
	Raw materials	$	920		$	765
	Work in process		1,136			898
	Finished goods		1,443			1,140
	Inventories	$	3,499		$	2,803
	Inventories are stated at the lower of cost (first-in, first-out method) or market value. Market value for raw materials is based on replacement costs, and market value for work in process and finished goods is based on net realizable value. The company reviews inventories on hand at least quarterly and records provisions for estimated excess, slow-moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value.
	Property, Plant and Equipment, Net
	as of December 31 (in millions)	2013			2012
	Land	$	220		$	190
	Buildings and leasehold improvements		2,670			2,181
	Machinery and equipment		7,360			6,691
	Equipment with customers		1,361			1,295
	Construction in progress		2,184			1,512
	Total property, plant and equipment, at cost		13,795			11,869
	Accumulated depreciation		(5,963	)		(5,771	)
	Property, plant and equipment (PP&E), net	$	7,832		$	6,098
	Depreciation expense is calculated using the straight-line method over the estimated useful lives of the related assets, which range from 20 to 50 years for buildings and improvements and from three to 15 years for machinery and equipment. Leasehold improvements are amortized over the life of the related facility lease (including any renewal periods, if appropriate) or the asset, whichever is shorter. Baxter capitalizes certain computer software and software development costs incurred in connection with developing or obtaining software for internal use as part of machinery and equipment. Capitalized software costs are amortized on a straight-line basis over the estimated useful lives of the software, and are included in depreciation expense below. Straight-line and accelerated methods of depreciation are used for income tax purposes. Depreciation expense was $681 million in 2013, $597 million in 2012 and $572 million in 2011. Repairs and maintenance expense was $351 million in 2013, $297 million in 2012 and $269 million in 2011.
	Acquisitions
	Results of operations of acquired companies are included in the company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.
	Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of regulatory, development and commercial milestone payments, in addition to sales-based payments, and are valued using discounted cash flow techniques. The fair value of development and commercial milestone payments reflects management’s expectations of probability of payment, and increases as the probability of payment increases or expectation of timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or expectation of timing of payment is accelerated.
	Research and Development
	Research and development (R&D) costs are expensed as incurred. Acquired in-process R&D (IPR&D) is the value assigned to technology or products under development acquired in a business combination which have not received regulatory approval and have no alternative future use. Valuations are generally completed for business acquisitions using a discounted cash flow analysis, incorporating the stage of completion and consideration of market participant assumptions. The most significant estimates and assumptions inherent in a discounted cash flow analysis include the amount and timing of projected future cash flows, the discount rate used to measure the risks inherent in future cash flows, the assessment of the asset’s life cycle, and competitive and other trends impacting the asset, including consideration of technical, legal, regulatory, economic and other factors. Each of these factors can significantly affect the value of the IPR&D.
	Acquired IPR&D is capitalized as an indefinite-lived intangible asset. Development costs incurred after the acquisition are expensed as incurred. Upon receipt of regulatory approval of the related technology or product, the indefinite-lived intangible asset is accounted for as a finite-lived intangible asset and generally amortized on a straight-line basis over the estimated economic life of the related product, subject to impairment reviews as discussed below. If the R&D project is abandoned, the indefinite-lived asset is charged to expense.
	R&D acquired in transactions that are not business acquisitions is expensed immediately. Payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized over the remaining estimated economic life of the related product.
	Collaborative Arrangements
	In the normal course of business, Baxter enters into collaborative arrangements with third parties. Certain of these collaborative arrangements include joint operating activities involving active participation by both partners, where both Baxter and the other entity are exposed to risks and rewards dependent on the commercial success of the activity. These collaborative arrangements exist in both of the company’s segments, take a number of forms and structures, principally pertain to the joint development and commercialization of new products, and are designed to enhance and expedite long-term sales and profitability growth.
	The company’s joint product development and commercialization arrangements generally provide that Baxter license certain rights to develop, market, and sometimes manufacture, a product under development. Baxter’s consideration for the rights generally consists of some combination of upfront payments, contingent milestone payments relating to the achievement of specified development, clinical, regulatory and sales milestones, and royalties. Baxter may also be responsible for ongoing R&D cost reimbursements and costs associated with certain development, manufacturing and commercial activities associated with these arrangements. Joint steering committees exist to manage the various stages and activities of the arrangement. Control over the R&D activities may be shared, may be held by Baxter, or may be held by the partner, and governance may contractually change during the development or later periods. Baxter typically controls the commercialization phase, sometimes purchasing inventories from the collaboration partner.
	During the development phase, Baxter’s R&D costs are expensed as incurred. These costs may include upfront and milestone payments made to the partner prior to the date the product receives regulatory approval, in addition to potential R&D cost reimbursements. Milestone payments made to the partner subsequent to regulatory approval are capitalized as other intangible assets and amortized to cost of sales over the estimated economic life of the related product. Royalty payments are expensed as cost of sales when they become due and payable. Any purchases of inventory from the partner during the development stage are expensed as R&D, while such purchases during the commercialization phase are capitalized as inventory and recognized as cost of sales when the related finished products are sold. Baxter generally records the amount invoiced to the third-party customer for the finished product as sales, as Baxter is the principal and primary obligor in the arrangement.
	Payments to collaborative partners classified in cost of sales were not significant in 2013, 2012 and 2011. Payments to collaborative partners classified in R&D expenses were $129 million, $138 million and $18 million in 2013, 2012 and 2011, respectively. In 2013 and 2012, the payments related primarily to upfront payments for the business development arrangements described in Note 4. In 2011, the payments primarily related to the development of longer-acting forms of blood clotting proteins to treat hemophilia and a home hemodialysis (HHD) device.
	Business Optimization Charges
	The company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee termination costs are primarily recorded when actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. Refer to the discussion below regarding the accounting for asset impairment charges.
	Impairment Reviews
	Baxter has made and continues to make significant investments in assets, including inventory and PP&E, which relate to potential new products or modifications to existing products. Additionally, Baxter has made and continues to make significant investments related to business development activities, which result in the acquisition of certain intangible assets and other long-lived assets. The company’s ability to realize value from these investments is contingent on, among other things, regulatory approvals, market acceptance of these new or modified products, and realization of synergies associated with business acquisitions. The company may not be able to realize the expected returns from these investments, potentially resulting in asset impairments in the future.
	Goodwill
	Goodwill is not amortized, but is subject to an impairment review annually and whenever indicators of impairment exist. Goodwill would be impaired if the carrying amount of a reporting unit exceeded the fair value of that reporting unit, calculated as the present value of estimated cash flows discounted using a risk-free market rate adjusted for a market participant’s view of similar companies and perceived risks in the cash flows. The implied fair value of goodwill is then determined by subtracting the fair value of all identifiable net assets other than goodwill from the fair value of the reporting unit, with an impairment charge recorded for the excess, if any, of carrying amount of goodwill over the implied fair value.
	The company assesses goodwill for impairment based on its reporting units, which are the same as its operating segments, BioScience and Medical Products. As of December 31, 2013, the date of the company’s annual impairment review, the fair values of the company’s reporting units were substantially in excess of their carrying values.
	Intangible Assets Not Subject to Amortization
	Indefinite-lived intangible assets, such as trademarks with indefinite lives and certain acquired IPR&D, are subject to an impairment review annually and whenever indicators of impairment exist. Indefinite-lived intangible assets would be impaired if the carrying amount of the asset exceeded the fair value of the asset.
	Other Long-Lived Assets
	The company reviews the carrying amounts of long-lived assets, other than goodwill and intangible assets not subject to amortization, for potential impairment when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Examples of such a change in circumstances include a significant decrease in market price, a significant adverse change in the extent or manner in which an asset is being used, or a significant adverse change in the legal or business climate. In evaluating recoverability, the company groups assets and liabilities at the lowest level such that the identifiable cash flows relating to the group are largely independent of the cash flows of other assets and liabilities. The company then compares the carrying amounts of the assets or asset groups with the related estimated undiscounted future cash flows. In the event impairment exists, an impairment charge is recorded as the amount by which the carrying amount of the asset or asset group exceeds the fair value. Depending on the asset and the availability of information, fair value may be determined by reference to estimated selling values of assets in similar condition, or by using a discounted cash flow model. In addition, the remaining amortization period for the impaired asset would be reassessed and, if necessary, revised.
	Shipping and Handling Costs
	Shipping costs, which are costs incurred to physically move product from Baxter’s premises to the customer’s premises, are classified as marketing and administrative expenses. Handling costs, which are costs incurred to store, move and prepare products for shipment, are classified as cost of sales. Approximately $293 million in 2013, $265 million in 2012 and $260 million in 2011 of shipping costs were classified in marketing and administrative expenses.
	Income Taxes
Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The company maintains valuation allowances unless it is more likely than not that the deferred tax asset will be realized. With respect to uncertain tax positions, the company determines whether the position is more likely than not to be sustained upon examination, based on the technical merits of the position. Any tax position that meets the more-likely-than-not recognition threshold is measured and recognized in the consolidated financial statements at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The liability relating to uncertain tax positions is classified as current in the consolidated balance sheets to the extent the company anticipates making a payment within one year. Interest and penalties associated with income taxes are classified in the income tax expense line in the consolidated statements of income.
Foreign Currency Translation
Currency translation adjustments (CTA) related to foreign operations are included in other comprehensive income (OCI). For foreign operations in highly inflationary economies, translation gains and losses are included in other (income) expense, net, and were not material in 2013, 2012 and 2011.
Derivatives and Hedging Activities
All derivative instruments are recognized as either assets or liabilities at fair value in the consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. Based upon the exposure being hedged, the company designates its hedging instruments as cash flow or fair value hedges.
For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is accumulated in accumulated other comprehensive income (AOCI) and then recognized in earnings consistent with the underlying hedged item. Option premiums or net premiums paid are initially recorded as assets and reclassified to OCI over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in net sales, cost of sales, and net interest expense, and primarily related to forecasted third-party sales denominated in foreign currencies, forecasted intercompany sales denominated in foreign currencies and anticipated issuances of debt, respectively.
For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. Fair value hedges are classified in net interest expense, as they hedge the interest rate risk associated with certain of the company’s fixed-rate debt.
For derivative instruments that are not designated as hedges, the change in fair value is recorded directly to other (income) expense, net.
If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, the company discontinues hedge accounting prospectively. If the company removes the cash flow hedge designation because the hedged forecasted transactions are no longer probable of occurring, any gains or losses are immediately reclassified from AOCI to earnings. Gains or losses relating to terminations of effective cash flow hedges in which the forecasted transactions are still probable of occurring are deferred and recognized consistent with the income or loss recognition of the underlying hedged items. If the company terminates a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged items at the date of termination is amortized to earnings over the remaining term of the hedged item.
Derivatives, including those that are not designated as a hedge, are principally classified in the operating section of the consolidated statements of cash flows in the same category as the related consolidated balance sheet account.
Refer to Note 8 for further information regarding the company’s derivative and hedging activities.
Changes in Accounting Standards
Effective January 1, 2013, the company has prospectively adopted new accounting guidance that requires an entity to report the effect of significant reclassifications out of AOCI on the respective line items in the consolidated statement of income. Refer to Note 13 for related disclosures.
On January 1, 2012, the company adopted a new accounting standard which eliminated the company’s previous election to present other comprehensive income within the consolidated statements of changes in equity, and provided the option to present the components of net income and other comprehensive income either as one continuous statement of comprehensive income or as two separate but consecutive statements. The standard is reflected in the company’s consolidated statements of comprehensive income, presented as a separate consecutive statement to the consolidated statements of income, and was retrospectively applied to all prior periods presented.

Supplemental_Financial_Informa

Supplemental Financial Information	12 Months Ended
	Dec. 31, 2013
Supplemental Financial Information	'
	NOTE 2
	SUPPLEMENTAL FINANCIAL INFORMATION
	Other Long-Term Assets
	as of December 31 (in millions)	2013			2012
	Deferred income taxes	$	876		$	1,156
	Other long-term receivables		216			154
	Other		442			406
	Other long-term assets	$	1,534		$	1,716
	Accounts Payable and Accrued Liabilities
	as of December 31 (in millions)	2013			2012
	Accounts payable, principally trade	$	1,103		$	766
	Income taxes payable		302			451
	Deferred income taxes		760			878
	Common stock dividends payable		266			246
	Employee compensation and withholdings		667			567
	Property, payroll and certain other taxes		237			152
	Infusion pump reserves		64			37
	Business optimization reserves		199			151
	Accrued rebates		346			291
	Other		922			870
	Accounts payable and accrued liabilities	$	4,866		$	4,409
	Other Long-Term Liabilities
	as of December 31 (in millions)	2013			2012
	Pension and other employee benefits	$	2,049		$	2,427
	Litigation reserves		72			32
	Infusion pump reserves		19			90
	Business optimization reserves		89			69
	Contingent payment liabilities		340			86
	Other		782			369
	Other long-term liabilities	$	3,351		$	3,073
	Net Interest Expense
	years ended December 31 (in millions)	2013			2012			2011
	Interest costs	$	225		$	165		$	132
	Interest costs capitalized		(70	)		(52	)		(40	)
	Interest expense		155			113			92
	Interest income		(27	)		(26	)		(38	)
	Net interest expense	$	128		$	87		$	54
	Other (Income) Expense, Net
	years ended December 31 (in millions)	2013			2012			2011
	Impairment charges	$	21		$	9		$	62
	Net gains related to contingent payment liabilities		(8	)		(91	)		—
	Foreign exchange		26			(49	)		(10	)
	Securitization and factoring arrangements		18			18			14
	Equity method investments		(24	)		1			4
	Noncontrolling interests		(31	)		(28	)		—
	Other		(11	)		(15	)		13
	Other (income) expense, net	$	(9	)	$	(155	)	$	83
	Other (income) expense, net includes the benefit from net losses attributable to noncontrolling interests of $31 million and $28 million in 2013 and 2012, respectively, which has been prospectively reclassified as other (income) expense, net effective January 1, 2012 based on materiality.
	During 2012, the company recorded gains of $53 million and $38 million related to the reduction of contingent payment liabilities for certain milestones associated with the 2011 acquisition of Prism Pharmaceuticals, Inc. (Prism) and the 2010 acquisition of ApaTech Limited (ApaTech), respectively. The $53 million gain related to the Prism acquisition was included in the Medical Products segment’s pre-tax income and the $38 million gain related to the ApaTech acquisition was included in the BioScience segment’s pre-tax income. Refer to Note 9 for further information about these gains.
	During 2011, the company recorded impairment charges of $62 million principally related to the write-down of the company’s Greek government bonds, which was recorded at the corporate level and not allocated to a segment.
	Sale of Business
	In May 2011, the company completed the divestiture of its U.S. multi-source generic injectables business to Hikma Pharmaceuticals PLC (Hikma). The consideration for the divestiture arrangement totaled $104 million, after closing-related adjustments. Hikma acquired Baxter’s high-volume, multi-source generic injectable products in vials and ampoules, including chronic pain, anti-infective and anti-emetic products, along with a manufacturing facility located in Cherry Hill, New Jersey, and a warehouse and distribution center located in Memphis, Tennessee.
	Net sales related to the U.S. multi-source generic injectables business, which were reported in the Medical Products segment prior to the divestiture, totaled $58 million in 2011. Pre-tax earnings related to this business were not significant to Baxter’s consolidated financial statements in 2011.
	Exercise of SIGMA Option
	In April 2012, the company exercised its option to purchase the remaining equity of SIGMA for a cash payment of $90 million. Since the 2009 acquisition of a 40% stake in SIGMA, the company has consolidated the financial statements of SIGMA, with the equity owned by existing SIGMA equity holders reported as noncontrolling interests. As a result, the exercise of the option was treated as an equity transaction and no additional assets were recognized by Baxter related to the additional ownership interest acquired. On the date of exercise, the carrying value of the noncontrolling interest was eliminated to reflect Baxter’s change in ownership interest in SIGMA’s equity and the carrying value of the call option was also eliminated. The exercise of the SIGMA purchase option had no direct impact on the company’s results of operations, and the payment was classified as a financing activity on the consolidated statement of cash flows. Effective as of the date of the option exercise, 100% of SIGMA’s pre-tax income has been reflected in the company’s results of operations and, as a result, the company no longer reports noncontrolling interest related to SIGMA.

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share	'
	NOTE 3
	EARNINGS PER SHARE
	The numerator for both basic and diluted earnings per share (EPS) is net income attributable to Baxter. The denominator for basic EPS is the weighted-average number of common shares outstanding during the period. The dilutive effect of outstanding stock options, restricted stock units (RSUs) and performance share units (PSUs) is reflected in the denominator for diluted EPS using the treasury stock method.
	The following is a reconciliation of basic shares to diluted shares.
	years ended December 31 (in millions)	2013		2012		2011
	Basic shares		543		551		569
	Effect of dilutive securities		6		5		4
	Diluted shares		549		556		573
	The effect of dilutive securities included unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excluded stock options to purchase 5 million, 16 million and 19 million shares in 2013, 2012 and 2011, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS. Refer to Note 11 for additional information regarding items impacting basic shares.

Acquisitions_and_Collaboration

Acquisitions and Collaborations	12 Months Ended
	Dec. 31, 2013
Acquisitions and Collaborations	'
	NOTE 4
	ACQUISITIONS AND COLLABORATIONS
	Acquisition of Gambro
	Description of transaction
	On September 6, 2013, Baxter acquired 100 percent of the voting equity interests in Indap Holding AB, the holding company for Gambro, a privately held dialysis product company based in Lund, Sweden. Gambro is a global medical technology company focused on developing, manufacturing and supplying dialysis products and therapies for patients with acute or chronic kidney disease. The transaction provides Baxter with a broad and complementary dialysis product portfolio, while further advancing the company’s geographic footprint in the dialysis business. In addition, the company has augmented its pipeline with Gambro’s next-generation monitors, dialyzers, devices and dialysis solutions.
	Fair value of consideration transferred and net assets acquired
	The total cash consideration for the acquisition, as reduced by assumed debt of $221 million, was $3.7 billion. In the fourth quarter of 2013, the company substantially completed its valuation of the consideration transferred and certain assets acquired and liabilities assumed. As a result, Baxter adjusted its preliminary estimates of the fair value of assets acquired and liabilities assumed as of the acquisition date to reflect the updated valuations. The measurement period adjustments included reductions of $360 million, $128 million and $118 million to other intangible assets, property, plant and equipment, and other long-term liabilities, respectively, in addition to other immaterial adjustments to working capital. The adjustments above resulted in a corresponding increase in goodwill of $368 million. The measurement period adjustments did not have a material impact on Baxter’s results of operations in 2013.
	The following table summarizes the fair value of the consideration transferred and the amounts recognized for assets acquired and liabilities assumed as of the acquisition date. Additional measurement period adjustments may occur as the company finalizes its valuation of the acquisition date assets acquired and liabilities assumed.
	(in millions)
	Consideration transferred
	Cash		$	3,704
	Fair value of consideration transferred		$	3,704
	Assets acquired and liabilities assumed
	Cash		$	88
	Accounts receivable			490
	Inventories			368
	Prepaid expenses and other			54
	Property, plant, and equipment			726
	Other intangible assets			1,290
	Other assets			11
	Current-maturities of long-term debt and lease obligations			(2	)
	Accounts payable and accrued liabilities			(340	)
	Long-term debt and lease obligations			(261	)
	Other long-term liabilities (including pension obligations of $209)			(340	)
	Total identifiable net assets			2,084
	Goodwill			1,620
	Total assets acquired and liabilities assumed		$	3,704
	The results of operations, assets and liabilities of Gambro are included in the Medical Products segment, together with the related goodwill. Goodwill includes expected synergies, as well as an expanded dialysis product portfolio and global footprint for the company’s Medical Products business, particularly the Renal franchise. The goodwill is not deductible for tax purposes. Other intangible assets include developed technology of $916 million, trademarks of $206 million, and indefinite-lived IPR&D of $168 million. Other intangible assets, excluding IPR&D, are being amortized on a straight-line basis over a weighted-average estimated useful life of approximately 15.0 years, as of the date of acquisition. The acquired IPR&D relates to next generation monitors, dialyzers, fluids, and other technologies used in both chronic and acute therapies. The projects range in levels of completion and are expected to be completed over the next five years. The value of the IPR&D was calculated using cash flow projections adjusted for the inherent technical, regulatory, commercial and obsolescence risk in such activities, discounted at a rate of 12%. Additional research and development will be required before these projects reach technological feasibility, and, as of the acquisition date, incremental R&D costs of approximately $85 million are expected to complete the projects.
	Long-term debt and lease obligations includes $221 million of Gambro’s pre-existing Euro-denominated debt assumed by Baxter on the date of closing, which was subsequently paid off in September 2013. The debt settlement has been classified as a financing activity in the consolidated statement of cash flows.
	Acquisition-related costs
	The company incurred acquisition-related costs of $101 million during 2013, which were recorded in marketing and administrative expenses.
	Actual and pro forma impact of acquisition
	The following table presents information for Gambro that has been included in Baxter’s consolidated statement of income from the acquisition date through December 31, 2013.
	(in millions)		Gambro’s operations
			included in Baxter’s results
	Net sales		$	513
	Net loss		$	(45	)
	Net loss related to Gambro includes purchase accounting impacts related to fair value adjustments associated with acquisition-date inventory that was sold in 2013 (approximately $62 million on a pre-tax basis).
	The following table presents supplemental pro forma information as if the acquisition of Gambro had occurred on January 1, 2012 for the years ended December 31, 2013 and 2012.
			Unaudited Pro Forma Consolidated Results
			Years ended December 31,
	(in millions, except per share information)		2013			2012
	Net sales		$	16,288		$	15,767
	Net income			2,138			2,021
	Basic earnings per share		$	3.94		$	3.67
	Diluted earnings per share		$	3.89		$	3.63
	The unaudited pro forma consolidated results were prepared using the acquisition method of accounting and are based on the historical information of Baxter and Gambro. The unaudited pro forma consolidated results are not necessarily indicative of what the consolidated results of operations would have been had the acquisition been completed on January 1, 2012. In addition, the unaudited pro forma consolidated results are not projections of future results of operations of the combined company nor do they reflect the expected realization of any cost savings or synergies associated with the acquisition.
	The unaudited pro forma consolidated results reflect primarily the following pro forma pre-tax adjustments:
		•		Conversion of Gambro’s historical results of operations from International Financial Reporting Standards (IFRS) to GAAP.
		•		Elimination of Gambro’s historical intangible asset amortization expense and property, plant and equipment depreciation expense.
		•		Addition of amortization expense related to the fair value of identifiable intangible assets acquired.
		•		Addition of depreciation expense related to the fair value of property, plant and equipment acquired.
		•		Elimination of a $62 million charge related to the fair value of acquisition-date inventory from the year ended December 31, 2013.
		•		Addition of a $62 million charge related to the fair value of acquisition-date inventory to the year ended December 31, 2012.
		•		Elimination of Gambro’s historical interest expense and addition of interest expense associated with debt that was issued in 2013 to partially finance the acquisition.
		•		Elimination of $244 million of acquisition, integration and currency-related charges from the year ended December 31, 2013 and addition of these costs to the year ended December 31, 2012. These costs were directly attributable to the acquisition and non-recurring in nature, and included acquisition and integration related charges incurred by Baxter, in addition to post-acquisition restructuring costs and losses from foreign currency hedging activity related to the acquisition.
	Other Acquisitions
	The following table summarizes the fair value of consideration transferred and the recognized amounts of the assets acquired and liabilities assumed as of the acquisition date for the company’s other significant acquisitions in 2013, 2012 and 2011.
	(in millions)		2013			2012		2011
			Inspiration / Ipsen			Synovis		Baxa			Prism
			OBI-1 Business
	Consideration transferred
	Cash, net of cash acquired		$	51		$	304	$	358		$	170
Contingent payments			269			—		—			67
Fair value of consideration transferred		$	320		$	304	$	358		$	237
Assets acquired and liabilities assumed
Other intangible assets		$	288		$	115	$	145		$	229
Other assets (liabilities), net			25			25		(24	)		(64	)
Total identifiable net assets			313			140		121			165
Goodwill			7			164		237			72
Total assets acquired and liabilities assumed		$	320		$	304	$	358		$	237
Pro forma financial information has not been included because these acquisitions, individually and in the aggregate, did not have a material impact on the company’s financial position or results of operations for the years ended December 31, 2013, 2012 and 2011.
The company’s acquisitions have provided Baxter with complementary and expanded product portfolios in its BioScience and Medical Products businesses. Additional information regarding the above acquisitions has been provided below.
Inspiration / Ipsen OBI-1 business
In March 2013, Baxter acquired the investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals, Inc. (Inspiration), as well as certain other OBI-1 related assets, including manufacturing operations, from Ipsen Pharma S.A.S. (Ipsen) in conjunction with Inspiration’s bankruptcy proceedings. OBI-1 is a recombinant porcine factor VIII (rpFVIII) being investigated for treatment of bleeding in people with acquired hemophilia A and congenital hemophilia A patients with inhibitors. Ipsen was Inspiration’s senior secured creditor and had been providing Inspiration with debtor-in-possession financing to fund Inspiration’s operations and the sales process. Additionally, Ipsen was the owner of certain assets acquired by Baxter in the transaction.
The acquired net assets comprised a business based on the acquired inputs, processes and outputs and, as a result, the transaction has been accounted for as an acquisition of a business. In March 2013, Baxter made an upfront payment of $51 million for the Inspiration / Ipsen OBI-1 business. The terms of the acquisition also included contingent consideration, including up to $135 million in payments related to the achievement of certain regulatory and sales milestones. Additionally, Baxter will be responsible for specified sales-based payments.
The estimated fair value of contingent payment liabilities at the acquisition date was $269 million, based on the probability of achieving the specified milestones and sales-based payments and the discounting of expected future cash flows, and was recorded in other long-term liabilities as part of the consideration transferred. As of December 31, 2013, the estimated fair value of the contingent payments was $291 million, with changes in the estimated fair value recognized in earnings. Refer to Note 9 for additional information regarding the Inspiration / Ipsen OBI-1 business contingent payment liability.
Goodwill of $7 million principally includes the value associated with the assembled workforce at the acquired manufacturing facility. The goodwill is deductible for tax purposes. Other intangible assets of $288 million related to acquired IPR&D activities, which were accounted for as indefinite-lived intangible assets. The acquired IPR&D primarily relates to certain indications for OBI-1 related to the treatment of people with acquired hemophilia A and congenital hemophilia A patients. The projects range in levels of completion and are expected to be completed over the next five years. The value of the IPR&D was calculated using cash flow projections adjusted for the inherent technical, regulatory, commercial and obsolescence risk in such activities, discounted at a rate of 13%. Additional research and development will be required before the activities related to OBI-1 reach technological feasibility, and, as of the acquisition date, incremental R&D costs of approximately $50 million are expected to complete the projects.
The results of operations, assets and liabilities of the Inspiration / Ipsen OBI-1 business are included in the BioScience segment, together with the related goodwill.
Synovis Life Technologies, Inc.
In February 2012, the company acquired Synovis Life Technologies, Inc. (Synovis), a publicly-traded company which develops, manufactures and markets biological and mechanical products for soft tissue repair used in a variety of surgical procedures.
Goodwill of $164 million includes expected synergies and other benefits the company believes will result from the acquisition, including an expanded product portfolio and the impact of a larger sales force to support surgeons across a range of procedures. The goodwill is not deductible for tax purposes. Other intangible assets of $115 million relate to developed technology and are being amortized on a straight-line basis over an estimated average useful life of 12 years.
The results of operations, assets and liabilities of Synovis are included in the BioScience segment, together with the related goodwill.
Baxa Corporation
In November 2011, the company acquired privately-held Baxa Corporation (Baxa), which manufactures and markets devices, systems and software for the safe and efficient preparation, handling, packaging and administration of fluid medications.
Goodwill of $237 million includes expected synergies and other benefits the company believes will result from the acquisition, including additional growth opportunities and an enhanced ability to treat all patient segments. The goodwill is not deductible for tax purposes. Other intangible assets of $145 million primarily relate to customer relationships and are being amortized on a straight-line basis over an estimated average useful life of 13 years, as of the date of the acquisition. The results of operations, assets and liabilities of Baxa are included in the Medical Products segment, together with the related goodwill.
Prism Pharmaceuticals, Inc.
In May 2011, the company acquired privately-held Prism Pharmaceuticals, Inc. (Prism), a specialty pharmaceutical company whose products include NEXTERONE (amiodarone HCl), an antiarrhythmic agent used for ventricular tachyarrhythmias, or fast forms of irregular heartbeat.
Goodwill of $72 million includes expected synergies in manufacturing and formulation expertise and other benefits the company believes will result from the acquisition, including opportunities for revenue growth through existing sales channels. The goodwill is not deductible for tax purposes. Other intangible assets of $225 million, excluding IPR&D of $4 million, primarily relate to developed technology and are being amortized on a straight-line basis over an estimated average useful life of 14 years, as of the date of the acquisition. The results of operations, assets and liabilities of Prism are included in the Medical Products segment, together with the related goodwill.
The terms of the acquisition included contingent payments of up to $168 million associated with the achievement of specified sales milestones through 2017. The estimated fair value of the contingent payments at the acquisition date was $67 million, based on the probability of achieving the specified sales milestones, and was recorded in other long-term liabilities as part of the consideration transferred. As of December 31, 2013, the estimated fair value of the contingent payments was $17 million, with changes in the estimated fair value recognized in earnings. Refer to Note 9 for additional information regarding the Prism contingent payment liability.
Collaborations
Cell Therapeutics, Inc.
In November 2013, Baxter entered into an exclusive worldwide licensing agreement with Cell Therapeutics, Inc. (Cell Therapeutics), to develop and commercialize pacritinib, a novel investigational JAK2/FLT3 inhibitor with activity against genetic mutations linked to myelofibrosis, leukemia and certain solid tumors. Pacritinib is currently in Phase III development for patients with myelofibrosis, a chronic malignant bone marrow disorder. Under the terms of the agreement, Baxter gained exclusive commercialization rights for all indications for pacritinib outside the United States and Baxter and Cell Therapeutics will jointly commercialize pacritinib in the United States. In the fourth quarter of 2013, Baxter recognized an R&D charge of $33 million related to an upfront cash payment associated with the execution of the agreement. As of December 31, 2013, Baxter may make additional payments of up to $112 million related to the achievement of clinical, regulatory and commercial milestones, in addition to future sales milestones and royalties.
In November 2013, Baxter acquired approximately 16 million shares of Cell Therapeutics common stock for $27 million.
Coherus Biosciences, Inc.
In August 2013, Baxter and Coherus Biosciences, Inc. (Coherus) entered into an exclusive collaboration to develop and commercialize a biosimilar to etanercept for Europe, Canada, Brazil and certain other markets. Baxter also has specified rights to include additional products in the collaboration. In the fourth quarter of 2013, Baxter recognized an R&D charge of $30 million related to its decision to continue to pursue development of etanercept. Additionally, in the fourth quarter of 2013, Baxter recognized an R&D charge of $15 million related to a milestone payment under the agreement. As of December 31, 2013, Baxter may make additional payments of up to $154 million relating to the achievement of development and regulatory milestones, as well as royalties based on net sales.
JW Holdings Corporation
In July 2013, Baxter and JW Holdings Corporation (JW Holdings) entered into a collaboration agreement for parenteral nutritional products containing a novel formulation of omega 3 lipids. Baxter has exclusive rights to co-develop and distribute the products globally, with the exception of Korea. In the third quarter of 2013, Baxter recognized an R&D charge of $25 million related to an upfront cash payment associated with the execution of the agreement. As of December 31, 2013, Baxter may make additional payments of up to $11 million relating to the achievement of regulatory milestones, in addition to future royalties.
Onconova Therapeutics, Inc.
In September 2012, Baxter executed a licensing agreement with Onconova Therapeutics, Inc. (Onconova) for rigosertib, a novel targeted anti-cancer compound for the treatment of a group of rare hematologic malignancies called Myelodysplastic Syndromes and pancreatic cancer. The agreement provides Baxter with commercialization rights for the compound in Europe for those indications. In the third quarter of 2012, Baxter recognized an R&D charge of $50 million related to an upfront cash payment associated with the execution of the agreement. As of December 31, 2013, Baxter may make additional payments of up to $357 million related to the achievement of development and regulatory milestones, in addition to future sales milestones and royalties.
In July 2012, Baxter acquired approximately 3 million shares of Onconova preferred stock for $50 million. Refer to Note 9 for additional information regarding this investment.
Chatham Therapeutics, LLC
In May 2012, Baxter executed an exclusive agreement with Chatham Therapeutics, LLC (Chatham), an affiliate of Asklepios BioPharmaceutical, Inc., for the development and commercialization of potential treatments for hemophilia B utilizing Chatham’s gene therapy technology. Under the agreement, Baxter and Chatham will investigate Chatham’s gene therapy technology through U.S.-based hemophilia B clinical trials and Baxter has global rights for the marketing and commercialization of new treatments. In the second quarter of 2012, Baxter recognized an R&D charge of $30 million related to upfront cash payments associated with the execution of the agreement. As of December 31, 2013, Baxter may make additional payments of up to $60 million over the next several years related to the achievement of development and commercial milestones. In addition, Baxter has certain responsibilities related to development and commercialization activities under the agreement.
Momenta Pharmaceuticals, Inc.
In 2011, the company announced a global collaboration with Momenta Pharmaceuticals, Inc. (Momenta) to develop and commercialize biosimilars. In February 2012, Baxter made an upfront cash payment of $33 million to Momenta for the development of up to six biosimilars, which was recognized as an R&D charge. As of December 31, 2013, Baxter may make additional payments of up to approximately $131 million over the next several years related to option exercises and the achievement of technical, development and regulatory milestones for these products. Baxter may be responsible for additional future payments contingent upon the company’s exercise of the remaining product options. The arrangement also includes specified funding by Baxter, as well as other responsibilities, relating to development and commercialization activities.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets, Net	12 Months Ended
	Dec. 31, 2013
Goodwill and Other Intangible Assets, Net	'
	NOTE 5
	GOODWILL AND OTHER INTANGIBLE ASSETS, NET
	Goodwill
	The following is a summary of the activity in goodwill by segment.
	(in millions)	BioScience			Medical			Total
					Products
	December 31, 2011	$	806		$	1,511		$	2,317
	Additions		161			21			182
	Currency translation and other adjustments		8			(5	)		3
	December 31, 2012		975			1,527			2,502
	Additions		7			1,622			1,629
	Currency translation and other adjustments		9			65			74
	December 31, 2013	$	991		$	3,214		$	4,205
	Goodwill additions in 2013 principally related to the third quarter acquisition of Gambro in the Medical Products segment and the first quarter acquisition of the Inspiration / Ipsen OBI-1 business in the BioScience segment. Goodwill additions in 2012 principally related to the acquisition of Synovis and an additional $19 million from the 2012 acquisition of Laboratoire Fasonut (Fasonut), a privately-held French pharmaceutical company specializing in parenteral nutrition compounding for hospitals, in which Baxter had previously held a 20% equity interest. Synovis is included in the BioScience segment and Fasonut is included in the Medical Products segment. See Note 4 for further information.
	As of December 31, 2013, there were no accumulated goodwill impairment losses.
	Other Intangible Assets, Net
	The following is a summary of the company’s other intangible assets.
	(in millions)	Developed technology,			Other amortized			Indefinite-lived		Total
		including patents			intangible assets			intangible assets
	December 31, 2013
	Gross other intangible assets	$	2,144		$	494		$	465	$	3,103
	Accumulated amortization		(665	)		(144	)		—		(809	)
	Other intangible assets, net	$	1,479		$	350		$	465	$	2,294
	December 31, 2012
	Gross other intangible assets	$	1,192		$	280		$	22	$	1,494
	Accumulated amortization		(578	)		(102	)		—		(680	)
	Other intangible assets, net	$	614		$	178		$	22	$	814
	Intangible asset amortization expense was $129 million in 2013, $101 million in 2012 and $81 million in 2011. The anticipated annual amortization expense for intangible assets recorded as of December 31, 2013 is $182 million in 2014, $180 million in 2015, $177 million in 2016, $159 million in 2017 and $154 million in 2018.
	Refer to Note 4 for further information regarding significant acquisitions impacting other intangible assets, net.

Infusion_Pump_and_Business_Opt

Infusion Pump and Business Optimization Charges	12 Months Ended
	Dec. 31, 2013
Infusion Pump and Business Optimization Charges	'
	NOTE 6
	INFUSION PUMP AND BUSINESS OPTIMIZATION CHARGES
	Infusion Pump Charges
	From 2005 through 2012, the company recorded total charges and adjustments of $888 million related to COLLEAGUE and SYNDEO infusion pumps, including $742 million of cash costs and $146 million principally related to asset impairments.
	During 2012, the company recorded an adjustment of $37 million in cost of sales to reduce the COLLEAGUE infusion pump reserves as the company substantially completed its recall activities in the United States. The company also further refined the original expectations for cash and non-cash activities based on expected usage of the reserves and recorded a $63 million adjustment to increase reserves for cash costs with a corresponding decrease to non-cash reserves, which had no impact on the results of operations. The net impact of these adjustments was an increase in cash reserves of $26 million during 2012.
	During 2013, the company further refined its expectations for cash and non-cash activities based on expected usage of the reserves and recorded a $17 million adjustment to decrease reserves for cash costs with a corresponding increase to non-cash reserves, which had no impact on the results of operations. The following table summarizes cash activity in the company’s COLLEAGUE and SYNDEO infusion pump reserves through December 31, 2013.
	(in millions)
	Charges and adjustments in 2005 through 2011	$	716
	Utilization in 2005 through 2011		(440	)
	Reserves at December 31, 2011		276
	Utilization		(175	)
	Other		26
	Reserves at December 31, 2012		127
	Utilization		(27	)
	Other		(17	)
	Reserves at December 31, 2013	$	83
	The reserve for remediation activities in the United States has been substantially utilized, with remaining reserves related to remediation activities outside of the United States continuing to be utilized through 2015. In January 2013, Baxter received license approvals in Canada for a replacement infusion pump that will allow the company to complete remediation activities in Canada. The company believes that the remaining infusion pump reserves are adequate. However, additional adjustments may be recorded in the future as the programs are completed.
	It is possible that substantial additional cash and non-cash charges may be required in future periods based on new information, changes in estimates, and actions the company may be required to undertake in markets outside the United States.
	Business Optimization Charges
	In 2013, 2012 and 2011, the company recorded total charges of $314 million, $150 million and $192 million, respectively, primarily related to costs associated with optimizing its overall cost structure on a global basis, as the company streamlined its international operations, rationalized its manufacturing facilities, enhanced its general and administrative infrastructure and re-aligned certain R&D activities. The charges included severance costs, as well as asset impairments and contract terminations associated with discontinued products and projects. The total 2013 business optimization charges also included severance and other non-cash impairment losses associated with the discontinuation of certain R&D programs associated with the Vaccines franchise, in addition to Gambro post-acquisition restructuring activities. In 2013, the company also recorded adjustments of $20 million to previous business optimization reserves that are no longer probable of being utilized, which were recorded in cost of sales.
	Included in the 2013, 2012 and 2011 charges were cash costs of $182 million, $98 million and $156 million, respectively, principally pertaining to severance and other employee-related costs in Europe and the United States. Also included in total charges were asset impairments relating to fixed assets, inventory and other assets associated with discontinued products and projects. These other costs totaled $132 million, $52 million and $36 million in 2013, 2012 and 2011, respectively.
	Of the total 2013 charge, $145 million was recorded in cost of sales, $96 million was recorded in marketing and administrative expenses, and $73 million was recorded in research and development expenses. Of the total 2012 charge, $62 million was recorded in cost of sales, $60 million was recorded in marketing and administrative expenses, and $28 million was recorded in research and development expenses. Of the total 2011 charge, $95 million was recorded in cost of sales and $97 million was recorded in marketing and administrative expenses.
	The following table summarizes cash activity in the reserves related to the company’s business optimization initiatives.
	(in millions)
	Reserve at December 31, 2010	$	180
	2011 Charge		156
	Utilization in 2011		(110	)
	CTA		(1	)
	Reserve at December 31, 2011		225
	2012 Charge		98
	Utilization in 2012		(99	)
	CTA		(4	)
	Reserve at December 31, 2012		220
	2013 Charge		182
	Reserve adjustments		(20	)
	Utilization in 2013		(98	)
	CTA		4
	Reserve at December 31, 2013	$	288
	The reserves are expected to be substantially utilized by the end of 2015. The company believes that the reserves are adequate. However, adjustments may be recorded in the future as the programs are completed.

Debt_Credit_Facilities_and_Lea

Debt, Credit Facilities and Lease Commitments	12 Months Ended
	Dec. 31, 2013
Debt, Credit Facilities and Lease Commitments	'
	NOTE 7
	DEBT, CREDIT FACILITIES AND LEASE COMMITMENTS
	Debt Outstanding
	At December 31, 2013 and 2012, the company had the following debt outstanding.
	as of December 31 (in millions)				2013				2012
	Commercial paper				$	—			$	—
	Other short-term debt					181				27
	Short-term debt				$	181			$	27
	as of December 31 (in millions)		Effective interest				20132				20122
			rate in 20131
	1.8% notes due 2013			1.70%			$	—			$	301
	4.0% notes due 2014			4.10%				351				358
	Floating rate notes due 2014			0.70%				500				—
	Variable-rate loan due 2015			0.90%				194				243
	4.625% notes due 2015			4.80%				625				646
	5.9% notes due 2016			6.00%				622				631
	0.95% notes due 2016			1.10%				500				—
	1.85% notes due 2017			2.00%				500				500
	Variable-rate loan due 2017			1.10%				136				170
	5.375% notes due 2018			5.50%				499				499
	1.85% notes due 2018			1.90%				750				—
	4.5% notes due 2019			4.60%				534				566
	4.25% notes due 2020			4.40%				299				299
	2.40% notes due 2022			2.50%				684				697
	3.2% notes due 2023			3.20%				1,246				—
	6.625% debentures due 2028			6.70%				133				133
	6.25% notes due 2037			6.30%				499				499
	3.65% notes due 2042			3.70%				298				298
	4.5% notes due 2043			4.40%				500				—
	Other			—				115				63
	Total debt and capital lease obligations							8,985				5,903
	Current portion							(859	)			(323	)
	Long-term portion						$	8,126			$	5,580
	1	Excludes the effect of any related interest rate swaps.
	2	Book values include any discounts, premiums and adjustments related to hedging instruments.
	Significant Debt Issuances
	In June 2013, the company issued $500 million of floating rate senior notes maturing in December 2014, $500 million of senior notes bearing a coupon rate of 0.95% and maturing in June 2016, $750 million of senior notes bearing a coupon rate of 1.85% and maturing in June 2018, $1.25 billion of senior notes bearing a coupon rate of 3.2% and maturing in June 2023, and $500 million of senior notes bearing a coupon rate of 4.5% and maturing in June 2043. The interest rate on the floating rate senior notes was 0.4126% as of December 31, 2013. Approximately $3.0 billion of the net proceeds from the June 2013 debt issuances was used to finance the acquisition of Gambro in 2013 and the remainder was used for general corporate purposes, including the repayment of commercial paper.
	In August 2012, the company issued $1.0 billion of senior notes, with $700 million maturing in August 2022 and bearing a 2.40% coupon rate, and $300 million maturing in August 2042 and bearing a 3.65% coupon rate. In December 2011, the company issued $500 million of senior notes maturing in January 2017 and bearing a 1.85% coupon rate.
	The net proceeds of the August 2012 debt issuance were used for general corporate purposes, which included capital expenditures associated with previously announced plans to expand capacity to support longer-term growth of the company’s plasma-based treatments. The net proceeds of the debt issuances from prior years were used for general corporate purposes, which in some cases included the refinancing of indebtedness. The debt instruments are unsecured and include certain covenants, including restrictions relating to the company’s creation of secured debt.
	Commercial Paper
	During 2013, the company issued and redeemed commercial paper, and there was no balance outstanding at December 31, 2013 and December 31, 2012.
	Credit Facilities
	The company had $2.7 billion of cash and equivalents at December 31, 2013, and $3.3 billion of cash and equivalents at December 31, 2012. The company’s primary revolving credit facility has a maximum capacity of $1.5 billion and matures in June 2015. The company also maintains a Euro-denominated revolving credit facility with a maximum capacity of approximately $413 million at December 31, 2013. In 2013, the company amended the agreement related to this facility to extend the maturity date to December 2014. The terms of the Euro-denominated credit facility did not substantially change, however certain provisions were amended to more closely align with the company’s primary credit facility. As of December 31, 2013 approximately $124 million was outstanding under the Euro-denominated facility and there were no outstanding borrowings under the primary revolving credit facility. In 2012, there were no outstanding borrowings under either of these facilities. The company’s facilities enable the company to borrow funds on an unsecured basis at variable interest rates, and contain various covenants, including a maximum net-debt-to-capital ratio. At December 31, 2013, the company was in compliance with the financial covenants in these agreements. The non-performance of any financial institution supporting either of the credit facilities would reduce the maximum capacity of these facilities by each institution’s respective commitment.
	The company also maintains other credit arrangements, which totaled $587 million at December 31, 2013 and $332 million at December 31, 2012. Borrowings outstanding under these facilities totaled $181 million at December 31, 2013 and $27 million at December 31, 2012.
	In January 2013, Baxter entered into an agreement related to a 364-day bridge loan facility with a maximum capacity of $3.1 billion in connection with the planned acquisition of Gambro. This facility was terminated in the second quarter of 2013 as a result of the company’s June 2013 issuance of debt. The company recognized a $13 million expense related to bridge loan facility structuring and commitment fees in other (income) expense, net during the second quarter of 2013.
	Leases
	The company leases certain facilities and equipment under capital and operating leases expiring at various dates. The leases generally provide for the company to pay taxes, maintenance, insurance and certain other operating costs of the leased property. Most of the operating leases contain renewal options. Operating lease rent expense was $214 million in 2013, $202 million in 2012 and $203 million in 2011.
	Future Minimum Lease Payments and Debt Maturities
	as of and for the years ended December 31 (in millions)		Operating		Debt maturities
			leases		and capital
					leases
	2014		$   216		$	859
	2015		180			813
	2016		158			1,111
	2017		140			647
	2018		120			1,262
	Thereafter		271			4,328
	Total obligations and commitments		1,085			9,020
	Interest on capital leases, discounts and premiums, and adjustments relating to		n/a			(35	)
	hedging instruments
	Total debt and lease obligations		$1,085		$	8,985

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Activity	12 Months Ended
	Dec. 31, 2013
Derivative Instruments and Hedging Activity	'
	NOTE 8
	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITY
	Foreign Currency and Interest Rate Risk Management
	The company operates on a global basis and is exposed to the risk that its earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. The company’s hedging policy attempts to manage these risks to an acceptable level based on the company’s judgment of the appropriate trade-off between risk, opportunity and costs.
	The company is primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, Japanese Yen, British Pound, Australian Dollar, Canadian Dollar, Brazilian Real, Colombian Peso and Swedish Krona. The company manages its foreign currency exposures on a consolidated basis, which allows the company to net exposures and take advantage of any natural offsets. In addition, the company uses derivative and nonderivative instruments to further reduce the net exposure to foreign exchange. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from foreign exchange. Financial market and currency volatility may limit the company’s ability to cost-effectively hedge these exposures.
	The company is also exposed to the risk that its earnings and cash flows could be adversely impacted by fluctuations in interest rates. The company’s policy is to manage interest costs using a mix of fixed- and floating-rate debt that the company believes is appropriate. To manage this mix in a cost-efficient manner, the company periodically enters into interest rate swaps in which the company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount.
	The company does not hold any instruments for trading purposes and none of the company’s outstanding derivative instruments contain credit-risk-related contingent features.
	Cash Flow Hedges
	The company may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. The company periodically uses forward-starting interest rate swaps and treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt. Certain other firm commitments and forecasted transactions are also periodically hedged. Cash flow hedges primarily related to forecasted intercompany sales denominated in foreign currencies, and anticipated issuances of debt.
	The notional amounts of foreign exchange contracts were $2.1 billion and $1.5 billion as of December 31, 2013 and 2012, respectively. The company did not have any interest rate contracts designated as cash flow hedges outstanding at December 31, 2013. As of December 31, 2012, $250 million of interest rate contracts designated as cash flow hedges were outstanding. The maximum term over which the company has cash flow hedge contracts in place related to forecasted transactions at December 31, 2013 is 24 months.
	Fair Value Hedges
	The company uses interest rate swaps to convert a portion of its fixed-rate debt into variable-rate debt. These instruments hedge the company’s earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate.
	The total notional amount of interest rate contracts designated as fair value hedges was $1.2 billion and $500 million as of December 31, 2013 and 2012, respectively.
	Dedesignations
	In 2013, the company had $1 billion of interest rate contracts designated as cash flow hedges that matured or were terminated, resulting in a net gain of $5 million that was deferred in AOCI. The company determined that certain forecasted transactions associated with these contracts were no longer probable of occurring and therefore dedesignated the hedge relationship, which, together with ineffectiveness, resulted in the immediate reclassification of a net gain of $11 million from AOCI to net interest expense. The remaining deferred net loss of $6 million from the matured or terminated interest rate contracts is being amortized as an increase to net interest expense over the remaining terms of the underlying debt.
	The company terminated $175 million of interest rate contracts in 2012, which had been designated as fair value hedges. The termination resulted in a net gain of $21 million in 2012 that was deferred and is being amortized as a reduction of net interest expense over the remaining terms of the underlying debt.
	There were no hedge dedesignations in 2012 resulting from changes in the company’s assessment of the probability that the hedged forecasted transactions would occur.
	Undesignated Derivative Instruments
	The company uses forward contracts to hedge earnings from the effects of foreign exchange relating to certain of the company’s intercompany and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges and the terms of these instruments generally do not exceed one month.
	The total notional amount of undesignated derivative instruments was $381 million as of December 31, 2013 and $3.2 billion as of December 31, 2012. In the fourth quarter of 2012 and the first quarter of 2013, the company entered into option contracts with a total notional amount of $3.7 billion to hedge anticipated foreign currency cash outflows associated with the planned acquisition of Gambro. These contracts matured in June 2013, and in the second quarter of 2013, the company entered into undesignated forward contracts with a total notional amount of $1.5 billion also to hedge anticipated foreign currency cash outflows associated with the planned acquisition of Gambro, which matured in 2013.
	The company recorded losses of $23 million in 2013 associated with the Gambro-related option and forward contracts.
	Gains and Losses on Derivative Instruments
	The following tables summarize the gains and losses on the company’s derivative instruments for the years ended December 31, 2013 and 2012.
		Gain (loss)							Location of gain (loss) in			Gain (loss)
		recognized in OCI							income statement			reclassified from
												AOCI into income
	(in millions)	2013				2012						2013			2012
	Cash flow hedges
	Interest rate contracts	$	26			$	(10	)		Net interest expense		$	10		$	—
	Foreign exchange contracts		1				(3	)		Net sales			(1	)		(3	)
	Foreign exchange contracts		36				—			Cost of sales			32			3
	Total	$	63			$	(13	)				$	41		$	—
		Location of gain (loss) in				Gain (loss)
		income statement				recognized in income
	(in millions)					2013			2012
	Fair value hedges
	Interest rate contracts		Net interest expense			$	(46	)	$	11
	Undesignated derivative instruments
	Foreign exchange contracts		Other (income) expense, net			$	11		$	(7	)
	For the company’s fair value hedges, equal and offsetting gain of $46 million and loss of $11 million was recognized in net interest expense in 2013 and 2012, respectively, as adjustments to the underlying hedged items, fixed-rate debt. Ineffectiveness related to the company’s cash flow and fair value hedges for the year ended December 31, 2013 was not material.
	The following table summarizes net-of-tax activity in AOCI, a component of shareholders’ equity, related to the company’s cash flow hedges.
	as of and for the years ended December 31 (in millions)	2013				2012			2011
	Accumulated other comprehensive (loss) income balance at beginning of year	$	(5	)		$	2		$	(3	)
	Gain (loss) in fair value of derivatives during the year		41				(7	)		(31	)
	Amount reclassified to earnings during the year		(26	)			—			36
	Accumulated other comprehensive income (loss) balance at end of year	$	10			$	(5	)	$	2
	As of December 31, 2013, $3 million of deferred, net after-tax gains on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings.
	Fair Values of Derivative Instruments
	The following table summarizes the classification and fair value amounts of derivative instruments reported in the consolidated balance sheet as of December 31, 2013.
		Derivatives in asset positions						Derivatives in liability positions
	(in millions)	Balance sheet location		Fair				Balance sheet location	Fair
				value					value
	Derivative instruments designated as hedges
		Other long-term assets		$	35			Other long-term liabilities	$	14
	Interest rate contracts
	Foreign exchange contracts	Prepaid expenses and other			37			Accounts payable		7
								and accrued liabilities
	Total derivative instruments designated as hedges			$	72				$	21
	Undesignated derivative instruments
	Foreign exchange contracts	Prepaid expenses and other		$	—			Accounts payable	$	1
								and accrued liabilities
	Total derivative instruments			$	72				$	22
	The following table summarizes the classification and fair value amounts of derivative instruments reported in the consolidated balance sheet as of December 31, 2012.
	Derivatives in asset positions						Derivatives in liability positions
(in millions)	Balance sheet location		Fair				Balance sheet location	Fair
			value					value
Derivative instruments designated as hedges
Interest rate contracts	Other long-term assets		$	67			Accounts payable and accrued liabilities	$	21
Foreign exchange contracts	Prepaid expenses and other			28			Accounts payable		5
							and accrued liabilities
Total derivative instruments designated as hedges			$	95				$	26
Undesignated derivative instruments
Foreign exchange contracts	Prepaid expenses and other		$	47			Accounts payable	$	11
							and accrued liabilities
Total derivative instruments			$	142				$	37
While the company’s derivatives are all subject to master netting arrangements, the company presents its assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, the company is not required to post collateral for any of its outstanding derivatives. The following table provides information on the company’s derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty:
	December 31, 2013							December 31, 2012
(in millions)	Asset				Liability			Asset			Liability
Gross amounts recognized in the consolidated balance sheet	$	72			$	22		$	142		$	37
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet		(17	)			(17	)		(37	)		(37	)
Total	$	55			$	5		$	105		$	—

Financial_Instruments_and_Rela

Financial Instruments and Related Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Financial Instruments and Related Fair Value Measurements	'
	NOTE 9
	FINANCIAL INSTRUMENTS AND RELATED FAIR VALUE MEASUREMENTS
	Receivable Securitizations
	For trade receivables originated in Japan, the company has entered into agreements with financial institutions in which the entire interest in and ownership of the receivable is sold. The company continues to service the receivables in its Japanese securitization arrangement. Servicing assets or liabilities are not recognized because the company receives adequate compensation to service the sold receivables. The Japanese securitization arrangement includes limited recourse provisions, which are not material.
	The following is a summary of the activity relating to the securitization arrangement.
	as of and for the years ended December 31 (in millions)		2013			2012			2011
	Sold receivables at beginning of year		$	157		$	160		$	157
	Proceeds from sales of receivables			506			630			615
	Cash collections (remitted to the owners of the receivables)			(519	)		(624	)		(622	)
	Effect of currency exchange rate changes			(30	)		(9	)		10
	Sold receivables at end of year		$	114		$	157		$	160
	The net losses relating to the sales of receivables were immaterial for each year.
	Concentrations of Credit Risk
	The company invests excess cash in certificates of deposit or money market funds and diversifies the concentration of cash among different financial institutions. With respect to financial instruments, where appropriate, the company has diversified its selection of counterparties, and has arranged collateralization and master-netting agreements to minimize the risk of loss.
	The company continues to do business with foreign governments in certain countries, including Greece, Spain, Portugal and Italy, that have experienced a deterioration in credit and economic conditions. As of December 31, 2013 and 2012, the company’s net accounts receivable from the public sector in Greece, Spain, Portugal and Italy totaled $561 million and $385 million, respectively, (of which $29 million and $66 million, respectively, related to Greece). The company’s net accounts receivable from the public sector for the countries identified above increased by $176 million during 2013 primarily as a result of the acquisition of Gambro. Refer to the discussion below for information regarding the Greek government bonds previously held by the company.
	Global economic conditions and liquidity issues in certain countries have resulted, and may continue to result, in delays in the collection of receivables and credit losses. Global economic conditions, governmental actions and customer-specific factors may require the company to re-evaluate the collectibility of its receivables and the company could potentially incur additional credit losses. These conditions may also impact the stability of the Euro.
	Fair Value Measurements
	The fair value hierarchy under the accounting standard for fair value measurements consists of the following three levels:
		•		Level 1 — Quoted prices in active markets that the company has the ability to access for identical assets or liabilities;
		•		Level 2 — Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuations in which all significant inputs are observable in the market; and
		•		Level 3 — Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability.
	The following tables summarize the bases used to measure financial assets and liabilities that are carried at fair value on a recurring basis in the consolidated balance sheets.
					Basis of fair value measurement
	(in millions)		Balance at		Quoted prices in	Significant other		Significant
			December 31,		active markets for	observable inputs		unobservable inputs
			2013		identical assets	(Level 2)		(Level 3)
					(Level 1)
	Assets
	Foreign currency hedges		$  37		$  —	$  37		$  —
	Interest rate hedges		35		—	35		—
	Available-for-sale securities
	Equity securities		102		102	—		—
	Foreign government debt securities		18		—	18		—
	Total assets		$192		$102	$  90		$  —
	Liabilities
	Foreign currency hedges		$    8		$  —	$8		$  —
	Interest rate hedges		14		—	14		—
	Contingent payments related to acquisitions		340		—	—		340
	and investments
	Total liabilities		$362		$  —	$  22		$340
					Basis of fair value measurement
	(in millions)		Balance at		Quoted prices in	Significant other		Significant
			December 31,		active markets for	observable inputs		unobservable inputs
			2012		identical assets	(Level 2)		(Level 3)
					(Level 1)
	Assets
	Foreign currency hedges		$  75		$  —	$  75		$  —
	Interest rate hedges		67		—	67		—
	Available-for-sale securities
	Equity securities		15		15	—		—
	Preferred Stock		51		—	—		51
	Foreign government debt securities		16		—	16		—
	Total assets		$224		$  15	$158		$  51
	Liabilities
	Foreign currency hedges		$  16		$  —	$  16		$  —
	Interest rate hedges		21		—	21		—
	Contingent payments related to acquisitions		86		—	—		86
	and investments
	Total liabilities		$123		$  —	$  37		$  86
	As of December 31, 2013, cash and equivalents of $2.7 billion included money market funds of approximately $568 million, which would be considered Level 2 in the fair value hierarchy.
	For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The majority of the derivatives entered into by the company are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs are considered observable and vary depending on the type of derivative, and include contractual terms, interest rate yield curves, foreign exchange rates and volatility. The fair values of foreign government debt securities are obtained from pricing services or broker/dealers who use proprietary pricing applications, which include observable market information for like or same securities. The preferred stock is valued based upon recent transactions, as well as the financial information of the investee.
	Contingent payments related to acquisitions consist of regulatory, development and commercial milestone payments, in addition to sales-based payments, and are valued using discounted cash flow techniques. The fair value of regulatory, development and commercial milestone payments reflects management’s expectations of probability of payment, and increases as the probability of payment increases or expectation of timing of payments is accelerated. As of December 31, 2013, management’s expected weighted-average probability of payment for regulatory, development and commercial milestone payments expected to occur was approximately 64%. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increase or expectation of timing of payment is accelerated.
	At December 31, 2013, the company held available-for-sale equity securities that had an amortized cost basis and fair value of $111 million and $102 million, respectively. The company had net unrealized losses of $9 million, comprised of unrealized losses of $31 million, which are temporary in nature, and unrealized gains of $22 million. At December 31, 2012, the amortized cost basis and fair value of the available-for-sale equity securities was $13 million and $15 million, respectively, with $2 million in cumulative unrealized gains. As of December 31, 2013 and 2012, the cumulative unrealized gains for the company’s available-for-sale debt securities were less than $1 million.
In July 2012, Baxter acquired approximately 3 million shares of Onconova preferred stock for $50 million, which the company classified as available-for-sale debt securities as a result of certain mandatory redemption rights held by Baxter. In 2013, Baxter reclassified the securities to available-for-sale equity securities as a result of the conversion of the preferred stock to common stock upon the completion of Onconova’s initial public offering.
The company recognized losses totaling $8 million in 2012 related to unrealized and realized losses associated with the company’s Greek government and European Financial Stability Facility bonds, which Baxter sold for $14 million in the second quarter of 2012.
In February 2012, as a result of the company’s acquisition of Synovis, the company acquired marketable securities, which included municipal securities, corporate bonds, and U.S. government agency issues, which had been classified as available-for-sale, with primarily all of these securities maturing within one year. The company received proceeds of $45 million from the sale and maturity of all of these securities in 2012.
Refer to Note 12 for fair value disclosures related to the company’s pension plans.
The following table is a reconciliation of the fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions and preferred stock.
(in millions)		Contingent			Preferred
		payments			stock
Fair value as of December 31, 2011		$	234		$	—
Purchases			—			50
Payments			(40	)		—
Gains recognized in earnings			(108	)		—
CTA			—			1
Fair value as of December 31, 2012			86			51
Purchases			269			—
Payments			(2	)		—
Net gains recognized in earnings			(17	)		—
CTA			4			—
Conversion to a publicly traded equity security			—			(51	)
Fair value as of December 31, 2013		$	340		$	—
The company’s additions in 2013 principally related to contingent payment liabilities of $269 million associated with the acquisition of the Inspiration / Ipsen OBI-1 business in the first quarter of 2013.
The company’s payments in 2012 principally related to milestones associated with the SIGMA agreement. The gains recognized in earnings in 2012 included $38 million related to the reduction of the contingent payment liabilities for certain milestones associated with ApaTech. In addition, 2012 includes a $53 million gain recognized in earnings related to a reduction of the contingent payment liabilities for certain milestones associated with the 2011 acquisition of Prism. These gains were reported in other (income) expense, net. The contingent liabilities were reduced based on updated information indicating that the probability of achieving certain milestones was lower than previously expected.
As discussed further in Note 6, the company recorded asset impairment charges related to its COLLEAGUE and SYNDEO infusion pumps and business optimization initiatives in 2013, 2012, and 2011. As these assets had no alternative use and no salvage value, the fair values, measured using significant unobservable inputs (Level 3), were assessed to be zero.
Book Values and Fair Values of Financial Instruments
In addition to the financial instruments that the company is required to recognize at fair value on the consolidated balance sheets, the company has certain financial instruments that are recognized at historical cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized on the consolidated balance sheets and the approximate fair values.
		Book values						Approximate
								fair values
as of December 31 (in millions)		2013			2012			2013			2012
Assets
Long-term insurance receivables		$	2		$	2		$	2		$	2
Investments			53			46			53			49
Liabilities
Short-term debt			181			27			181			27
Current maturities of long-term debt and lease obligations			859			323			862			324
Long-term debt and lease obligations			8,126			5,580			8,298			6,201
Long-term litigation liabilities			72			32			70			31
The following tables summarize the bases used to measure the approximate fair value of the financial instruments as of December 31, 2013 and 2012.
					Basis of fair value measurement
(in millions)		Balance as of			Quoted prices in			Significant other			Significant
		December 31,			active markets for			observable inputs			unobservable inputs
		2013			identical assets			(Level 2)			(Level 3)
					(Level 1)
Assets
Long-term insurance receivables		$	2		$	—		$	—		$	2
Investments			53			—			17			36
Total assets		$	55		$	—		$	17		$	38
Liabilities
Short-term debt		$	181		$	—		$	181		$	—
Current maturities of long-term debt and lease obligations			862			—			862			—
Long-term debt and lease obligations			8,298			—			8,298			—
Long-term litigation liabilities			70			—			—			70
Total liabilities		$	9,411		$	—		$	9,341		$	70
					Basis of fair value measurement
(in millions)		Balance as of			Quoted prices in			Significant other			Significant
		December 31,			active markets for			observable inputs			unobservable inputs
		2012			identical assets			(Level 2)			(Level 3)
					(Level 1)
Assets
Long-term insurance receivables		$	2		$	—		$	—		$	2
Investments			49			—			19			30
Total assets		$	51		$	—		$	19		$	32
Liabilities
Short-term debt		$	27		$	—		$	27		$	—
Current maturities of long-term debt and lease obligations			324			—			324			—
Long-term debt and lease obligations			6,201			—			6,201			—
Long-term litigation liabilities			31			—			—			31
Total liabilities		$	6,583		$	—		$	6,552		$	31
The estimated fair values of long-term insurance receivables and long-term litigation liabilities were computed by discounting the expected cash flows based on currently available information, which in many cases does not include final orders or settlement agreements. The discount factors used in the calculations reflect the non-performance risk of the insurance providers and the company, respectively.
Investments in 2013 and 2012 include certain cost method investments and held-to-maturity debt securities.
The fair value of held-to-maturity debt securities is calculated using a discounted cash flow model that incorporates observable inputs, including interest rate yields, which represents a Level 2 basis of fair value measurement. In determining the fair value of cost method investments, the company takes into consideration recent transactions, as well as the financial information of the investee, which represents a Level 3 basis of fair value measurement.
The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instrument. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with the company’s credit risk. The carrying values of the other financial instruments approximate their fair values due to the short-term maturities of most of these assets and liabilities.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies	'
	NOTE 10
	COMMITMENTS AND CONTINGENCIES
	Joint Development and Commercialization Arrangements
	As discussed in Note 1, the company has entered into certain collaborative arrangements which include contingent milestone payments. At December 31, 2013, the company’s unfunded contingent milestone payments associated with all of its arrangements totaled $2.0 billion. This total excludes any contingent royalties. Based on the company’s projections, any contingent payments made in the future will be more than offset over time by the estimated net future cash flows relating to the rights acquired for those payments. The majority of the contingent payments relate to arrangements in the BioScience segment and principally relate to the business development arrangements described in Note 4.
	Other Commitments
	In connection with the company’s initiative to invest in early-stage products and therapies, the company has unfunded commitments of $50 million as a limited partner in multiple investment companies as of December 31, 2013.
	Indemnifications
	During the normal course of business, Baxter makes indemnities, commitments and guarantees pursuant to which the company may be required to make payments related to specific transactions. Indemnifications include: (i) intellectual property indemnities to customers in connection with the use, sales or license of products and services; (ii) indemnities to customers in connection with losses incurred while performing services on their premises; (iii) indemnities to vendors and service providers pertaining to claims based on negligence or willful misconduct; and (iv) indemnities involving the representations and warranties in certain contracts. In addition, under Baxter’s Amended and Restated Certificate of Incorporation, and consistent with Delaware General Corporation Law, the company has agreed to indemnify its directors and officers for certain losses and expenses upon the occurrence of certain prescribed events. The majority of these indemnities, commitments and guarantees do not provide for any limitation on the maximum potential for future payments that the company could be obligated to make. To help address some of these risks, the company maintains various insurance coverages. Based on historical experience and evaluation of the agreements, the company does not believe that any significant payments related to its indemnities will occur, and therefore the company has not recorded any associated liabilities.
	Legal Contingencies
	Refer to Note 15 for a discussion of the company’s legal contingencies.

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2013
Shareholders' Equity	'
	NOTE 11
	SHAREHOLDERS’ EQUITY
	Stock-Based Compensation
	The company’s stock-based compensation generally includes stock options, restricted stock units (RSUs), performance share units (PSUs) and purchases under the company’s employee stock purchase plan. Shares issued relating to the company’s stock-based plans are generally issued out of treasury stock.
	In 2011, shareholders approved the Baxter International Inc. 2011 Incentive Plan which provides for 40 million additional shares of common stock available for issuance with respect to awards for participants. As of December 31, 2013, approximately 40 million authorized shares are available for future awards under the company’s stock-based compensation plans.
	Stock Compensation Expense
	Stock compensation expense recognized in the consolidated statements of income was $150 million, $130 million and $119 million in 2013, 2012 and 2011, respectively. The related tax benefit recognized was $45 million in 2013, $40 million in 2012 and $36 million in 2011.
	Stock compensation expense is recorded at the corporate level and is not allocated to a segment. Over 70% of stock compensation expense is classified in marketing and administrative expenses, with the remainder classified in cost of sales and R&D expenses. Costs capitalized in the consolidated balance sheets at December 31, 2013 and 2012 were not significant.
	Stock compensation expense is based on awards expected to vest, and therefore has been reduced by estimated forfeitures.
	Stock Options
	Stock options are granted to employees and non-employee directors with exercise prices at least equal to 100% of the market value on the date of grant. Stock options granted to employees generally vest in one-third increments over a three-year period. Stock options granted to non-employee directors generally cliff-vest 100% one year from the grant date. Stock options typically have a contractual term of 10 years. The grant-date fair value, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the substantive vesting period.
	The fair value of stock options is determined using the Black-Scholes model. The weighted-average assumptions used in estimating the fair value of stock options granted during each year, along with the weighted-average grant-date fair values, were as follows.
	years ended December 31	2013			2012		2011
	Expected volatility		25%			25%		25%
	Expected life (in years)		5.5			5.5		5
	Risk-free interest rate		0.90%			1.00%		2.20%
	Dividend yield		2.60%			2.30%		2.30%
	Fair value per stock option		$12			$10		$10
	Effective with the March 2012 annual stock compensation grants, the company’s expected volatility assumption is based on a weighted-average of the historical volatility of Baxter’s stock and the implied volatility from traded options on Baxter’s stock, with historical volatility more heavily weighted. Prior to the March 2012 grants, the expected volatility assumption was based on an equal weighting of the historical and implied volatilities. The expected life assumption is primarily based on the vesting terms of the stock option, historical employee exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield reflects historical experience as well as future expectations over the expected life of the option.
	The following table summarizes stock option activity for the year ended December 31, 2013 and stock option information at December 31, 2013.
	(options and aggregate intrinsic values in thousands)	Options			Weighted-		Weighted-average		Aggregate
					average		remaining		intrinsic
					exercise		contractual		value
					price		term (in years)
	Outstanding at January 1, 2013		32,055		$	52.62
	Granted		6,354			70.23
	Exercised		(8,517	)		50.15
	Forfeited		(679	)		62.26
	Expired		(84	)		40.26
	Outstanding at December 31, 2013		29,129		$	57		6.2	$	361,468
	Vested or expected to vest as of December 31, 2013		28,642		$	56.82		6.1	$	360,329
	Exercisable at December 31, 2013		17,732		$	52.64		4.7	$	293,590
	The aggregate intrinsic value in the table above represents the difference between the exercise price and the company’s closing stock price on the last trading day of the year. The total intrinsic value of options exercised was $176 million, $129 million and $102 million in 2013, 2012 and 2011, respectively.
	As of December 31, 2013, $58 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over a weighted-average period of approximately 1.6 years.
	RSUs
	RSUs are granted to employees and non-employee directors. RSUs granted to employees generally vest in one-third increments over a three-year period. RSUs granted to non-employee directors generally cliff-vest one year from the grant date. The grant-date fair value, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the substantive vesting period. The fair value of RSUs is determined based on the number of shares granted and the quoted price of the company’s common stock on the date of grant.
	The following table summarizes nonvested RSU activity for the year ended December 31, 2013.
	(share units in thousands)	Share units			Weighted-average
					grant-date
					fair value
	Nonvested RSUs at January 1, 2013		1,979		$55.36
	Granted		1,043		70.09
	Vested		(647	)	54.96
	Forfeited		(157	)	60.55
	Nonvested RSUs at December 31, 2013		2,218		$62.06
	As of December 31, 2013, $68 million of unrecognized compensation cost related to RSUs is expected to be recognized as expense over a weighted-average period of approximately 1.7 years. The weighted-average grant-date fair value of RSUs in 2013, 2012 and 2011 was $70.09, $57.03 and $53.87, respectively. The fair value of RSUs vested in 2013, 2012 and 2011 was $47 million, $21 million and $7 million, respectively.
	PSUs
	As part of an overall periodic evaluation of the company’s stock compensation programs, the company changed the vesting condition for 50% of the PSUs granted to senior management beginning with its 2013 annual equity awards. The vesting condition for the new PSUs is based on return on invested capital, with annual performance targets set at the beginning of the year for each tranche of the award during the three-year service period. The holder of the new PSUs is entitled to receive a number of shares of common stock equal to a percentage, ranging from 0% to 200%, of the PSUs granted, depending on the actual results compared to the annual performance targets.
	Compensation cost for the new PSUs is measured based on the fair value of the awards on the date that the specific vesting terms for each tranche of the award are established. The fair value of the awards is determined based on the quoted price of the company’s stock on the grant date for each tranche of the award. The compensation cost for these PSUs is adjusted at each reporting date to reflect the estimated probability of achieving the vesting condition. The probability of achieving the vesting condition has not materially changed during the year ended December 31, 2013.
	The remaining 50% of the PSUs continue to include conditions for vesting based on Baxter stock performance relative to the company’s peer group, similar to previous years, whereby a holder of these PSUs is entitled to receive a number of shares of common stock equal to a percentage, ranging from 0% to 200%, of these PSUs granted. The grant-date fair value, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the substantive vesting period.
	The fair value of the remaining PSUs continues to be determined using a Monte Carlo model. A Monte Carlo model uses stock price volatility and other variables to estimate the probability of satisfying the market conditions and the resulting fair value of the award. The assumptions used in estimating the fair value of these PSUs granted during the period, along with the grant-date fair values, were as follows.
	years ended December 31	2013			2012		2011
	Baxter volatility		21%			24%		28%
	Peer group volatility		13%-38%			14%-50%		19%-55%
	Correlation of returns		0.37-0.62			0.26-0.54		0.29-0.61
	Risk-free interest rate		0.30%			0.40%		1.20%
	Fair value per PSU		$67			$72		$62
	Unrecognized compensation cost related to all granted unvested PSUs of $15 million at December 31, 2013 is expected to be recognized as expense over a weighted-average period of 1.6 years.
	The following table summarizes nonvested PSU activity for the year ended December 31, 2013.
	(share units in thousands)	Share units			Weighted-average
					grant-date
					fair value
	Nonvested PSUs at January 1, 2013		804		$66.63
Granted		251		68.04
Vested		(387	)	61.62
Forfeited		(23	)	61.2
Nonvested PSUs at December 31, 2013		645		$70.18
Employee Stock Purchase Plan
Nearly all employees are eligible to participate in the company’s employee stock purchase plan. The employee purchase price is 85% of the closing market price on the purchase date.
In 2011, shareholders approved the Baxter International Inc. Employee Stock Purchase Plan which reflected the merger of the previous plans for U.S. and international employees. This employee stock purchase plan provides for 10 million shares of common stock available for issuance to eligible participants.
During 2013, 2012 and 2011, the company issued approximately 0.8 million, 0.9 million and 0.9 million shares, respectively, under the prior and current employee stock purchase plans. The number of shares under subscription at December 31, 2013 totaled approximately 1.0 million.
Realized Excess Income Tax Benefits and the Impact on the Statement of Cash Flows
Realized excess tax benefits associated with stock compensation are presented in the consolidated statement of cash flows as an outflow within the operating section and an inflow within the financing section. Realized excess tax benefits from stock-based compensation were $34 million, $24 million and $21 million in 2013, 2012 and 2011, respectively.
Cash Dividends
Total cash dividends declared per common share for 2013, 2012, and 2011 were $1.920, $1.570, and $1.265, respectively. In November 2013, the board of directors declared a quarterly dividend of $0.49 per share ($1.96 per share on an annualized basis), which was paid on January 3, 2014 to shareholders of record as of December 6, 2013.
In May 2013, the board of directors declared a quarterly dividend of $0.49 per share ($1.96 per share on an annualized basis), which represented an increase of 9% over the previous quarterly rate. In July 2012, the board of directors declared a quarterly dividend of $0.45 per share ($1.80 per share on an annualized basis), which represented an increase of 34% over the previous quarterly rate.
Stock Repurchase Programs
As authorized by the board of directors, the company repurchases its stock depending on the company’s cash flows, net debt level and market conditions. The company repurchased 13 million shares for $0.9 billion in 2013, 25 million shares for $1.5 billion in 2012, and 30 million shares for $1.6 billion in 2011. In July 2012, the board of directors authorized the repurchase of up to $2.0 billion of the company’s common stock and $1.0 billion remained available as of December 31, 2013.

Retirement_and_Other_Benefit_P

Retirement and Other Benefit Programs	12 Months Ended
	Dec. 31, 2013
Retirement and Other Benefit Programs	'
	NOTE 12
	RETIREMENT AND OTHER BENEFIT PROGRAMS
	The company sponsors a number of qualified and nonqualified pension plans for eligible employees. The company also sponsors certain unfunded contributory healthcare and life insurance benefits for substantially all domestic retired employees. Newly hired employees in the United States and Puerto Rico are not eligible to participate in the pension plans but receive a higher level of company contributions in the defined contribution plans. In September 2013, Baxter completed its acquisition of Gambro and assumed a net pension liability of approximately $212 million from Gambro-related pension plans, of which $209 million has been classified as a noncurrent liability. The Gambro pension plans were recorded at fair value on the date of acquisition and were re-measured at year-end as part of the company’s annual re-measurement of pension plan obligations and plan assets.
	On August 31, 2012, Baxter announced an offer to terminated-vested participants in the U.S. pension plan (approximately 16,000 participants) to pay a lump-sum payment which would fully settle the company’s pension plan obligation to these participants. The company offered the one-time voluntary lump-sum payment in an effort to reduce its long-term pension obligations and ongoing annual pension expense. The final acceptance rate by participants was approximately 50 percent, which resulted in a final payout of $377 million from plan assets in December 2012. The company recorded a non-cash settlement charge of $164 million in the fourth quarter of 2012 to immediately expense the unrealized actuarial losses related to the obligations that were settled, which were previously deferred in AOCI. The settlement charge was recognized in marketing and administrative expenses since the terminated-vested participants subject to the settlement were no longer contributing to the activities of the company.
	Reconciliation of Pension and Other Postemployment Benefits (OPEB) Plan Obligations, Assets and Funded Status
	The benefit plan information in the table below pertains to all of the company’s pension and OPEB plans, both in the United States and in other countries.
			Pension benefits						OPEB
	as of and for the years ended December 31 (in millions)		2013			2012			2013			2012
	Benefit obligations
	Beginning of period		$	5,364		$	4,944		$	650		$	618
	Service cost			137			110			10			7
	Interest cost			207			235			26			29
	Participant contributions			9			9			11			14
	Actuarial (gain)/loss			(350	)		652			(99	)		18
	Benefit payments			(203	)		(196	)		(34	)		(36	)
	Settlements			(4	)		(387	)		—			—
	Acquisition			220			—			—			—
	Foreign exchange and other			45			(3	)		—			—
	End of period			5,425			5,364			564			650
	Fair value of plan assets
	Beginning of period			3,642			3,673			—			—
	Actual return on plan assets			464			464			—			—
	Employer contributions			67			78			23			22
	Participant contributions			9			9			11			14
	Benefit payments			(203	)		(196	)		(34	)		(36	)
	Settlements			(4	)		(387	)		—			—
	Acquisition			8			—			—			—
	Foreign exchange and other			17			1			—			—
	End of period			4,000			3,642			—			—
	Funded status at December 31		$	(1,425	)	$	(1,722	)	$	(564	)	$	(650	)
	Amounts recognized in the consolidated balance sheets
	Noncurrent asset		$	50		$	38		$	—		$	—
	Current liability			(29	)		(19	)		(24	)		(25	)
	Noncurrent liability			(1,446	)		(1,741	)		(540	)		(625	)
	Net liability recognized at December 31		$	(1,425	)	$	(1,722	)	$	(564	)	$	(650	)
	Accumulated Benefit Obligation Information
	The pension obligation information in the table above represents the projected benefit obligation (PBO). The PBO incorporates assumptions relating to future compensation levels. The accumulated benefit obligation (ABO) is the same as the PBO except that it includes no assumptions relating to future compensation levels. The ABO for all of the company’s pension plans was $5.00 billion and $4.95 billion at the 2013 and 2012 measurement dates, respectively.
	The information in the funded status table above represents the totals for all of the company’s pension plans. The following is information relating to the individual plans in the funded status table above that have an ABO in excess of plan assets.
	as of December 31 (in millions)		2013			2012
	ABO		$	4,780		$	4,816
	Fair value of plan assets			3,710			3,452
	The following is information relating to the individual plans in the funded status table above that have a PBO in excess of plan assets (many of which also have an ABO in excess of assets, and are therefore also included in the table directly above).
	as of December 31 (in millions)		2013			2012
	PBO		$	5,260		$	5,211
	Fair value of plan assets			3,785			3,452
	Expected Net Pension and OPEB Plan Payments for the Next 10 Years
	(in millions)		Pension			OPEB
			benefits
	2014		$	219		$	24
	2015			231			27
	2016			243			28
	2017			261			30
	2018			275			32
	2019 through 2023			1,608			172
	Total expected net benefit payments for next 10 years		$	2,837		$	313
	The expected net benefit payments above reflect the company’s share of the total net benefits expected to be paid from the plans’ assets (for funded plans) or from the company’s assets (for unfunded plans). The total expected OPEB benefit payments for the next ten years are net of approximately $49 million of expected federal subsidies relating to the Medicare Prescription Drug, Improvement and Modernization Act, including $3 million, $4 million, $4 million, $4 million and $5 million in each of the years 2014, 2015, 2016, 2017 and 2018, respectively.
	Amounts Recognized in AOCI
	The pension and OPEB plans’ gains or losses, prior service costs or credits, and transition assets or obligations not yet recognized in net periodic benefit cost are recognized on a net-of-tax basis in AOCI and will be amortized from AOCI to net periodic benefit cost in the future.
	The following is a summary of the pre-tax losses included in AOCI at December 31, 2013 and December 31, 2012.
	(in millions)		Pension			OPEB
			benefits
	Actuarial loss		$	1,455		$	55
	Prior service cost (credit) and transition obligation			—			(1	)
Total pre-tax loss recognized in AOCI at December 31, 2013		$	1,455		$	54
Actuarial loss		$	2,247		$	163
Prior service cost (credit) and transition obligation			1			(1	)
Total pre-tax loss recognized in AOCI at December 31, 2012		$	2,248		$	162
Refer to Note 13 for the net-of-tax balances included in AOCI as of each of the year-end dates. The following is a summary of the net-of-tax amounts recorded in OCI relating to pension and OPEB plans.
years ended December 31 (in millions)		2013			2012			2011
Gain (charge) arising during the year, net of tax expense (benefit) of $221 in 2013, ($143) in 2012 and ($214) in 2011		$	426		$	(353	)	$	(375	)
Settlement charge, net of tax expense of $65 in 2012			—			103			—
Amortization of loss to earnings, net of tax expense of $88 in 2013, $77 in 2012 and $63 in 2011			166			139			112
Pension and other employee benefits gain (charge)		$	592		$	(111	)	$	(263	)
Due to the settlement of certain of the company’s pension obligations in 2012, $168 million ($103 million on an after-tax basis) of prior unrecognized actuarial losses have been recognized from AOCI into the company’s earnings. The impact of the settlement on AOCI was more than offset by the prior year actuarial losses. In 2013, the OCI activity for pension and OPEB plans related almost entirely to actuarial losses. Activity relating to prior service costs and credits and transition obligations was insignificant.
Amounts Expected to be Amortized From AOCI to Net Periodic Benefit Cost in 2014
With respect to the AOCI balance at December 31, 2013, the following is a summary of the pre-tax amounts expected to be amortized to net periodic benefit cost in 2014.
(in millions)		Pension			OPEB
		benefits
Actuarial loss		$	144		$	—
Prior service cost (credit) and transition obligation			—			—
Total pre-tax amount expected to be amortized from AOCI to net pension and OPEB cost in 2014		$	144		$	—
Net Periodic Benefit Cost
years ended December 31 (in millions)		2013			2012			2011
Pension benefits
Service cost		$	137		$	110		$	112
Interest cost			207			235			237
Expected return on plan assets			(254	)		(288	)		(303	)
Amortization of net losses and other deferred amounts			245			209			177
Settlement losses			1			168			—
Net periodic pension benefit cost		$	336		$	434		$	223
OPEB
Service cost		$	10		$	7		$	6
Interest cost			26			29			28
Amortization of net loss and prior service credit			9			7			(2	)
Net periodic OPEB cost		$	45		$	43		$	32
Weighted-Average Assumptions Used in Determining Benefit Obligations at the Measurement Date
		Pension benefits						OPEB
		2013			2012			2013			2012
Discount rate
U.S. and Puerto Rico plans			4.85%			3.95%			4.90%			4.00%
International plans			3.41%			3.19%			n/a			n/a
Rate of compensation increase
U.S. and Puerto Rico plans			3.80%			4.50%			n/a			n/a
International plans			3.29%			3.51%			n/a			n/a
Annual rate of increase in the per-capita cost			n/a			n/a			6.25%			6.50%
Rate decreased to			n/a			n/a			5.00%			5.00%
by the year ended			n/a			n/a			2019			2019
The assumptions above, which were used in calculating the December 31, 2013 measurement date benefit obligations, will be used in the calculation of net periodic benefit cost in 2014.
Weighted-Average Assumptions Used in Determining Net Periodic Benefit Cost
		Pension benefits									OPEB
		2013			2012			2011			2013			2012		2011
Discount rate
U.S. and Puerto Rico plans			3.95%			4.80%			5.45%			4.00%			4.75%		5.40%
International plans			3.19%			4.48%			4.57%			n/a			n/a		n/a
Expected return on plan assets
U.S. and Puerto Rico plans			7.50%			7.75%			8.25%			n/a			n/a		n/a
International plans			6.33%			6.85%			7.29%			n/a			n/a		n/a
Rate of compensation increase
U.S. and Puerto Rico plans			4.50%			4.50%			4.50%			n/a			n/a		n/a
International plans			3.51%			3.54%			3.57%			n/a			n/a		n/a
Annual rate of increase in the per-capita cost			n/a			n/a			n/a			6.50%			7.00%		7.50%
Rate decreased to			n/a			n/a			n/a			5.00%			5.00%		5.00%
by the year ended			n/a			n/a			n/a			2019			2016		2016
The company establishes the expected return on plan assets assumption primarily based on a review of historical compound average asset returns, both company-specific and relating to the broad market (based on the company’s asset allocation), as well as an analysis of current market and economic information and future expectations. The company plans to use a 7.50% assumption for its U.S. and Puerto Rico plans for 2014.
Effect of a One-Percent Change in Assumed Healthcare Cost Trend Rate on the OPEB Plan
		One percent						One percent
		increase						decrease
years ended December 31 (in millions)		2013			2012			2013			2012
Effect on total of service and interest cost components of OPEB cost		$	6		$	5		$	(5	)	$	(4	)
Effect on OPEB obligation		$	74		$	92		$	(61	)	$	(74	)
Pension Plan Assets
An investment committee of members of senior management is responsible for supervising, monitoring and evaluating the invested assets of the company’s funded pension plans. The investment committee, which meets at least quarterly, abides by documented policies and procedures relating to investment goals, targeted asset allocations, risk management practices, allowable and prohibited investment holdings, diversification, use of derivatives, the relationship between plan assets and benefit obligations, and other relevant factors and considerations.
The investment committee’s documented policies and procedures include the following:
	•		Ability to pay all benefits when due;
	•		Targeted long-term performance expectations relative to applicable market indices, such as Standard & Poor’s, Russell, MSCI EAFE, and other indices;
	•		Targeted asset allocation percentage ranges (summarized below), and periodic reviews of these allocations;
	•		Diversification of assets among third-party investment managers, and by geography, industry, stage of business cycle and other measures;
	•		Specified investment holding and transaction prohibitions (for example, private placements or other restricted securities, securities that are not traded in a sufficiently active market, short sales, certain derivatives, commodities and margin transactions);
	•		Specified portfolio percentage limits on holdings in a single corporate or other entity (generally 5%, except for holdings in U.S. government or agency securities);
	•		Specified average credit quality for the fixed-income securities portfolio (at least A- by Standard & Poor’s or A3 by Moody’s);
	•		Specified portfolio percentage limits on foreign holdings; and
	•		Periodic monitoring of investment manager performance and adherence to the investment committee’s policies.
Plan assets are invested using a total return investment approach whereby a mix of equity securities, debt securities and other investments are used to preserve asset values, diversify risk and exceed the planned benchmark investment return. Investment strategies and asset allocations are based on consideration of plan liabilities, the plans’ funded status and other factors, such as the plans’ demographics and liability durations. Investment performance is reviewed by the investment committee on a quarterly basis and asset allocations are reviewed at least annually.
Plan assets are managed in a balanced portfolio comprised of two major components: equity securities and fixed income securities. The target allocations for plan assets are 60 percent in equity securities and 40 percent in fixed income securities and other holdings. The documented policy includes an allocation range based on each individual investment type within the major components that allows for a variance from the target allocations of approximately 5 percentage points. Equity securities primarily include common stock of U.S. and international companies, common/collective trust funds, mutual funds, and partnership investments. Fixed income securities and other holdings primarily include cash, money market funds with an original maturity of three months or less, U.S. and foreign government and governmental agency issues, corporate bonds, municipal securities, hedge funds, derivative contracts and asset-backed securities.
While the investment committee provides oversight over plan assets for U.S. and international plans, the summary above is specific to the plans in the United States. The plan assets for international plans are managed and allocated by the entities in each country, with input and oversight provided by the investment committee. The plan assets for the U.S. and international plans are included in the table below.
The following tables summarize the bases used to measure the pension plan assets and liabilities that are carried at fair value on a recurring basis.
										Basis of fair value measurement
(in millions)								Balance at		Quoted prices in	Significant other		Significant
								December 31, 2013		active markets for	observable inputs		unobservable
										identical assets	(Level 2)		inputs
										(Level 1)			(Level 3)
Assets
Fixed income securities
Cash and cash equivalents								$   267		$     24	$   243		$     —
U.S. government and government agency issues								287		—	287		—
Corporate bonds								637		—	637		—
Equity securities
Common stock:
Large cap								974		974	—		—
Mid cap								442		442	—		—
Small cap								93		93	—		—
							Total common stock	1,509		1,509	—		—
Mutual funds								381		180	201		—
Common/collective trust funds								617		—	612		5
Partnership investments								199		—	—		199
Other holdings								103		10	91		2
Collateral held on loaned securities								248		—	248		—
Liabilities
Collateral to be paid on loaned securities								-248		-88	-160		—
Fair value of pension plan assets								$4,000		$1,635	$2,159		$   206
										Basis of fair value measurement
(in millions)								Balance at		Quoted prices in	Significant other		Significant
								December 31, 2012		active markets for	observable inputs		unobservable
										identical assets	(Level 2)		inputs
										(Level 1)			(Level 3)
Assets
Fixed income securities
Cash and cash equivalents								$   324		$   210	$   114		$     —
U.S. government and government agency issues								252		—	252		—
Corporate bonds								657		—	657		—
Equity securities
Common stock:
Large cap								807		807	—		—
Mid cap								426		426	—		—
Small cap								121		121	—		—
							Total common stock	1,354		1,354	—		—
Mutual funds								317		143	174		—
Common/collective trust funds								467		—	462		5
Partnership investments								180		—	—		180
Other holdings								91		8	81		2
Collateral held on loaned securities								168		—	168		—
Liabilities
Collateral to be paid on loaned securities								-168		-60	-108		—
Fair value of pension plan assets								$3,642		$1,655	$1,800		$   187
The following is a reconciliation of changes in fair value measurements that used significant unobservable inputs (Level 3).
(in millions)		Total			Common/collective			Partnership			Other holdings
					trust funds			investments
Balance at December 31, 2011		$	176		$	4		$	170		$	2
Actual return on plan assets still held at year end			12			1			11			—
Actual return on plan assets sold during the year			—			—			—			—
Purchases, sales and settlements			(1	)		—			(1	)		—
Balance at December 31, 2012			187			5			180			2
Actual return on plan assets still held at year end			8			—			8			—
Actual return on plan assets sold during the year			—			—			—			—
Purchases, sales and settlements			11			—			11			—
Balance at December 31, 2013		$	206		$	5		$	199		$	2
The assets and liabilities of the company’s pension plans are valued using the following valuation methods:
Investment category		Valuation methodology
Cash and cash equivalents		These largely consist of a short-term investment fund, U.S. Dollars and foreign currency. The fair value of the short-term investment fund is based on the net asset value
U.S. government and government agency issues		Values are based on reputable pricing vendors, who typically use pricing matrices or models that use observable inputs
Corporate bonds		Values are based on reputable pricing vendors, who typically use pricing matrices or models that use observable inputs
Common stock		Values are based on the closing prices on the valuation date in an active market on national and international stock exchanges
Mutual funds		Values are based on the net asset value of the units held in the respective fund which are obtained from national and international exchanges or based on the net asset value of the underlying assets of the fund provided by the fund manager
Common/collective trust funds		Values are based on the net asset value of the units held at year end
Partnership investments		Values are based on the estimated fair value of the participation by the company in the investment as determined by the general partner or investment manager of the respective partnership
Other holdings		The value of these assets vary by investment type, but primarily are determined by reputable pricing vendors, who use pricing matrices or models that use observable inputs
Collateral held on loaned securities		Values are based on the net asset value per unit of the fund in which the collateral is invested
Collateral to be paid on loaned securities		Values are based on the fair value of the underlying securities loaned on the valuation date
Expected Pension and OPEB Plan Funding
The company’s funding policy for its pension plans is to contribute amounts sufficient to meet legal funding requirements, plus any additional amounts that the company may determine to be appropriate considering the funded status of the plans, tax deductibility, the cash flows generated by the company, and other factors. Volatility in the global financial markets could have an unfavorable impact on future funding requirements. The company has no obligation to fund its principal plans in the United States in 2014. The company continually reassesses the amount and timing of any discretionary contributions. The company expects to make cash contributions to its pension plans of at least $42 million in 2014, primarily related to the company’s international plans. The company expects to have net cash outflows relating to its OPEB plan of approximately $25 million in 2014.
The table below details the funded status percentage of the company’s pension plans as of December 31, 2013, including certain plans that are unfunded in accordance with the guidelines of the company’s funding policy outlined above.
		United States and Puerto Rico						International
as of December 31, 2013 (in millions)		Qualified			Nonqualified			Funded			Unfunded			Total
		plans			plan			plans			plans
Fair value of plan assets		$	3,253			n/a		$	747			n/a		$	4,000
PBO			3,750		$	191			1,152		$	332			5,425
Funded status percentage			87%			n/a			65%			n/a			74%
U.S. Defined Contribution Plan
Most U.S. employees are eligible to participate in a qualified defined contribution plan. Company contributions were $45 million in 2013, $39 million in 2012 and $37 million in 2011.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	12 Months Ended
	Dec. 31, 2013
Accumulated Other Comprehensive Income	'
	NOTE 13
	ACCUMULATED OTHER COMPREHENSIVE INCOME
	Comprehensive income includes all changes in shareholders’ equity that do not arise from transactions with shareholders, and consists of net income, currency translation adjustments (CTA), pension and other employee benefits, unrealized gains and losses on cash flow hedges and unrealized gains and losses on unrestricted available-for-sale marketable equity securities. The following is a net-of-tax summary of the changes in AOCI by component for the year ended December 31, 2013.
	(in millions)		Currency			Pension and			Hedging			Other			Total
			translation			other employee			activities
			adjustments			benefits
	Gains (losses)
	Balance as of December 31, 2012		($	1,227	)	($	1,619	)		($5	)	$	41		($	2,810	)
	Other comprehensive income (loss) before reclassifications			236			426			41			(13	)		690
	Amounts reclassified from AOCI(a)			—			166			(26	)		4			144
	Net other comprehensive income (loss)			236			592			15			(9	)		834
	Balance as of December 31, 2013		($	991	)	($	1,027	)		$10		$	32		($	1,976	)
	(a)	See table below for details about the reclassifications for the year ended December 31, 2013.
	The following is a summary of the amounts reclassified from AOCI to net income during the year ended December 31, 2013.
			Adjustments reclassified
			from AOCI (a)
	(in millions)		2013			Location of impact in income statement
	Amortization of pension and other employee benefits items
	Actuarial losses and other		($	254)	(b)
				(254	)	Total before tax
				88		Tax benefit
			($	166	)	Net of tax
	Gains (losses) on hedging activities
	Interest rate contracts		$	10		Net interest expense
	Foreign exchange contracts			(1	)	Net sales
	Foreign exchange contracts			32		Cost of sales
				41		Total before tax
				(15	)	Tax expense
			$	26		Net of tax
	Other
	Other-than-temporary impairment of available-for-sale equity securities		$	(6	)	Other (income) expense, net
				(6	)	Total before tax
				2		Tax benefit
				(4	)	Net of tax
	Total reclassification for the period		($	144	)	Total net of tax
	(a)	Amounts in parentheses indicate reductions to net income.
	(b)	These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 12.
	Refer to Note 12 for additional information regarding the amortization of pension and other employee benefits items and Note 8 for additional information regarding hedging activity.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
	NOTE 14
	INCOME TAXES
	Income Before Income Tax Expense by Category
	years ended December 31 (in millions)	2013			2012			2011
	United States	$	446		$	386		$	399
	International		2,103			2,503			2,410
	Income before income taxes	$	2,549		$	2,889		$	2,809
	Income Tax Expense
	years ended December 31 (in millions)	2013			2012			2011
	Current
	United States
	Federal	$	296		$	122		$	75
	State and local		28			55			32
	International		437			403			274
	Current income tax expense		761			580			381
	Deferred
	United States
	Federal		(147	)		112			155
	State and local		(5	)		(81	)		(6	)
	International		(72	)		(48	)		23
	Deferred income tax (benefit) expense		(224	)		(17	)		172
	Income tax expense	$	537		$	563		$	553
	Deferred Tax Assets and Liabilities
	as of December 31 (in millions)	2013			2012
	Deferred tax assets
	Accrued expenses	$	426		$	171
	Retirement benefits		669			804
	Tax credits and net operating losses		426			169
	Valuation allowances		(137	)		(104	)
	Total deferred tax assets		1,384			1,040
	Deferred tax liabilities
	Subsidiaries’ unremitted earnings		265			222
	Asset basis differences		849			294
	Total deferred tax liabilities		1,114			516
	Net deferred tax asset	$	270		$	524
	At December 31, 2013, the company had U.S. operating loss carryforwards totaling $142 million, of which approximately $125 million were acquired from Gambro. The U.S. operating loss carryforwards expire between 2014 and 2032. At December 31, 2013, the company had foreign operating loss carryforwards totaling $1.3 billion, of which $992 million were acquired from Gambro, and foreign tax credit carryforwards totaling $65 million. Of these foreign amounts, $8 million expires in 2014, $4 million expires in 2015, $31 million expires in 2016, $49 million expires in 2017, $37 million expires in 2018, $2 million expires in 2019, $100 million expires after 2019 and $1.1 billion has no expiration date. Realization of these operating loss and tax credit carryforwards depends on generating sufficient taxable income in future periods. A valuation allowance of $137 million and $104 million was recorded at December 31, 2013 and 2012, respectively, to reduce the deferred tax assets associated with net operating loss and tax credit carryforwards, because the company does not believe it is more likely than not that these assets will be fully realized prior to expiration. The company will continue to evaluate the need for additional valuation allowances and, as circumstances change, the valuation allowance may change.
	Income Tax Expense Reconciliation
	years ended December 31 (in millions)	2013			2012			2011
	Income tax expense at U.S. statutory rate	$	892		$	1,011		$	983
	Tax incentives		(240	)		(277	)		(360	)
	State and local taxes		22			(11	)		25
	Foreign tax benefit		(122	)		(177	)		(118	)
	Contingent tax matters		26			30			39
	Other factors		(41	)		(13	)		(16	)
	Income tax expense	$	537		$	563		$	553
	The company recognized deferred US income tax expense of $47 million during 2013 relating to 2013 earnings outside the United States that are not deemed indefinitely reinvested. The company continues to evaluate whether to indefinitely reinvest earnings in certain foreign jurisdictions as it continues to analyze the company’s global financial structure. Currently, management intends to continue to reinvest past earnings in several jurisdictions outside of the United States indefinitely, particularly due to the company’s acquisition of Gambro which used substantial foreign cash, and therefore has not recognized U.S. income tax expense on these earnings. U.S. federal and state income taxes, net of applicable credits, on these foreign unremitted earnings of $12.2 billion as of December 31, 2013 would be approximately $3.8 billion. As of December 31, 2012 the foreign unremitted earnings and U.S. federal and state income tax amounts were $10.6 billion and $3.4 billion, respectively.
	Effective Income Tax Rate
	The effective income tax rate was 21% in 2013 and 20% in both 2012 and 2011. As detailed in the income tax expense reconciliation table above, the company’s effective tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate. In addition, the effective tax rate can be impacted each period by discrete factors and events.
	Factors impacting the company’s effective tax rate in 2013 included the favorable settlement of the company’s bilateral Advance Pricing Agreement proceedings between the U.S. government and the government of Switzerland with respect to intellectual property, product, and service transfer pricing arrangements, which was offset by other contingent tax matters principally related to transfer pricing. Additionally, the effective tax rate was unfavorably impacted by increases in valuation allowances in respect of the tax benefit from losses that the company does not believe that it is more likely than not to realize and interest expense related to the company’s unrecognized tax benefits. Partially offsetting these unfavorable items were $16 million of U.S. R&D credits. Additionally, the company’s effective tax rate was impacted by a change in the earnings mix from lower tax to higher tax rate jurisdictions compared to the prior year.
	Factors impacting the company’s effective tax rate in 2012 were gains of $53 million and $38 million for the reduction of certain contingent payment liabilities related to the prior acquisitions of Prism and ApaTech, respectively, for which there were no tax charges. Also impacting the effective tax rate was a cost of sales reduction of $37 million for an adjustment to the COLLEAGUE infusion pump reserves when the company substantially completed the recall in the United States in 2012, for which there was no tax charge. These items were offset by a change in the earnings mix from lower tax to higher tax rate jurisdictions compared to the prior year period.
	Factors impacting the company’s effective tax rate in 2011 were tax benefits from the business optimization charge, the average wholesale price (AWP) litigation and historical price reporting charge, and other charges in 2011 which were incurred in jurisdictions with rates higher than the effective rate.
	Unrecognized Tax Benefits
	The company classifies interest and penalties associated with income taxes in the income tax expense line in the consolidated statements of income. Net interest and penalties recorded during 2013, 2012 and 2011 were $1 million, $12 million and $18 million, respectively. The liability recorded at December 31, 2013 and 2012 related to interest and penalties was $124 million and $103 million, respectively.
	The following is a reconciliation of the company’s unrecognized tax benefits for the years ended December 31, 2013, 2012 and 2011.
	as of and for the years ended (in millions)	2013			2012			2011
	Balance at beginning of the year	$	437		$	443		$	423
	Increase associated with tax positions taken during the current year		31			25			37
	Increase (decrease) associated with tax positions taken during a prior year		38			(9	)		15
	Settlements		(216	)		(21	)		(18	)
	Decrease associated with lapses in statutes of limitations		(3	)		(1	)		(14	)
	Balance at end of the year	$	287		$	437		$	443
	Of the gross unrecognized tax benefits, $393 million and $517 million were recognized as liabilities in the consolidated balance sheets as of December 31, 2013 and 2012, respectively.
	None of the positions included in the liability for uncertain tax positions related to tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility.
Tax Incentives
The company has received tax incentives in Puerto Rico, Switzerland, and certain other taxing jurisdictions outside the United States. The financial impact of the reductions as compared to the statutory tax rates is indicated in the income tax expense reconciliation table above. The tax reductions as compared to the local statutory rate favorably impacted earnings per diluted share by $0.44 in 2013, $0.50 in 2012 and $0.56 in 2011. The Puerto Rico grant provides that the company’s manufacturing operations are and will be partially exempt from local taxes until the year 2018. The Switzerland grant provides that the company’s manufacturing operations will be partially exempt from local taxes until the year 2014, at which time the tax rate will be approximately 8%. As a result of a restructuring of the company’s Swiss legal entities in 2013, the effective tax rate on manufacturing operation in Switzerland will be under 1% for several years after 2013.
Examinations of Tax Returns
As of December 31, 2013, Baxter had ongoing audits in the United States, Germany, Austria, Italy, Turkey, and other jurisdictions. Baxter expects to reduce the amount of its liability for uncertain tax positions within the next 12 months by $75 million due principally to the resolution of tax disputes in Sweden and Turkey. While the final outcome of these matters is inherently uncertain, the company believes it has made adequate tax provisions for all years subject to examination.

Legal_Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2013
Legal Proceedings	'
	NOTE 15
	LEGAL PROCEEDINGS
	Baxter is involved in product liability, patent, commercial, and other legal matters that arise in the normal course of the company’s business. The company records a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of December 31, 2013, the company’s total recorded reserves with respect to legal matters were $160 million and the total related receivables were $7 million.
	Baxter has established reserves for certain of the matters discussed below. The company is not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While the liability of the company in connection with the claims cannot be estimated with any certainty and although the resolution in any reporting period of one or more of these matters could have a significant impact on the company’s results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on the company’s consolidated financial position. While the company believes that it has valid defenses in these matters, litigation is inherently uncertain, excessive verdicts do occur, and the company may incur material judgments or enter into material settlements of claims.
	In addition to the matters described below, the company remains subject to other potential administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on the company’s operations and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, the company may be exposed to significant litigation concerning the scope of the company’s and others’ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations.
	General litigation
	Baxter is a defendant in a number of suits alleging that certain of the company’s current and former executive officers and its board of directors failed to adequately oversee the operations of the company and issued materially false and misleading statements regarding the company’s plasma-based therapies business, the company’s remediation of its COLLEAGUE infusion pumps, its heparin product, and other quality issues. Plaintiffs allege these actions damaged the company and its shareholders by resulting in a decline in stock price in the second quarter of 2010, payment of excess compensation to the board of directors and certain of the company’s current and former executive officers, and other damage to the company. In August 2013, the U.S. Court of Appeals for the Seventh Circuit reinstated a consolidated derivative suit filed in the U.S.D.C. for the Northern District of Illinois that had earlier been dismissed by the district court in September 2012. In January 2014, an independent special litigation committee was established by the company’s board of directors to determine whether it is in the best interests of the company and its shareholders to pursue or otherwise resolve the claims raised in and arising from this matter. Two other derivative actions have been filed in state court: one pending in the Circuit Court of Lake County, Illinois has been stayed pending the outcome of the federal action and another, in Delaware Chancery Court, that Baxter has moved to dismiss. In addition, a consolidated alleged class action is pending in the U.S.D.C. for the Northern District of Illinois against the company and certain of its current executive officers seeking to recover the lost value of investors’ stock and the parties are currently proceeding with discovery. In April 2013, the company filed its opposition to the plaintiff’s motion to certify a class action.
	The company is a defendant, along with others, in a number of lawsuits consolidated for pretrial proceedings in the U.S.D.C. for the Northern District of Illinois alleging that Baxter and certain of its competitors conspired to restrict output and artificially increase the price of plasma-derived therapies since 2003. Some of the complaints attempt to state a claim for class action relief and some cases demand treble damages. In January 2012, the court granted the company’s motion to dismiss certain federal claims brought by indirect purchasers and returned the remaining indirect purchaser claims to the court of original jurisdiction (U.S.D.C. for the Northern District of California) in August 2012. The indirect purchaser complaint was amended to remove class action allegations in May 2013. In January 2014, the company provisionally settled with the direct purchaser plaintiffs for $64 million, pending final approval of the settlement by the court which is anticipated in the first half of 2014. As of December 31, 2013, the company has a litigation reserve to cover the settlement.
	Product liability litigation
	In connection with the recall of heparin products in the United States, approximately 30 lawsuits remain pending alleging that plaintiffs suffered various reactions to a heparin contaminant, in some cases resulting in fatalities. The majority of these cases are subject to settlement agreements but remain pending while settlement documentation is being completed.
	Other
	The company was the recipient of an inquiry from the U.S. Department of Justice (DOJ) and the SEC that was part of a broader review of industry practices for compliance with the U.S. Foreign Corrupt Practices Act. In January 2014, the company was notified by both the DOJ and the SEC that their respective investigations were closed as to Baxter without any further action taken by either agency.
	In the fourth quarter of 2012, the company received two investigative demands from the United States Attorney for the Western District of North Carolina for information regarding its quality and manufacturing practices and procedures at its North Cove facility. The company is fully cooperating with this investigation.

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2013
Segment Information	'
	NOTE 16
	SEGMENT INFORMATION
	Baxter’s two segments, BioScience and Medical Products, are strategic businesses that are managed separately because each business develops, manufactures and markets distinct products and services. The segments and a description of their products and services are as follows:
	The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines.
	The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. Baxter enhanced its leadership in renal therapies with the acquisition of Gambro and now offers a comprehensive portfolio to meet the needs of patients across the treatment continuum. The portfolio includes innovative technologies and therapies for peritoneal dialysis (PD), in-center hemodialysis (HD), home hemodialysis (HHD), continuous renal replacement therapy (CRRT) and additional dialysis services.
	Also included in the Medical Products business are revenues and costs related to the manufacturing, distribution and other transition agreements with Fenwal Inc. associated with the 2007 divestiture of the Transfusion Therapies business. Post-divestiture revenues associated with these transition agreements had been reported at the corporate level (Corporate) and not allocated to a segment prior to January 1, 2012. The prior period segment presentation has been recast to conform to the current period presentation.
	The company uses more than one measurement and multiple views of data to measure segment performance and to allocate resources to the segments. However, the dominant measurements are consistent with the company’s consolidated financial statements and, accordingly, are reported on the same basis in this report. The company evaluates the performance of its segments and allocates resources to them primarily based on pre-tax income along with cash flows and overall economic returns. Intersegment sales are generally accounted for at amounts comparable to sales to unaffiliated customers, and are eliminated in consolidation. The accounting policies of the segments are substantially the same as those described in the summary of significant accounting policies in Note 1.
	Effective in 2012, the segment measures of total assets and capital expenditures reflect a re-allocation of certain assets between segments to reflect management’s use of updated segment measures to allocate resources. The prior period presentation has been recast to conform to the current period presentation. The impact on the segment measures in prior periods was a shift between Medical Products and BioScience of $988 million and $25 million for total assets and capital expenditures in 2011, respectively. The company considered the impact of this re-allocation on the goodwill impairment reviews completed in prior years and there was no impact as the fair values of the company’s reporting units were substantially in excess of the carrying values.
	Certain items are maintained at Corporate and are not allocated to a segment. They primarily include most of the company’s debt and cash and equivalents and related net interest expense, certain foreign exchange fluctuations (principally relating to intercompany receivables, payables and loans denominated in a foreign currency) and the majority of the foreign currency hedging activities, corporate headquarters costs, stock compensation expense, certain non-strategic investments and related income and expense, certain employee benefit plan costs (including the 2012 pension settlement charges), certain nonrecurring gains and losses, certain other charges (such as business optimization, AWP litigation and historical price reporting, and asset impairment), contributions to the Baxter International Foundation, deferred income taxes, and certain litigation liabilities and related receivables. With respect to depreciation and amortization and expenditures for long-lived assets, the difference between the segment totals and the consolidated totals principally relate to assets maintained at Corporate.
	Segment Information
	as of and for the years ended December 31 (in millions)		BioScience			Medical			Other			Total
						Products
	2013
	Net sales			$6,564		$	8,695		$	—		$	15,259
	Depreciation and amortization			263			472			88			823
	Pre-tax income (loss)			2,435			1,398			(1,284	)		2,549
	Assets			8,967			12,269			4,633			25,869
	Capital expenditures			868			530			127			1,525
	2012
	Net sales			$6,237		$	7,953		$	—		$	14,190
	Depreciation and amortization			243			385			84			712
	Pre-tax income (loss)			2,309			1,592			(1,012	)		2,889
	Assets			7,380			7,568			5,442			20,390
	Capital expenditures			570			495			96			1,161
	2011
	Net sales			$6,053		$	7,840		$	—		$	13,893
	Depreciation and amortization			209			341			120			670
	Pre-tax income (loss)			2,416			1,522			(1,129	)		2,809
	Assets			6,533			7,495			5,045			19,073
	Capital expenditures			370			467			123			960
	Pre-Tax Income Reconciliation
	years ended December 31 (in millions)		2013			2012			2011
	Total pre-tax income from segments		$	3,833		$	3,901		$	3,938
	Unallocated amounts
	Net interest expense			(128	)		(87	)		(54	)
	Certain foreign exchange fluctuations and hedging activities			83			53			(16	)
	Stock compensation			(150	)		(130	)		(119	)
	Business optimization charges			(280	)		(150	)		(192	)
	AWP litigation and historical price reporting charge			—			—			(79	)
	Asset impairment and other charges			—			—			(103	)
	Pension settlement charges			—			(168	)		—
	Certain tax and legal reserves			(104	)		—			—
	Other Corporate items			(705	)		(530	)		(566	)
	Consolidated income before income taxes		$	2,549		$	2,889		$	2,809
	Assets Reconciliation
	as of December 31 (in millions)		2013			2012
	Total segment assets		$	21,236		$	14,948
	Cash and equivalents			2,733			3,270
	Deferred income taxes			1,269			1,500
	PP&E, net			437			461
	Other Corporate assets			194			211
	Consolidated total assets		$	25,869		$	20,390
	Geographic Information
	Net sales are based on product shipment destination and assets are based on physical location.
	years ended December 31 (in millions)		2013			2012			2011
	Net sales
	United States		$	6,451		$	6,056		$	5,709
	Europe			4,597			4,196			4,392
	Asia-Pacific			2,378			2,229			2,107
	Latin America and Canada			1,833			1,709			1,685
	Consolidated net sales		$	15,259		$	14,190		$	13,893
	as of December 31 (in millions)		2013			2012			2011
	Total assets
United States		$	7,141		$	8,034		$	7,524
Europe			14,541			8,597			8,096
Asia-Pacific			2,347			1,943			1,807
Latin America and Canada			1,840			1,816			1,646
Consolidated total assets		$	25,869		$	20,390		$	19,073
as of December 31 (in millions)		2013			2012			2011
PP&E, net
United States		$	3,091		$	2,333		$	2,091
Austria			914			802			786
Other countries			3,827			2,963			2,648
Consolidated PP&E, net		$	7,832		$	6,098		$	5,525
Significant Product Sales
Effective January 1, 2013, Baxter transitioned to a commercial franchise structure for reporting net sales within each segment. Prior period net sales have been reclassified to reflect the new commercial franchise structure. The following is a summary of net sales as a percentage of consolidated net sales for the company’s commercial franchises.
years ended December 31		2013			2012			2011
Hemophilia1			23%			23%			23%
Fluid Systems2			20%			21%			21%
Renal3			20%			18%			18%
BioTherapeutics4			14%			15%			14%
Specialty Pharmaceuticals5			10%			10%			10%
1	Includes sales of recombinant FVIII products (ADVATE and RECOMBINATE) and plasma-derived hemophilia products (primarily FVII, FVIII and FEIBA).
2	Principally includes IV therapies, infusion pumps, administration sets, and premixed drug platforms.
3	Consists of PD and HD therapies.
4	Includes sales of the company’s liquid formulation of the antibody-replacement therapy immunoglobulin product (GAMMAGARD LIQUID) and other plasma-based therapies such as albumin and alpha-1 antitrypsin products.
5	Principally includes nutrition and anesthesia products.

Quarterly_Financial_Results_an

Quarterly Financial Results and Market for the Company's Stock	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Results and Market for the Company's Stock	'
	NOTE 17
	QUARTERLY FINANCIAL RESULTS AND MARKET FOR THE COMPANY’S STOCK (UNAUDITED)
	years ended December 31 (in millions, except per share data)		First		Second		Third		Fourth		Full year
			quarter		quarter		quarter		quarter
	2013
	Net sales		$	3,448	$	3,669	$	3,774	$	4,368	$	15,259
	Gross margin1			1,756		1,939		1,946		1,954		7,595
	Net income attributable to Baxter1			552		590		544		326		2,012
	Earnings per common share1
	Basic			1.01		1.09		1		0.6		3.7
	Diluted			1		1.07		0.99		0.59		3.66
	Cash dividends declared per common share			0.45		0.49		0.49		0.49		1.92
	Market price per common share
	High			72.64		73.04		74.43		69.55		74.43
	Low			66.42		68.1		65.69		63.89		63.89
	2012
	Net sales		$	3,388	$	3,572	$	3,477	$	3,753	$	14,190
	Gross margin2			1,714		1,872		1,810		1,905		7,301
	Net income attributable to Baxter2			588		661		583		494		2,326
	Earnings per common share2
	Basic			1.05		1.2		1.07		0.9		4.22
	Diluted			1.04		1.19		1.06		0.89		4.18
	Cash dividends declared per common share			0.335		0.335		0.45		0.45		1.57
	Market price per common share
	High			60.26		60.27		61.15		68.81		68.81
	Low			49.66		49.03		53.58		60.09		49.03
	1	The first quarter of 2013 included currency-related charges of $28 million related to the Venezuelan currency devaluation in February 2013 and derivative instruments entered into to hedge anticipated foreign currency cash outflows for the planned acquisition of Gambro (Gambro-related derivatives), in addition to charges of $17 million associated with Gambro pre-acquisition costs. The second quarter of 2013 included losses of $55 million for Gambro-related derivatives, charges of $23 million related to Gambro pre-acquisition costs and a net benefit of $2 million related to business optimization activity. The third quarter of 2013 included Gambro acquisition and integration charges of $58 million, tax and legal reserves of $83 million, business development charges of $25 million related to upfront payments for collaboration agreements, and a net gain of $20 million principally associated with Gambro-related derivatives. The fourth quarter of 2013 included business development charges of $78 million related to upfront and milestone payments for collaboration agreements, business optimization charges of $282 million, Gambro acquisition and integration charges of $94 million and product-related charges of $17 million, principally related to remediation efforts for modifications to the SIGMA Spectrum Infusion Pump.
	2	The first quarter of 2012 included a $53 million gain related to the reduction of a contingent payment liability for certain milestones associated with the 2011 acquisition of Prism and business development charges of $48 million which primarily related to an R&D charge associated with the company’s collaboration with Momenta. The second quarter of 2012 included a $38 million gain related to the reduction of a contingent payment liability for certain milestones associated with the 2010 acquisition of ApaTech, business development charges of $30 million which related to an R&D charge associated with the company’s collaboration with Chatham and a $23 million net benefit from reserve adjustments which primarily related to an adjustment to the COLLEAGUE infusion pump reserves. The third quarter of 2012 included an R&D charge of $50 million related to the company’s agreement with Onconova. The fourth quarter of 2012 included charges of $170 million primarily related to the settlement of certain pension obligations and $150 million related to business optimization initiatives (of which $62 million was recorded in cost of sales).
	Baxter common stock is listed on the New York, Chicago and SIX Swiss stock exchanges. The New York Stock Exchange is the principal market on which the company’s common stock is traded. At January 31, 2014, there were 36,629 holders of record of the company’s common stock.

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts	'
	SCHEDULE II
					Additions		Charged
							(credited)
							to other
	Valuation and Qualifying Accounts		Balance at		Charged to		accounts (1)			Deductions			Balance at
	(in millions)		beginning		costs and					from			end of
			of period		expenses					reserves (2)			period
	Year ended December 31, 2013:
	Allowance for doubtful accounts		$	127		26		27			(11	)	$	169
	Inventory reserves		$	284		217		1			(241	)	$	261
	Deferred tax asset valuation allowance		$	104		13		25			(5	)	$	137
	Year ended December 31, 2012:
	Allowance for doubtful accounts		$	128		12		(2	)		(11	)	$	127
	Inventory reserves		$	302		199		4			(221	)	$	284
	Deferred tax asset valuation allowance		$	116		10		(4	)		(18	)	$	104
	Year ended December 31, 2011:
	Allowance for doubtful accounts		$	139		32		(6	)		(37	)	$	128
	Inventory reserves		$	359		144		(10	)		(191	)	$	302
	Deferred tax asset valuation allowance		$	118		11		(4	)		(9	)	$	116
	-1	Valuation accounts of acquired or divested companies and foreign currency translation adjustments.
	-2	Deductions from reserves includes the write-off of previously reserved inventory that was used in research and development (R&D) and recorded in R&D expenses in the year reserved.
	Reserves are deducted from assets to which they apply.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Nature of Operations	'
	Nature of Operations
	Baxter International Inc. (Baxter or the company), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. The company operates in two segments, BioScience and Medical Products, which are described in Note 16
Use of Estimates	'
	Use of Estimates
	The preparation of the financial statements in conformity with generally accepted accounting principles (GAAP) requires the company to make estimates and assumptions that affect reported amounts and related disclosures. Actual results could differ from those estimates.
Basis of Consolidation	'
	Basis of Consolidation
	The consolidated financial statements include the accounts of Baxter and its majority-owned subsidiaries, any minority-owned subsidiaries that Baxter controls, and variable interest entities (VIEs) in which Baxter is the primary beneficiary, after elimination of intercompany transactions. During 2012, the company exercised its option to purchase the remaining equity of Sigma International General Medical Apparatus, LLC (SIGMA), which Baxter previously consolidated as the primary beneficiary of a VIE. The company has not subsequently entered into any new arrangements in which it determined that it was the primary beneficiary of a VIE, and there were no VIEs consolidated by the company as of December 31, 2013. Refer to Note 2 for additional information about the SIGMA option exercise.
	On September 6, 2013, Baxter acquired Indap Holding AB, the holding company for Gambro AB (Gambro), a privately held dialysis product company based in Lund, Sweden, for cash consideration of $3.7 billion. Beginning September 6, 2013, Baxter’s financial statements include the assets, liabilities, and operating results of Gambro. Refer to Note 4 for additional information.
	Certain reclassifications have been made to conform the prior period consolidated financial statements to the current period presentation.
Revenue Recognition	'
	Revenue Recognition
	The company recognizes revenues from product sales and services when earned. Specifically, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectibility is reasonably assured. For product sales, revenue is not recognized until title and risk of loss have transferred to the customer. The shipping terms for the majority of the company’s revenue arrangements are FOB destination. The recognition of revenue is delayed if there are significant post-delivery obligations, such as training, installation or other services. Provisions for discounts, rebates to customers, chargebacks to wholesalers and returns are provided for at the time the related sales are recorded, and are reflected as a reduction to gross sales to arrive at net sales.
	The company sometimes enters into arrangements in which it commits to delivering multiple products or services to its customers. In these cases, total arrangement consideration is allocated to the deliverables based on their relative selling prices. Then the allocated consideration is recognized as revenue in accordance with the principles described above. Selling prices are determined by applying a selling price hierarchy. Selling prices are determined using vendor specific objective evidence (VSOE), if it exists. Otherwise, selling prices are determined using third party evidence (TPE). If neither VSOE nor TPE is available, the company uses its best estimate of selling prices.
Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts
	In the normal course of business, the company provides credit to its customers, performs credit evaluations of these customers and maintains reserves for potential credit losses. In determining the amount of the allowance for doubtful accounts, the company considers, among other items, historical credit losses, the past-due status of receivables, payment histories and other customer-specific information. Receivables are written off when the company determines they are uncollectible. The allowance for doubtful accounts was $169 million at December 31, 2013 and $127 million at December 31, 2012.
Product Warranties	'
	Product Warranties
	The company provides for the estimated costs relating to product warranties at the time the related revenue is recognized. The cost is determined based on actual company experience for the same or similar products, as well as other relevant information. Product warranty liabilities are adjusted based on changes in estimates.
Cash and Equivalents	'
	Cash and Equivalents
	Cash and equivalents include cash, certificates of deposit and money market funds with an original maturity of three months or less.
Inventories	'
	Inventories
	as of December 31 (in millions)	2013			2012
	Raw materials	$	920		$	765
	Work in process		1,136			898
	Finished goods		1,443			1,140
	Inventories	$	3,499		$	2,803
	Inventories are stated at the lower of cost (first-in, first-out method) or market value. Market value for raw materials is based on replacement costs, and market value for work in process and finished goods is based on net realizable value. The company reviews inventories on hand at least quarterly and records provisions for estimated excess, slow-moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value.
Property, Plant and Equipment, Net	'
	Property, Plant and Equipment, Net
	as of December 31 (in millions)	2013			2012
	Land	$	220		$	190
	Buildings and leasehold improvements		2,670			2,181
	Machinery and equipment		7,360			6,691
	Equipment with customers		1,361			1,295
	Construction in progress		2,184			1,512
	Total property, plant and equipment, at cost		13,795			11,869
	Accumulated depreciation		(5,963	)		(5,771	)
	Property, plant and equipment (PP&E), net	$	7,832		$	6,098
	Depreciation expense is calculated using the straight-line method over the estimated useful lives of the related assets, which range from 20 to 50 years for buildings and improvements and from three to 15 years for machinery and equipment. Leasehold improvements are amortized over the life of the related facility lease (including any renewal periods, if appropriate) or the asset, whichever is shorter. Baxter capitalizes certain computer software and software development costs incurred in connection with developing or obtaining software for internal use as part of machinery and equipment. Capitalized software costs are amortized on a straight-line basis over the estimated useful lives of the software, and are included in depreciation expense below. Straight-line and accelerated methods of depreciation are used for income tax purposes. Depreciation expense was $681 million in 2013, $597 million in 2012 and $572 million in 2011. Repairs and maintenance expense was $351 million in 2013, $297 million in 2012 and $269 million in 2011.
Acquisitions	'
	Acquisitions
	Results of operations of acquired companies are included in the company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.
	Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of regulatory, development and commercial milestone payments, in addition to sales-based payments, and are valued using discounted cash flow techniques. The fair value of development and commercial milestone payments reflects management’s expectations of probability of payment, and increases as the probability of payment increases or expectation of timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or expectation of timing of payment is accelerated.
Research and Development	'
	Research and Development
	Research and development (R&D) costs are expensed as incurred. Acquired in-process R&D (IPR&D) is the value assigned to technology or products under development acquired in a business combination which have not received regulatory approval and have no alternative future use. Valuations are generally completed for business acquisitions using a discounted cash flow analysis, incorporating the stage of completion and consideration of market participant assumptions. The most significant estimates and assumptions inherent in a discounted cash flow analysis include the amount and timing of projected future cash flows, the discount rate used to measure the risks inherent in future cash flows, the assessment of the asset’s life cycle, and competitive and other trends impacting the asset, including consideration of technical, legal, regulatory, economic and other factors. Each of these factors can significantly affect the value of the IPR&D.
	Acquired IPR&D is capitalized as an indefinite-lived intangible asset. Development costs incurred after the acquisition are expensed as incurred. Upon receipt of regulatory approval of the related technology or product, the indefinite-lived intangible asset is accounted for as a finite-lived intangible asset and generally amortized on a straight-line basis over the estimated economic life of the related product, subject to impairment reviews as discussed below. If the R&D project is abandoned, the indefinite-lived asset is charged to expense.
	R&D acquired in transactions that are not business acquisitions is expensed immediately. Payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized over the remaining estimated economic life of the related product.
Collaborative Arrangements	'
	Collaborative Arrangements
	In the normal course of business, Baxter enters into collaborative arrangements with third parties. Certain of these collaborative arrangements include joint operating activities involving active participation by both partners, where both Baxter and the other entity are exposed to risks and rewards dependent on the commercial success of the activity. These collaborative arrangements exist in both of the company’s segments, take a number of forms and structures, principally pertain to the joint development and commercialization of new products, and are designed to enhance and expedite long-term sales and profitability growth.
	The company’s joint product development and commercialization arrangements generally provide that Baxter license certain rights to develop, market, and sometimes manufacture, a product under development. Baxter’s consideration for the rights generally consists of some combination of upfront payments, contingent milestone payments relating to the achievement of specified development, clinical, regulatory and sales milestones, and royalties. Baxter may also be responsible for ongoing R&D cost reimbursements and costs associated with certain development, manufacturing and commercial activities associated with these arrangements. Joint steering committees exist to manage the various stages and activities of the arrangement. Control over the R&D activities may be shared, may be held by Baxter, or may be held by the partner, and governance may contractually change during the development or later periods. Baxter typically controls the commercialization phase, sometimes purchasing inventories from the collaboration partner.
	During the development phase, Baxter’s R&D costs are expensed as incurred. These costs may include upfront and milestone payments made to the partner prior to the date the product receives regulatory approval, in addition to potential R&D cost reimbursements. Milestone payments made to the partner subsequent to regulatory approval are capitalized as other intangible assets and amortized to cost of sales over the estimated economic life of the related product. Royalty payments are expensed as cost of sales when they become due and payable. Any purchases of inventory from the partner during the development stage are expensed as R&D, while such purchases during the commercialization phase are capitalized as inventory and recognized as cost of sales when the related finished products are sold. Baxter generally records the amount invoiced to the third-party customer for the finished product as sales, as Baxter is the principal and primary obligor in the arrangement.
	Payments to collaborative partners classified in cost of sales were not significant in 2013, 2012 and 2011. Payments to collaborative partners classified in R&D expenses were $129 million, $138 million and $18 million in 2013, 2012 and 2011, respectively. In 2013 and 2012, the payments related primarily to upfront payments for the business development arrangements described in Note 4. In 2011, the payments primarily related to the development of longer-acting forms of blood clotting proteins to treat hemophilia and a home hemodialysis (HHD) device.
Business Optimization Charges	'
	Business Optimization Charges
	The company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee termination costs are primarily recorded when actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. Refer to the discussion below regarding the accounting for asset impairment charges.
Impairment Reviews	'
	Impairment Reviews
	Baxter has made and continues to make significant investments in assets, including inventory and PP&E, which relate to potential new products or modifications to existing products. Additionally, Baxter has made and continues to make significant investments related to business development activities, which result in the acquisition of certain intangible assets and other long-lived assets. The company’s ability to realize value from these investments is contingent on, among other things, regulatory approvals, market acceptance of these new or modified products, and realization of synergies associated with business acquisitions. The company may not be able to realize the expected returns from these investments, potentially resulting in asset impairments in the future.
	Goodwill
	Goodwill is not amortized, but is subject to an impairment review annually and whenever indicators of impairment exist. Goodwill would be impaired if the carrying amount of a reporting unit exceeded the fair value of that reporting unit, calculated as the present value of estimated cash flows discounted using a risk-free market rate adjusted for a market participant’s view of similar companies and perceived risks in the cash flows. The implied fair value of goodwill is then determined by subtracting the fair value of all identifiable net assets other than goodwill from the fair value of the reporting unit, with an impairment charge recorded for the excess, if any, of carrying amount of goodwill over the implied fair value.
	The company assesses goodwill for impairment based on its reporting units, which are the same as its operating segments, BioScience and Medical Products. As of December 31, 2013, the date of the company’s annual impairment review, the fair values of the company’s reporting units were substantially in excess of their carrying values.
	Intangible Assets Not Subject to Amortization
	Indefinite-lived intangible assets, such as trademarks with indefinite lives and certain acquired IPR&D, are subject to an impairment review annually and whenever indicators of impairment exist. Indefinite-lived intangible assets would be impaired if the carrying amount of the asset exceeded the fair value of the asset.
	Other Long-Lived Assets
	The company reviews the carrying amounts of long-lived assets, other than goodwill and intangible assets not subject to amortization, for potential impairment when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Examples of such a change in circumstances include a significant decrease in market price, a significant adverse change in the extent or manner in which an asset is being used, or a significant adverse change in the legal or business climate. In evaluating recoverability, the company groups assets and liabilities at the lowest level such that the identifiable cash flows relating to the group are largely independent of the cash flows of other assets and liabilities. The company then compares the carrying amounts of the assets or asset groups with the related estimated undiscounted future cash flows. In the event impairment exists, an impairment charge is recorded as the amount by which the carrying amount of the asset or asset group exceeds the fair value. Depending on the asset and the availability of information, fair value may be determined by reference to estimated selling values of assets in similar condition, or by using a discounted cash flow model. In addition, the remaining amortization period for the impaired asset would be reassessed and, if necessary, revised.
Shipping and Handling Costs	'
	Shipping and Handling Costs
	Shipping costs, which are costs incurred to physically move product from Baxter’s premises to the customer’s premises, are classified as marketing and administrative expenses. Handling costs, which are costs incurred to store, move and prepare products for shipment, are classified as cost of sales. Approximately $293 million in 2013, $265 million in 2012 and $260 million in 2011 of shipping costs were classified in marketing and administrative expenses.
Income Taxes	'
	Income Taxes
	Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The company maintains valuation allowances unless it is more likely than not that the deferred tax asset will be realized. With respect to uncertain tax positions, the company determines whether the position is more likely than not to be sustained upon examination, based on the technical merits of the position. Any tax position that meets the more-likely-than-not recognition threshold is measured and recognized in the consolidated financial statements at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The liability relating to uncertain tax positions is classified as current in the consolidated balance sheets to the extent the company anticipates making a payment within one year. Interest and penalties associated with income taxes are classified in the income tax expense line in the consolidated statements of income.
Foreign Currency Translation	'
	Foreign Currency Translation
	Currency translation adjustments (CTA) related to foreign operations are included in other comprehensive income (OCI). For foreign operations in highly inflationary economies, translation gains and losses are included in other (income) expense, net, and were not material in 2013, 2012 and 2011.
Derivatives and Hedging Activities	'
	Derivatives and Hedging Activities
	All derivative instruments are recognized as either assets or liabilities at fair value in the consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. Based upon the exposure being hedged, the company designates its hedging instruments as cash flow or fair value hedges.
	For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is accumulated in accumulated other comprehensive income (AOCI) and then recognized in earnings consistent with the underlying hedged item. Option premiums or net premiums paid are initially recorded as assets and reclassified to OCI over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in net sales, cost of sales, and net interest expense, and primarily related to forecasted third-party sales denominated in foreign currencies, forecasted intercompany sales denominated in foreign currencies and anticipated issuances of debt, respectively.
	For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. Fair value hedges are classified in net interest expense, as they hedge the interest rate risk associated with certain of the company’s fixed-rate debt.
	For derivative instruments that are not designated as hedges, the change in fair value is recorded directly to other (income) expense, net.
	If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, the company discontinues hedge accounting prospectively. If the company removes the cash flow hedge designation because the hedged forecasted transactions are no longer probable of occurring, any gains or losses are immediately reclassified from AOCI to earnings. Gains or losses relating to terminations of effective cash flow hedges in which the forecasted transactions are still probable of occurring are deferred and recognized consistent with the income or loss recognition of the underlying hedged items. If the company terminates a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged items at the date of termination is amortized to earnings over the remaining term of the hedged item.
	Derivatives, including those that are not designated as a hedge, are principally classified in the operating section of the consolidated statements of cash flows in the same category as the related consolidated balance sheet account.
	Refer to Note 8 for further information regarding the company’s derivative and hedging activities.
Changes in Accounting Standards	'
	Changes in Accounting Standards
	Effective January 1, 2013, the company has prospectively adopted new accounting guidance that requires an entity to report the effect of significant reclassifications out of AOCI on the respective line items in the consolidated statement of income. Refer to Note 13 for related disclosures.
	On January 1, 2012, the company adopted a new accounting standard which eliminated the company’s previous election to present other comprehensive income within the consolidated statements of changes in equity, and provided the option to present the components of net income and other comprehensive income either as one continuous statement of comprehensive income or as two separate but consecutive statements. The standard is reflected in the company’s consolidated statements of comprehensive income, presented as a separate consecutive statement to the consolidated statements of income, and was retrospectively applied to all prior periods presented.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Inventories	'
	as of December 31 (in millions)	2013			2012
	Raw materials	$	920		$	765
	Work in process		1,136			898
	Finished goods		1,443			1,140
	Inventories	$	3,499		$	2,803
Property, Plant and Equipment, Net	'
	as of December 31 (in millions)	2013			2012
	Land	$	220		$	190
	Buildings and leasehold improvements		2,670			2,181
	Machinery and equipment		7,360			6,691
	Equipment with customers		1,361			1,295
	Construction in progress		2,184			1,512
	Total property, plant and equipment, at cost		13,795			11,869
	Accumulated depreciation		(5,963	)		(5,771	)
	Property, plant and equipment (PP&E), net	$	7,832		$	6,098

Supplemental_Financial_Informa1

Supplemental Financial Information (Tables)	12 Months Ended
	Dec. 31, 2013
Other Long-Term Assets	'
	Other Long-Term Assets
	as of December 31 (in millions)	2013			2012
	Deferred income taxes	$	876		$	1,156
	Other long-term receivables		216			154
	Other		442			406
	Other long-term assets	$	1,534		$	1,716
Accounts Payable and Accrued Liabilities	'
	Accounts Payable and Accrued Liabilities
	as of December 31 (in millions)	2013			2012
	Accounts payable, principally trade	$	1,103		$	766
	Income taxes payable		302			451
	Deferred income taxes		760			878
	Common stock dividends payable		266			246
	Employee compensation and withholdings		667			567
	Property, payroll and certain other taxes		237			152
	Infusion pump reserves		64			37
	Business optimization reserves		199			151
	Accrued rebates		346			291
	Other		922			870
	Accounts payable and accrued liabilities	$	4,866		$	4,409
Other Long-Term Liabilities	'
	Other Long-Term Liabilities
	as of December 31 (in millions)	2013			2012
	Pension and other employee benefits	$	2,049		$	2,427
	Litigation reserves		72			32
	Infusion pump reserves		19			90
	Business optimization reserves		89			69
	Contingent payment liabilities		340			86
	Other		782			369
	Other long-term liabilities	$	3,351		$	3,073
Net Interest Expense	'
	Net Interest Expense
	years ended December 31 (in millions)	2013			2012			2011
	Interest costs	$	225		$	165		$	132
	Interest costs capitalized		(70	)		(52	)		(40	)
	Interest expense		155			113			92
	Interest income		(27	)		(26	)		(38	)
	Net interest expense	$	128		$	87		$	54
Other (Income) Expense, Net	'
	Other (Income) Expense, Net
	years ended December 31 (in millions)	2013			2012			2011
	Impairment charges	$	21		$	9		$	62
	Net gains related to contingent payment liabilities		(8	)		(91	)		—
	Foreign exchange		26			(49	)		(10	)
	Securitization and factoring arrangements		18			18			14
	Equity method investments		(24	)		1			4
	Noncontrolling interests		(31	)		(28	)		—
	Other		(11	)		(15	)		13
	Other (income) expense, net	$	(9	)	$	(155	)	$	83

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Reconciliation of Basic Shares to Diluted Shares	'
	The following is a reconciliation of basic shares to diluted shares.
	years ended December 31 (in millions)	2013		2012		2011
	Basic shares		543		551		569
	Effect of dilutive securities		6		5		4
	Diluted shares		549		556		573

Acquisitions_and_Collaboration1

Acquisitions and Collaborations (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Fair Value of Consideration Transferred and Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed	'
	The following table summarizes the fair value of the consideration transferred and the amounts recognized for assets acquired and liabilities assumed as of the acquisition date. Additional measurement period adjustments may occur as the company finalizes its valuation of the acquisition date assets acquired and liabilities assumed.
	(in millions)
	Consideration transferred
	Cash	$	3,704
	Fair value of consideration transferred	$	3,704
	Assets acquired and liabilities assumed
	Cash	$	88
	Accounts receivable		490
	Inventories		368
	Prepaid expenses and other		54
	Property, plant, and equipment		726
	Other intangible assets		1,290
	Other assets		11
	Current-maturities of long-term debt and lease obligations		(2	)
	Accounts payable and accrued liabilities		(340	)
	Long-term debt and lease obligations		(261	)
	Other long-term liabilities (including pension obligations of $209)		(340	)
	Total identifiable net assets		2,084
	Goodwill		1,620
	Total assets acquired and liabilities assumed	$	3,704
Subsidiary Information in Consolidated Statement of Income from Acquisition	'
	The following table presents information for Gambro that has been included in Baxter’s consolidated statement of income from the acquisition date through December 31, 2013.
	(in millions)	Gambro’s operations
		included in Baxter’s results
	Net sales	$	513
	Net loss	$	(45	)
Supplemental Pro Forma Information	'
	The following table presents supplemental pro forma information as if the acquisition of Gambro had occurred on January 1, 2012 for the years ended December 31, 2013 and 2012.
		Unaudited Pro Forma Consolidated Results
		Years ended December 31,
	(in millions, except per share information)	2013			2012
	Net sales	$	16,288		$	15,767
	Net income		2,138			2,021
	Basic earnings per share	$	3.94		$	3.67
	Diluted earnings per share	$	3.89		$	3.63
Summary of Fair Value of Consideration Transferred and Recognized Amounts of Assets Acquired and Liabilities Assumed	'
	The following table summarizes the fair value of consideration transferred and the recognized amounts of the assets acquired and liabilities assumed as of the acquisition date for the company’s other significant acquisitions in 2013, 2012 and 2011.
	(in millions)	2013			2012		2011
		Inspiration / Ipsen			Synovis		Baxa			Prism
		OBI-1 Business
	Consideration transferred
	Cash, net of cash acquired	$	51		$	304	$	358		$	170
	Contingent payments		269			—		—			67
	Fair value of consideration transferred	$	320		$	304	$	358		$	237
	Assets acquired and liabilities assumed
	Other intangible assets	$	288		$	115	$	145		$	229
	Other assets (liabilities), net		25			25		(24	)		(64	)
	Total identifiable net assets		313			140		121			165
	Goodwill		7			164		237			72
	Total assets acquired and liabilities assumed	$	320		$	304	$	358		$	237

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill	'
	The following is a summary of the activity in goodwill by segment.
	(in millions)	BioScience			Medical			Total
					Products
	December 31, 2011	$	806		$	1,511		$	2,317
	Additions		161			21			182
	Currency translation and other adjustments		8			(5	)		3
	December 31, 2012		975			1,527			2,502
	Additions		7			1,622			1,629
	Currency translation and other adjustments		9			65			74
	December 31, 2013	$	991		$	3,214		$	4,205
Other Intangible Assets, Net	'
	The following is a summary of the company’s other intangible assets.
	(in millions)	Developed technology,			Other amortized			Indefinite-lived		Total
		including patents			intangible assets			intangible assets
	December 31, 2013
	Gross other intangible assets	$	2,144		$	494		$	465	$	3,103
	Accumulated amortization		(665	)		(144	)		—		(809	)
	Other intangible assets, net	$	1,479		$	350		$	465	$	2,294
	December 31, 2012
	Gross other intangible assets	$	1,192		$	280		$	22	$	1,494
	Accumulated amortization		(578	)		(102	)		—		(680	)
	Other intangible assets, net	$	614		$	178		$	22	$	814

Infusion_Pump_and_Business_Opt1

Infusion Pump and Business Optimization Charges (Tables)	12 Months Ended
	Dec. 31, 2013
Infusion Pump Charges	'
	The following table summarizes cash activity in the company’s COLLEAGUE and SYNDEO infusion pump reserves through December 31, 2013.
	(in millions)
	Charges and adjustments in 2005 through 2011	$	716
	Utilization in 2005 through 2011		(440	)
	Reserves at December 31, 2011		276
	Utilization		(175	)
	Other		26
	Reserves at December 31, 2012		127
	Utilization		(27	)
	Other		(17	)
	Reserves at December 31, 2013	$	83
Business Optimization Charge	'
	The following table summarizes cash activity in the reserves related to the company’s business optimization initiatives.
	(in millions)
	Reserve at December 31, 2010	$	180
	2011 Charge		156
	Utilization in 2011		(110	)
	CTA		(1	)
	Reserve at December 31, 2011		225
	2012 Charge		98
	Utilization in 2012		(99	)
	CTA		(4	)
	Reserve at December 31, 2012		220
	2013 Charge		182
	Reserve adjustments		(20	)
	Utilization in 2013		(98	)
	CTA		4
	Reserve at December 31, 2013	$	288

Debt_Credit_Facilities_and_Lea1

Debt, Credit Facilities and Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Debt Outstanding	'
	At December 31, 2013 and 2012, the company had the following debt outstanding.
	as of December 31 (in millions)				2013				2012
	Commercial paper				$	—			$	—
	Other short-term debt					181				27
	Short-term debt				$	181			$	27
	as of December 31 (in millions)		Effective interest				20132				20122
			rate in 20131
	1.8% notes due 2013			1.70%			$	—			$	301
	4.0% notes due 2014			4.10%				351				358
	Floating rate notes due 2014			0.70%				500				—
	Variable-rate loan due 2015			0.90%				194				243
	4.625% notes due 2015			4.80%				625				646
	5.9% notes due 2016			6.00%				622				631
	0.95% notes due 2016			1.10%				500				—
	1.85% notes due 2017			2.00%				500				500
	Variable-rate loan due 2017			1.10%				136				170
	5.375% notes due 2018			5.50%				499				499
	1.85% notes due 2018			1.90%				750				—
	4.5% notes due 2019			4.60%				534				566
	4.25% notes due 2020			4.40%				299				299
	2.40% notes due 2022			2.50%				684				697
	3.2% notes due 2023			3.20%				1,246				—
	6.625% debentures due 2028			6.70%				133				133
	6.25% notes due 2037			6.30%				499				499
	3.65% notes due 2042			3.70%				298				298
	4.5% notes due 2043			4.40%				500				—
	Other			—				115				63
	Total debt and capital lease obligations							8,985				5,903
	Current portion							(859	)			(323	)
	Long-term portion						$	8,126			$	5,580
	1	Excludes the effect of any related interest rate swaps.
	2	Book values include any discounts, premiums and adjustments related to hedging instruments.
Future Minimum Lease Payments and Debt Maturities	'
	Future Minimum Lease Payments and Debt Maturities
	as of and for the years ended December 31 (in millions)		Operating		Debt maturities
			leases		and capital
					leases
	2014		$   216		$	859
	2015		180			813
	2016		158			1,111
	2017		140			647
	2018		120			1,262
	Thereafter		271			4,328
	Total obligations and commitments		1,085			9,020
	Interest on capital leases, discounts and premiums, and adjustments relating to		n/a			(35	)
	hedging instruments
	Total debt and lease obligations		$1,085		$	8,985

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Activity (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Gains and Losses on Derivative Instruments	'
	The following tables summarize the gains and losses on the company’s derivative instruments for the years ended December 31, 2013 and 2012.
		Gain (loss)							Location of gain (loss) in			Gain (loss)
		recognized in OCI							income statement			reclassified from
												AOCI into income
	(in millions)	2013				2012						2013			2012
	Cash flow hedges
	Interest rate contracts	$	26			$	(10	)		Net interest expense		$	10		$	—
	Foreign exchange contracts		1				(3	)		Net sales			(1	)		(3	)
	Foreign exchange contracts		36				—			Cost of sales			32			3
	Total	$	63			$	(13	)				$	41		$	—
		Location of gain (loss) in				Gain (loss)
		income statement				recognized in income
	(in millions)					2013			2012
	Fair value hedges
	Interest rate contracts		Net interest expense			$	(46	)	$	11
	Undesignated derivative instruments
	Foreign exchange contracts		Other (income) expense, net			$	11		$	(7	)
Net of Tax Activity in Accumulated Other Comprehensive Income Related to Cash Flow Hedges	'
	The following table summarizes net-of-tax activity in AOCI, a component of shareholders’ equity, related to the company’s cash flow hedges.
	as of and for the years ended December 31 (in millions)	2013				2012			2011
	Accumulated other comprehensive (loss) income balance at beginning of year	$	(5	)		$	2		$	(3	)
	Gain (loss) in fair value of derivatives during the year		41				(7	)		(31	)
	Amount reclassified to earnings during the year		(26	)			—			36
	Accumulated other comprehensive income (loss) balance at end of year	$	10			$	(5	)	$	2
Classification and Fair Value Amounts of Derivative Instruments	'
	The following table summarizes the classification and fair value amounts of derivative instruments reported in the consolidated balance sheet as of December 31, 2013.
		Derivatives in asset positions						Derivatives in liability positions
	(in millions)	Balance sheet location		Fair				Balance sheet location	Fair
				value					value
	Derivative instruments designated as hedges
		Other long-term assets		$	35			Other long-term liabilities	$	14
	Interest rate contracts
	Foreign exchange contracts	Prepaid expenses and other			37			Accounts payable		7
								and accrued liabilities
	Total derivative instruments designated as hedges			$	72				$	21
	Undesignated derivative instruments
	Foreign exchange contracts	Prepaid expenses and other		$	—			Accounts payable	$	1
								and accrued liabilities
	Total derivative instruments			$	72				$	22
	The following table summarizes the classification and fair value amounts of derivative instruments reported in the consolidated balance sheet as of December 31, 2012.
		Derivatives in asset positions						Derivatives in liability positions
	(in millions)	Balance sheet location		Fair				Balance sheet location	Fair
				value					value
	Derivative instruments designated as hedges
	Interest rate contracts	Other long-term assets		$	67			Accounts payable and accrued liabilities	$	21
	Foreign exchange contracts	Prepaid expenses and other			28			Accounts payable		5
								and accrued liabilities
	Total derivative instruments designated as hedges			$	95				$	26
	Undesignated derivative instruments
	Foreign exchange contracts	Prepaid expenses and other		$	47			Accounts payable	$	11
								and accrued liabilities
	Total derivative instruments			$	142				$	37
Derivative Positions Presented on Net Basis	'
	The following table provides information on the company’s derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty:
		December 31, 2013							December 31, 2012
	(in millions)	Asset				Liability			Asset			Liability
	Gross amounts recognized in the consolidated balance sheet	$	72			$	22		$	142		$	37
	Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet		(17	)			(17	)		(37	)		(37	)
	Total	$	55			$	5		$	105		$	—

Financial_Instruments_and_Rela1

Financial Instruments and Related Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Activity Relating to Securitization Arrangement	'
	The following is a summary of the activity relating to the securitization arrangement.
	as of and for the years ended December 31 (in millions)	2013			2012			2011
	Sold receivables at beginning of year	$	157		$	160		$	157
	Proceeds from sales of receivables		506			630			615
	Cash collections (remitted to the owners of the receivables)		(519	)		(624	)		(622	)
	Effect of currency exchange rate changes		(30	)		(9	)		10
	Sold receivables at end of year	$	114		$	157		$	160
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	'
	The following tables summarize the bases used to measure financial assets and liabilities that are carried at fair value on a recurring basis in the consolidated balance sheets.
				Basis of fair value measurement
	(in millions)	Balance at		Quoted prices in	Significant other		Significant
		December 31,		active markets for	observable inputs		unobservable inputs
		2013		identical assets	(Level 2)		(Level 3)
				(Level 1)
	Assets
	Foreign currency hedges	$  37		$  —	$  37		$  —
	Interest rate hedges	35		—	35		—
	Available-for-sale securities
	Equity securities	102		102	—		—
	Foreign government debt securities	18		—	18		—
	Total assets	$192		$102	$  90		$  —
	Liabilities
	Foreign currency hedges	$    8		$  —	$8		$  —
	Interest rate hedges	14		—	14		—
	Contingent payments related to acquisitions	340		—	—		340
	and investments
	Total liabilities	$362		$  —	$  22		$340
				Basis of fair value measurement
	(in millions)	Balance at		Quoted prices in	Significant other		Significant
		December 31,		active markets for	observable inputs		unobservable inputs
		2012		identical assets	(Level 2)		(Level 3)
				(Level 1)
	Assets
	Foreign currency hedges	$  75		$  —	$  75		$  —
	Interest rate hedges	67		—	67		—
	Available-for-sale securities
	Equity securities	15		15	—		—
	Preferred Stock	51		—	—		51
	Foreign government debt securities	16		—	16		—
	Total assets	$224		$  15	$158		$  51
	Liabilities
	Foreign currency hedges	$  16		$  —	$  16		$  —
	Interest rate hedges	21		—	21		—
	Contingent payments related to acquisitions	86		—	—		86
	and investments
	Total liabilities	$123		$  —	$  37		$  86
Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs	'
	The following table is a reconciliation of the fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions and preferred stock.
	(in millions)	Contingent			Preferred
		payments			stock
	Fair value as of December 31, 2011	$	234		$	—
	Purchases		—			50
	Payments		(40	)		—
	Gains recognized in earnings		(108	)		—
	CTA		—			1
	Fair value as of December 31, 2012		86			51
	Purchases		269			—
	Payments		(2	)		—
	Net gains recognized in earnings		(17	)		—
	CTA		4			—
	Conversion to a publicly traded equity security		—			(51	)
	Fair value as of December 31, 2013	$	340		$	—
Book Values and Fair Values of Financial Instruments	'
	the following table provides the values recognized on the consolidated balance sheets and the approximate fair values.
		Book values						Approximate
								fair values
	as of December 31 (in millions)	2013			2012			2013			2012
	Assets
	Long-term insurance receivables	$	2		$	2		$	2		$	2
	Investments		53			46			53			49
	Liabilities
	Short-term debt		181			27			181			27
	Current maturities of long-term debt and lease obligations		859			323			862			324
	Long-term debt and lease obligations		8,126			5,580			8,298			6,201
	Long-term litigation liabilities		72			32			70			31
Summarization of Bases Used to Measure Fair Value of Financial Instruments	'
	The following tables summarize the bases used to measure the approximate fair value of the financial instruments as of December 31, 2013 and 2012.
					Basis of fair value measurement
	(in millions)	Balance as of			Quoted prices in			Significant other			Significant
		December 31,			active markets for			observable inputs			unobservable inputs
		2013			identical assets			(Level 2)			(Level 3)
					(Level 1)
	Assets
	Long-term insurance receivables	$	2		$	—		$	—		$	2
	Investments		53			—			17			36
	Total assets	$	55		$	—		$	17		$	38
	Liabilities
	Short-term debt	$	181		$	—		$	181		$	—
	Current maturities of long-term debt and lease obligations		862			—			862			—
	Long-term debt and lease obligations		8,298			—			8,298			—
	Long-term litigation liabilities		70			—			—			70
	Total liabilities	$	9,411		$	—		$	9,341		$	70
					Basis of fair value measurement
	(in millions)	Balance as of			Quoted prices in			Significant other			Significant
		December 31,			active markets for			observable inputs			unobservable inputs
		2012			identical assets			(Level 2)			(Level 3)
					(Level 1)
	Assets
	Long-term insurance receivables	$	2		$	—		$	—		$	2
	Investments		49			—			19			30
	Total assets	$	51		$	—		$	19		$	32
	Liabilities
	Short-term debt	$	27		$	—		$	27		$	—
	Current maturities of long-term debt and lease obligations		324			—			324			—
	Long-term debt and lease obligations		6,201			—			6,201			—
	Long-term litigation liabilities		31			—			—			31
	Total liabilities	$	6,583		$	—		$	6,552		$	31

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Stock Options Fair Value Assumptions	'
	The fair value of stock options is determined using the Black-Scholes model. The weighted-average assumptions used in estimating the fair value of stock options granted during each year, along with the weighted-average grant-date fair values, were as follows.
	years ended December 31	2013			2012		2011
	Expected volatility		25%			25%		25%
	Expected life (in years)		5.5			5.5		5
	Risk-free interest rate		0.90%			1.00%		2.20%
	Dividend yield		2.60%			2.30%		2.30%
	Fair value per stock option		$12			$10		$10
Summary of Stock Option Activity	'
	The following table summarizes stock option activity for the year ended December 31, 2013 and stock option information at December 31, 2013.
	(options and aggregate intrinsic values in thousands)	Options			Weighted-		Weighted-average		Aggregate
					average		remaining		intrinsic
					exercise		contractual		value
					price		term (in years)
	Outstanding at January 1, 2013		32,055		$	52.62
	Granted		6,354			70.23
	Exercised		(8,517	)		50.15
	Forfeited		(679	)		62.26
	Expired		(84	)		40.26
	Outstanding at December 31, 2013		29,129		$	57		6.2	$	361,468
	Vested or expected to vest as of December 31, 2013		28,642		$	56.82		6.1	$	360,329
	Exercisable at December 31, 2013		17,732		$	52.64		4.7	$	293,590
Summary of Nonvested Restricted Stock Units Activity	'
	The following table summarizes nonvested RSU activity for the year ended December 31, 2013.
	(share units in thousands)	Share units			Weighted-average
					grant-date
					fair value
	Nonvested RSUs at January 1, 2013		1,979		$55.36
	Granted		1,043		70.09
	Vested		(647	)	54.96
	Forfeited		(157	)	60.55
	Nonvested RSUs at December 31, 2013		2,218		$62.06
Performance Stock Units Fair Value	'
	The assumptions used in estimating the fair value of these PSUs granted during the period, along with the grant-date fair values, were as follows.
	years ended December 31	2013			2012		2011
	Baxter volatility		21%			24%		28%
	Peer group volatility		13%-38%			14%-50%		19%-55%
	Correlation of returns		0.37-0.62			0.26-0.54		0.29-0.61
	Risk-free interest rate		0.30%			0.40%		1.20%
	Fair value per PSU		$67			$72		$62
Summary of Nonvested Performance Stock Unit Activity	'
	The following table summarizes nonvested PSU activity for the year ended December 31, 2013.
	(share units in thousands)	Share units			Weighted-average
					grant-date
					fair value
	Nonvested PSUs at January 1, 2013		804		$66.63
	Granted		251		68.04
	Vested		(387	)	61.62
	Forfeited		(23	)	61.2
	Nonvested PSUs at December 31, 2013		645		$70.18

Retirement_and_Other_Benefit_P1

Retirement and Other Benefit Programs (Tables)	12 Months Ended
	Dec. 31, 2013
Reconciliation of Pension and Other Postemployment Benefits (OPEB) Plan Obligations, Assets and Funded Status	'
	The benefit plan information in the table below pertains to all of the company’s pension and OPEB plans, both in the United States and in other countries.
		Pension benefits						OPEB
	as of and for the years ended December 31 (in millions)	2013			2012			2013			2012
	Benefit obligations
	Beginning of period	$	5,364		$	4,944		$	650		$	618
	Service cost		137			110			10			7
	Interest cost		207			235			26			29
	Participant contributions		9			9			11			14
	Actuarial (gain)/loss		(350	)		652			(99	)		18
	Benefit payments		(203	)		(196	)		(34	)		(36	)
	Settlements		(4	)		(387	)		—			—
	Acquisition		220			—			—			—
	Foreign exchange and other		45			(3	)		—			—
	End of period		5,425			5,364			564			650
	Fair value of plan assets
	Beginning of period		3,642			3,673			—			—
	Actual return on plan assets		464			464			—			—
	Employer contributions		67			78			23			22
	Participant contributions		9			9			11			14
	Benefit payments		(203	)		(196	)		(34	)		(36	)
	Settlements		(4	)		(387	)		—			—
	Acquisition		8			—			—			—
	Foreign exchange and other		17			1			—			—
	End of period		4,000			3,642			—			—
	Funded status at December 31	$	(1,425	)	$	(1,722	)	$	(564	)	$	(650	)
	Amounts recognized in the consolidated balance sheets
	Noncurrent asset	$	50		$	38		$	—		$	—
	Current liability		(29	)		(19	)		(24	)		(25	)
	Noncurrent liability		(1,446	)		(1,741	)		(540	)		(625	)
	Net liability recognized at December 31	$	(1,425	)	$	(1,722	)	$	(564	)	$	(650	)
Information Relating to Individual Plans in Funded Status that have ABO in Excess of Plan Assets	'
	The following is information relating to the individual plans in the funded status table above that have an ABO in excess of plan assets.
	as of December 31 (in millions)	2013			2012
	ABO	$	4,780		$	4,816
	Fair value of plan assets		3,710			3,452
Information Relating to Individual Plans in Funded Status that have PBO in Excess of Plan Assets	'
	The following is information relating to the individual plans in the funded status table above that have a PBO in excess of plan assets (many of which also have an ABO in excess of assets, and are therefore also included in the table directly above).
	as of December 31 (in millions)	2013			2012
	PBO	$	5,260		$	5,211
	Fair value of plan assets		3,785			3,452
Expected Net Pension and OPEB Plan Payments for Next 10 Years	'
	Expected Net Pension and OPEB Plan Payments for the Next 10 Years
	(in millions)	Pension			OPEB
		benefits
	2014	$	219		$	24
	2015		231			27
	2016		243			28
	2017		261			30
	2018		275			32
	2019 through 2023		1,608			172
	Total expected net benefit payments for next 10 years	$	2,837		$	313
Summary of Pre-Tax losses Included in AOCI	'
	The following is a summary of the pre-tax losses included in AOCI at December 31, 2013 and December 31, 2012.
	(in millions)	Pension			OPEB
		benefits
	Actuarial loss	$	1,455		$	55
	Prior service cost (credit) and transition obligation		—			(1	)
	Total pre-tax loss recognized in AOCI at December 31, 2013	$	1,455		$	54
	Actuarial loss	$	2,247		$	163
	Prior service cost (credit) and transition obligation		1			(1	)
	Total pre-tax loss recognized in AOCI at December 31, 2012	$	2,248		$	162
Summary of Net-of-Tax Amounts Recorded in OCI Relating to Pension and OPEB Plans	'
	The following is a summary of the net-of-tax amounts recorded in OCI relating to pension and OPEB plans.
	years ended December 31 (in millions)	2013			2012			2011
	Gain (charge) arising during the year, net of tax expense (benefit) of $221 in 2013, ($143) in 2012 and ($214) in 2011	$	426		$	(353	)	$	(375	)
	Settlement charge, net of tax expense of $65 in 2012		—			103			—
	Amortization of loss to earnings, net of tax expense of $88 in 2013, $77 in 2012 and $63 in 2011		166			139			112
	Pension and other employee benefits gain (charge)	$	592		$	(111	)	$	(263	)
Summary of Pre-tax Amounts Expected to be Amortized to Net Periodic Benefit Cost in 2014	'
	the following is a summary of the pre-tax amounts expected to be amortized to net periodic benefit cost in 2014.
	(in millions)	Pension			OPEB
		benefits
	Actuarial loss	$	144		$	—
	Prior service cost (credit) and transition obligation		—			—
	Total pre-tax amount expected to be amortized from AOCI to net pension and OPEB cost in 2014	$	144		$	—
Net Periodic Benefit Cost	'
	Net Periodic Benefit Cost
	years ended December 31 (in millions)	2013			2012			2011
	Pension benefits
	Service cost	$	137		$	110		$	112
	Interest cost		207			235			237
	Expected return on plan assets		(254	)		(288	)		(303	)
	Amortization of net losses and other deferred amounts		245			209			177
	Settlement losses		1			168			—
	Net periodic pension benefit cost	$	336		$	434		$	223
	OPEB
	Service cost	$	10		$	7		$	6
	Interest cost		26			29			28
	Amortization of net loss and prior service credit		9			7			(2	)
	Net periodic OPEB cost	$	45		$	43		$	32
Weighted-Average Assumptions Used in Determining Benefit Obligations at Measurement Date	'
	Weighted-Average Assumptions Used in Determining Benefit Obligations at the Measurement Date
		Pension benefits						OPEB
		2013			2012			2013			2012
	Discount rate
	U.S. and Puerto Rico plans		4.85%			3.95%			4.90%			4.00%
	International plans		3.41%			3.19%			n/a			n/a
	Rate of compensation increase
	U.S. and Puerto Rico plans		3.80%			4.50%			n/a			n/a
	International plans		3.29%			3.51%			n/a			n/a
	Annual rate of increase in the per-capita cost		n/a			n/a			6.25%			6.50%
	Rate decreased to		n/a			n/a			5.00%			5.00%
	by the year ended		n/a			n/a			2019			2019
	Weighted-Average Assumptions Used in Determining Net Periodic Benefit Cost
		Pension benefits									OPEB
		2013			2012			2011			2013			2012		2011
	Discount rate
	U.S. and Puerto Rico plans		3.95%			4.80%			5.45%			4.00%			4.75%		5.40%
	International plans		3.19%			4.48%			4.57%			n/a			n/a		n/a
	Expected return on plan assets
	U.S. and Puerto Rico plans		7.50%			7.75%			8.25%			n/a			n/a		n/a
	International plans		6.33%			6.85%			7.29%			n/a			n/a		n/a
	Rate of compensation increase
	U.S. and Puerto Rico plans		4.50%			4.50%			4.50%			n/a			n/a		n/a
	International plans		3.51%			3.54%			3.57%			n/a			n/a		n/a
	Annual rate of increase in the per-capita cost		n/a			n/a			n/a			6.50%			7.00%		7.50%
	Rate decreased to		n/a			n/a			n/a			5.00%			5.00%		5.00%
	by the year ended		n/a			n/a			n/a			2019			2016		2016
Effect of One-Percent Change in Assumed Healthcare Cost Trend Rate on OPEB Plan	'
	Effect of a One-Percent Change in Assumed Healthcare Cost Trend Rate on the OPEB Plan
		One percent						One percent
		increase						decrease
	years ended December 31 (in millions)	2013			2012			2013			2012
	Effect on total of service and interest cost components of OPEB cost	$	6		$	5		$	(5	)	$	(4	)
	Effect on OPEB obligation	$	74		$	92		$	(61	)	$	(74	)
Fair Value of Pension Plan Assets and Liabilities	'
	The following tables summarize the bases used to measure the pension plan assets and liabilities that are carried at fair value on a recurring basis.
										Basis of fair value measurement
	(in millions)							Balance at		Quoted prices in	Significant other		Significant
								December 31, 2013		active markets for	observable inputs		unobservable
										identical assets	(Level 2)		inputs
										(Level 1)			(Level 3)
	Assets
	Fixed income securities
	Cash and cash equivalents							$   267		$     24	$   243		$     —
	U.S. government and government agency issues							287		—	287		—
	Corporate bonds							637		—	637		—
	Equity securities
	Common stock:
	Large cap							974		974	—		—
	Mid cap							442		442	—		—
	Small cap							93		93	—		—
							Total common stock	1,509		1,509	—		—
	Mutual funds							381		180	201		—
	Common/collective trust funds							617		—	612		5
	Partnership investments							199		—	—		199
	Other holdings							103		10	91		2
	Collateral held on loaned securities							248		—	248		—
	Liabilities
	Collateral to be paid on loaned securities							-248		-88	-160		—
	Fair value of pension plan assets							$4,000		$1,635	$2,159		$   206
										Basis of fair value measurement
	(in millions)							Balance at		Quoted prices in	Significant other		Significant
								December 31, 2012		active markets for	observable inputs		unobservable
										identical assets	(Level 2)		inputs
										(Level 1)			(Level 3)
	Assets
	Fixed income securities
	Cash and cash equivalents							$   324		$   210	$   114		$     —
	U.S. government and government agency issues							252		—	252		—
	Corporate bonds							657		—	657		—
	Equity securities
	Common stock:
	Large cap							807		807	—		—
	Mid cap							426		426	—		—
	Small cap							121		121	—		—
							Total common stock	1,354		1,354	—		—
	Mutual funds							317		143	174		—
	Common/collective trust funds							467		—	462		5
	Partnership investments							180		—	—		180
	Other holdings							91		8	81		2
	Collateral held on loaned securities							168		—	168		—
	Liabilities
	Collateral to be paid on loaned securities							-168		-60	-108		—
	Fair value of pension plan assets							$3,642		$1,655	$1,800		$   187
Changes in Fair Value Measurements that Used Significant Unobservable Inputs	'
	The following is a reconciliation of changes in fair value measurements that used significant unobservable inputs (Level 3).
	(in millions)	Total			Common/collective			Partnership			Other holdings
					trust funds			investments
	Balance at December 31, 2011	$	176		$	4		$	170		$	2
	Actual return on plan assets still held at year end		12			1			11			—
	Actual return on plan assets sold during the year		—			—			—			—
	Purchases, sales and settlements		(1	)		—			(1	)		—
	Balance at December 31, 2012		187			5			180			2
	Actual return on plan assets still held at year end		8			—			8			—
	Actual return on plan assets sold during the year		—			—			—			—
	Purchases, sales and settlements		11			—			11			—
	Balance at December 31, 2013	$	206		$	5		$	199		$	2
Funded Status Percentage of Pension Plans	'
	The table below details the funded status percentage of the company’s pension plans as of December 31, 2013, including certain plans that are unfunded in accordance with the guidelines of the company’s funding policy outlined above.
		United States and Puerto Rico						International
	as of December 31, 2013 (in millions)	Qualified			Nonqualified			Funded			Unfunded			Total
		plans			plan			plans			plans
	Fair value of plan assets	$	3,253			n/a		$	747			n/a		$	4,000
	PBO		3,750		$	191			1,152		$	332			5,425
	Funded status percentage		87%			n/a			65%			n/a			74%

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Changes in AOCI by Component	'
	The following is a net-of-tax summary of the changes in AOCI by component for the year ended December 31, 2013.
	(in millions)		Currency			Pension and			Hedging			Other			Total
			translation			other employee			activities
			adjustments			benefits
	Gains (losses)
	Balance as of December 31, 2012		($	1,227	)	($	1,619	)		($5	)	$	41		($	2,810	)
	Other comprehensive income (loss) before reclassifications			236			426			41			(13	)		690
	Amounts reclassified from AOCI(a)			—			166			(26	)		4			144
	Net other comprehensive income (loss)			236			592			15			(9	)		834
	Balance as of December 31, 2013		($	991	)	($	1,027	)		$10		$	32		($	1,976	)
	(a)	See table below for details about the reclassifications for the year ended December 31, 2013.
Summary of Reclassification from AOCI to Net Income	'
	The following is a summary of the amounts reclassified from AOCI to net income during the year ended December 31, 2013.
			Adjustments reclassified
			from AOCI (a)
	(in millions)		2013			Location of impact in income statement
	Amortization of pension and other employee benefits items
	Actuarial losses and other		($	254)	(b)
				(254	)	Total before tax
				88		Tax benefit
			($	166	)	Net of tax
	Gains (losses) on hedging activities
	Interest rate contracts		$	10		Net interest expense
	Foreign exchange contracts			(1	)	Net sales
	Foreign exchange contracts			32		Cost of sales
				41		Total before tax
				(15	)	Tax expense
			$	26		Net of tax
	Other
	Other-than-temporary impairment of available-for-sale equity securities		$	(6	)	Other (income) expense, net
				(6	)	Total before tax
				2		Tax benefit
				(4	)	Net of tax
	Total reclassification for the period		($	144	)	Total net of tax
	(a)	Amounts in parentheses indicate reductions to net income.
	(b)	These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 12.

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Before Income Tax Expense by Category	'
	Income Before Income Tax Expense by Category
	years ended December 31 (in millions)	2013			2012			2011
	United States	$	446		$	386		$	399
	International		2,103			2,503			2,410
	Income before income taxes	$	2,549		$	2,889		$	2,809
Income Tax Expense	'
	Income Tax Expense
	years ended December 31 (in millions)	2013			2012			2011
	Current
	United States
	Federal	$	296		$	122		$	75
	State and local		28			55			32
	International		437			403			274
	Current income tax expense		761			580			381
	Deferred
	United States
	Federal		(147	)		112			155
	State and local		(5	)		(81	)		(6	)
	International		(72	)		(48	)		23
	Deferred income tax (benefit) expense		(224	)		(17	)		172
	Income tax expense	$	537		$	563		$	553
Deferred Tax Assets and Liabilities	'
	Deferred Tax Assets and Liabilities
	as of December 31 (in millions)	2013			2012
	Deferred tax assets
	Accrued expenses	$	426		$	171
	Retirement benefits		669			804
	Tax credits and net operating losses		426			169
	Valuation allowances		(137	)		(104	)
	Total deferred tax assets		1,384			1,040
	Deferred tax liabilities
	Subsidiaries’ unremitted earnings		265			222
	Asset basis differences		849			294
	Total deferred tax liabilities		1,114			516
	Net deferred tax asset	$	270		$	524
Income Tax Expense Reconciliation	'
	Income Tax Expense Reconciliation
	years ended December 31 (in millions)	2013			2012			2011
	Income tax expense at U.S. statutory rate	$	892		$	1,011		$	983
	Tax incentives		(240	)		(277	)		(360	)
	State and local taxes		22			(11	)		25
	Foreign tax benefit		(122	)		(177	)		(118	)
	Contingent tax matters		26			30			39
	Other factors		(41	)		(13	)		(16	)
	Income tax expense	$	537		$	563		$	553
Reconciliation of Unrecognized Tax Benefits	'
	The following is a reconciliation of the company’s unrecognized tax benefits for the years ended December 31, 2013, 2012 and 2011.
	as of and for the years ended (in millions)	2013			2012			2011
	Balance at beginning of the year	$	437		$	443		$	423
	Increase associated with tax positions taken during the current year		31			25			37
	Increase (decrease) associated with tax positions taken during a prior year		38			(9	)		15
	Settlements		(216	)		(21	)		(18	)
	Decrease associated with lapses in statutes of limitations		(3	)		(1	)		(14	)
	Balance at end of the year	$	287		$	437		$	443

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Information	'
	Segment Information
	as of and for the years ended December 31 (in millions)		BioScience			Medical			Other			Total
						Products
	2013
	Net sales			$6,564		$	8,695		$	—		$	15,259
	Depreciation and amortization			263			472			88			823
	Pre-tax income (loss)			2,435			1,398			(1,284	)		2,549
	Assets			8,967			12,269			4,633			25,869
	Capital expenditures			868			530			127			1,525
	2012
	Net sales			$6,237		$	7,953		$	—		$	14,190
	Depreciation and amortization			243			385			84			712
	Pre-tax income (loss)			2,309			1,592			(1,012	)		2,889
	Assets			7,380			7,568			5,442			20,390
	Capital expenditures			570			495			96			1,161
	2011
	Net sales			$6,053		$	7,840		$	—		$	13,893
	Depreciation and amortization			209			341			120			670
	Pre-tax income (loss)			2,416			1,522			(1,129	)		2,809
	Assets			6,533			7,495			5,045			19,073
	Capital expenditures			370			467			123			960
Pre-Tax Income Reconciliation	'
	Pre-Tax Income Reconciliation
	years ended December 31 (in millions)		2013			2012			2011
	Total pre-tax income from segments		$	3,833		$	3,901		$	3,938
	Unallocated amounts
	Net interest expense			(128	)		(87	)		(54	)
	Certain foreign exchange fluctuations and hedging activities			83			53			(16	)
	Stock compensation			(150	)		(130	)		(119	)
	Business optimization charges			(280	)		(150	)		(192	)
	AWP litigation and historical price reporting charge			—			—			(79	)
	Asset impairment and other charges			—			—			(103	)
	Pension settlement charges			—			(168	)		—
	Certain tax and legal reserves			(104	)		—			—
	Other Corporate items			(705	)		(530	)		(566	)
	Consolidated income before income taxes		$	2,549		$	2,889		$	2,809
Assets Reconciliation	'
	Assets Reconciliation
	as of December 31 (in millions)		2013			2012
	Total segment assets		$	21,236		$	14,948
	Cash and equivalents			2,733			3,270
	Deferred income taxes			1,269			1,500
	PP&E, net			437			461
	Other Corporate assets			194			211
	Consolidated total assets		$	25,869		$	20,390
Geographic Information	'
	Net sales are based on product shipment destination and assets are based on physical location.
	years ended December 31 (in millions)		2013			2012			2011
	Net sales
	United States		$	6,451		$	6,056		$	5,709
	Europe			4,597			4,196			4,392
	Asia-Pacific			2,378			2,229			2,107
	Latin America and Canada			1,833			1,709			1,685
	Consolidated net sales		$	15,259		$	14,190		$	13,893
	as of December 31 (in millions)		2013			2012			2011
	Total assets
	United States		$	7,141		$	8,034		$	7,524
	Europe			14,541			8,597			8,096
	Asia-Pacific			2,347			1,943			1,807
	Latin America and Canada			1,840			1,816			1,646
	Consolidated total assets		$	25,869		$	20,390		$	19,073
	as of December 31 (in millions)		2013			2012			2011
	PP&E, net
	United States		$	3,091		$	2,333		$	2,091
	Austria			914			802			786
	Other countries			3,827			2,963			2,648
	Consolidated PP&E, net		$	7,832		$	6,098		$	5,525
Significant Product Sales	'
	Significant Product Sales
	Effective January 1, 2013, Baxter transitioned to a commercial franchise structure for reporting net sales within each segment. Prior period net sales have been reclassified to reflect the new commercial franchise structure. The following is a summary of net sales as a percentage of consolidated net sales for the company’s commercial franchises.
	years ended December 31		2013			2012			2011
	Hemophilia1			23%			23%			23%
	Fluid Systems2			20%			21%			21%
	Renal3			20%			18%			18%
	BioTherapeutics4			14%			15%			14%
	Specialty Pharmaceuticals5			10%			10%			10%
	1	Includes sales of recombinant FVIII products (ADVATE and RECOMBINATE) and plasma-derived hemophilia products (primarily FVII, FVIII and FEIBA).
	2	Principally includes IV therapies, infusion pumps, administration sets, and premixed drug platforms.
	3	Consists of PD and HD therapies.
	4	Includes sales of the company’s liquid formulation of the antibody-replacement therapy immunoglobulin product (GAMMAGARD LIQUID) and other plasma-based therapies such as albumin and alpha-1 antitrypsin products.
	5	Principally includes nutrition and anesthesia products.

Quarterly_Financial_Results_an1

Quarterly Financial Results and Market for the Company's Stock (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Results and Market for Company's Stock	'
	years ended December 31 (in millions, except per share data)		First		Second		Third		Fourth		Full year
			quarter		quarter		quarter		quarter
	2013
	Net sales		$	3,448	$	3,669	$	3,774	$	4,368	$	15,259
	Gross margin1			1,756		1,939		1,946		1,954		7,595
	Net income attributable to Baxter1			552		590		544		326		2,012
	Earnings per common share1
	Basic			1.01		1.09		1		0.6		3.7
	Diluted			1		1.07		0.99		0.59		3.66
	Cash dividends declared per common share			0.45		0.49		0.49		0.49		1.92
	Market price per common share
	High			72.64		73.04		74.43		69.55		74.43
	Low			66.42		68.1		65.69		63.89		63.89
	2012
	Net sales		$	3,388	$	3,572	$	3,477	$	3,753	$	14,190
	Gross margin2			1,714		1,872		1,810		1,905		7,301
	Net income attributable to Baxter2			588		661		583		494		2,326
	Earnings per common share2
	Basic			1.05		1.2		1.07		0.9		4.22
	Diluted			1.04		1.19		1.06		0.89		4.18
	Cash dividends declared per common share			0.335		0.335		0.45		0.45		1.57
	Market price per common share
	High			60.26		60.27		61.15		68.81		68.81
	Low			49.66		49.03		53.58		60.09		49.03
	1	The first quarter of 2013 included currency-related charges of $28 million related to the Venezuelan currency devaluation in February 2013 and derivative instruments entered into to hedge anticipated foreign currency cash outflows for the planned acquisition of Gambro (Gambro-related derivatives), in addition to charges of $17 million associated with Gambro pre-acquisition costs. The second quarter of 2013 included losses of $55 million for Gambro-related derivatives, charges of $23 million related to Gambro pre-acquisition costs and a net benefit of $2 million related to business optimization activity. The third quarter of 2013 included Gambro acquisition and integration charges of $58 million, tax and legal reserves of $83 million, business development charges of $25 million related to upfront payments for collaboration agreements, and a net gain of $20 million principally associated with Gambro-related derivatives. The fourth quarter of 2013 included business development charges of $78 million related to upfront and milestone payments for collaboration agreements, business optimization charges of $282 million, Gambro acquisition and integration charges of $94 million and product-related charges of $17 million, principally related to remediation efforts for modifications to the SIGMA Spectrum Infusion Pump.
	2	The first quarter of 2012 included a $53 million gain related to the reduction of a contingent payment liability for certain milestones associated with the 2011 acquisition of Prism and business development charges of $48 million which primarily related to an R&D charge associated with the company’s collaboration with Momenta. The second quarter of 2012 included a $38 million gain related to the reduction of a contingent payment liability for certain milestones associated with the 2010 acquisition of ApaTech, business development charges of $30 million which related to an R&D charge associated with the company’s collaboration with Chatham and a $23 million net benefit from reserve adjustments which primarily related to an adjustment to the COLLEAGUE infusion pump reserves. The third quarter of 2012 included an R&D charge of $50 million related to the company’s agreement with Onconova. The fourth quarter of 2012 included charges of $170 million primarily related to the settlement of certain pension obligations and $150 million related to business optimization initiatives (of which $62 million was recorded in cost of sales).

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended							1 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Sep. 30, 2013
				Building and Building Improvements	Building and Building Improvements	Machinery and Equipment	Machinery and Equipment	Gambro AB
				Minimum	Maximum	Minimum	Maximum
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'
Total cash payment for the acquisition	'	'	'	'	'	'	'	$3,704
Allowance for doubtful accounts	169	127	'	'	'	'	'	'
Depreciation and amortization expense	681	597	572	'	'	'	'	'
Repairs and maintenance expense	351	297	269	'	'	'	'	'
Estimated useful life	'	'	'	'20 years	'50 years	'3 years	'15 years	'
Payments to collaborative partners classified in research and development expenses	129	138	18	'	'	'	'	'
Shipping costs included in marketing and administrative expenses	$293	$265	$260	'	'	'	'	'
Tax position likely of being realized upon ultimate settlement	'Greater than 50%	'	'	'	'	'	'	'

Inventories_Detail

Inventories (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Inventory	'	'
Raw materials	$920	$765
Work in process	1,136	898
Finished goods	1,443	1,140
Inventories	$3,499	$2,803

Property_Plant_and_Equipment_N

Property, Plant and Equipment ,Net (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Millions, unless otherwise specified
Property, Plant and Equipment, Net	'	'	'
Land	$220	$190	'
Buildings and leasehold improvements	2,670	2,181	'
Machinery and equipment	7,360	6,691	'
Equipment with customers	1,361	1,295	'
Construction in progress	2,184	1,512	'
Total property, plant and equipment, at cost	13,795	11,869	'
Accumulated depreciation	-5,963	-5,771	'
Property, plant and equipment (PP&E), net	$7,832	$6,098	$5,525

Other_LongTerm_Assets_Detail

Other Long-Term Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Other Assets, Noncurrent	'	'
Deferred income taxes	$876	$1,156
Other long-term receivables	216	154
Other	442	406
Other long-term assets	$1,534	$1,716

Accounts_Payable_and_Accrued_L

Accounts Payable and Accrued Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Accounts Payable and Accrued Liabilities, Current	'	'
Accounts payable, principally trade	$1,103	$766
Income taxes payable	302	451
Deferred income taxes	760	878
Common stock dividends payable	266	246
Employee compensation and withholdings	667	567
Property, payroll and certain other taxes	237	152
Infusion pump reserves	64	37
Business optimization reserves	199	151
Accrued rebates	346	291
Other	922	870
Accounts payable and accrued liabilities	$4,866	$4,409

Other_LongTerm_Liabilities_Det

Other Long-Term Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Other Liabilities Noncurrent	'	'
Pension and other employee benefits	$2,049	$2,427
Litigation reserves	72	32
Infusion pump reserves	19	90
Business optimization reserves	89	69
Contingent payment liabilities	340	86
Other	782	369
Other long-term liabilities	$3,351	$3,073

Net_Interest_Expense_Detail

Net Interest Expense (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Interest Income Expense Net	'	'	'
Interest costs	$225	$165	$132
Interest costs capitalized	-70	-52	-40
Interest expense	155	113	92
Interest income	-27	-26	-38
Net interest expense	$128	$87	$54

Other_Income_Expense_Net_Detai

Other (Income) Expense, Net (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Other Nonoperating Income (Expense)	'	'	'
Impairment charges	$21	$9	$62
Net gains related to contingent payment liabilities	-8	-91	'
Foreign exchange	26	-49	-10
Securitization and factoring arrangements	18	18	14
Equity method investments	-24	1	4
Noncontrolling interests	-31	-28	'
Other	-11	-15	13
Other (income) expense, net	($9)	($155)	$83

Supplemental_Financial_Informa2

Supplemental Financial Information - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

31-May-11

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Mar. 31, 2012

Dec. 31, 2012

Jun. 30, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Apr. 30, 2012

Apr. 30, 2009

US Generic Injectables Business

New Greek Government Bonds

Prism Pharmaceuticals

Prism Pharmaceuticals

Apatech Limited

Apatech Limited

Apatech Limited

Sigma International

Sigma International

Sigma International

BioScience

Supplemental Financial Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss attributable to noncontrolling interest

'

$31

$28

'

'

'

'

'

'

'

'

'

'

'

Gains (loss) related to the reduction (increase) of contingent payment liabilities

'

-8

-91

'

'

'

53

53

38

38

38

'

'

'

Impairment charges

'

21

9

62

'

62

'

'

'

'

'

'

'

'

Total consideration for the divestiture arrangement

104

'

'

'

'

'

'

'

'

'

'

'

'

'

Net sales

'

'

'

'

58

'

'

'

'

'

'

'

'

'

Cash paid for exercise of purchase option

'

'

'

'

'

'

'

'

'

'

'

'

$90

'

Equity in acquiree

'

'

'

'

'

'

'

'

'

'

'

'

'

40.00%

SIGMA pre-tax income included in results of operations after option exercise

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

Reconciliation_of_Basic_Shares

Reconciliation of Basic Shares to Diluted Shares (Detail)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of Basic Shares to Diluted Shares	'	'	'
Basic shares	543	551	569
Effect of dilutive securities	6	5	4
Diluted shares	549	556	573

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of Basic Shares to Diluted Shares	'	'	'
Anti-dilutive securities excluded from computation of EPS	5	16	19

Acquisitions_and_Collaboration2

Acquisitions and Collaborations - Additional Information (Detail) (USD $)

12 Months Ended

1 Months Ended

3 Months Ended

4 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

1 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 06, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

Feb. 29, 2012

Feb. 29, 2012

Nov. 30, 2011

Nov. 30, 2011

31-May-11

Dec. 31, 2013

Dec. 31, 2013

31-May-11

Dec. 31, 2013

Nov. 30, 2013

Nov. 30, 2013

Dec. 31, 2013

Jul. 31, 2012

Sep. 30, 2012

Jul. 31, 2012

Dec. 31, 2013

Jun. 30, 2012

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Feb. 29, 2012

Dec. 31, 2013

Dec. 31, 2013

Feb. 29, 2012

Indap Holding AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Inspiration / Ipsen OBI-1 business

Inspiration / Ipsen OBI-1 business

Inspiration / Ipsen OBI-1 business

Inspiration / Ipsen OBI-1 business

Synovis Life Technologies Inc.

Synovis Life Technologies Inc.

Baxa Corporation

Baxa Corporation

Prism Pharmaceuticals

Prism Pharmaceuticals

Prism Pharmaceuticals

Prism Pharmaceuticals

Cell Therapeutics. Inc.

Cell Therapeutics. Inc.

Cell Therapeutics. Inc.

Cell Therapeutics. Inc.

Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc.

Chatham Therapeutics

Chatham Therapeutics

JW Holdings

JW Holdings

Coherus Biosciences

Coherus Biosciences

Momenta Pharmaceuticals

Momenta Pharmaceuticals

Momenta Pharmaceuticals

Momenta Pharmaceuticals

Fair Value Adjustment to Inventory

Fair Value Adjustment to Inventory

Acquisition, Integration and currency-related charges

Developed Technology Rights

Trademarks

IPR&D

In-process R&D (IPR&D)

Other Intangible Assets

Goodwill

Marketing and administrative

In-process R&D (IPR&D)

Regulatory and Sales Milestones

Developed Technology

Customer Relationship

Maximum

Developed Technology

Common Stock

Clinical, regulatory and commercial milestones

Preferred Stock

Maximum

Maximum

Maximum

Maximum

Product

Maximum

Maximum

Maximum

Product

Acquisitions And Collaborations [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of voting interest acquired

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total cash payment for the acquisition

'

'

'

'

$3,704

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business combination recognized liabilities assumed debt

'

'

'

'

221

'

221

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Measurement period adjustments, intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-360

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Measurement period adjustments, property, plant and equipment

'

'

'

'

'

128

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Measurement period adjustments, other long-term liabilities

'

'

'

'

'

118

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Measurement period adjustments, goodwill

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

368

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other intangible assets

'

'

'

'

1,290

'

1,290

'

'

'

'

916

206

168

'

'

'

'

288

'

288

'

115

115

145

145

229

'

'

225

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets, weighted average useful life

'

'

'

'

'15 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'12 years

'

'13 years

'

'14 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash flow projections discount rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

'

'

13.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development expense

1,246

1,156

946

'

'

'

'

'

'

'

'

'

'

'

85

'

'

'

'

'

50

'

'

'

'

'

'

'

'

'

33

'

'

'

'

50

'

'

30

'

25

'

15

'

33

'

'

'

Business combination acquisition-related cost

'

'

'

'

'

94

58

'

'

'

'

'

'

'

'

'

'

101

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

'

'

'

'

'

'

'

-45

62

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Elimination of acquisition costs

'

'

'

'

'

'

'

'

62

'

244

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Addition of acquisition costs

'

'

'

'

'

'

'

'

'

62

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition, cost of acquired entity, purchase price

3,851

515

590

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

51

'

'

'

304

'

358

'

170

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition contingent consideration

340

86

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

269

291

'

135

'

'

'

'

67

17

168

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill

4,205

2,502

2,317

'

1,620

'

1,620

'

'

'

'

'

'

'

'

'

'

'

7

'

'

'

164

'

237

'

72

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

In process research and development cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business collaboration contingent consideration potential cash payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

112

'

'

'

357

'

60

'

11

'

154

'

'

131

'

Shares of Common stock acquired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to acquire stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

27

'

'

'

50

'

'

'

'

'

'

'

'

'

'

'

Research and development expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$30

'

'

'

'

'

Shares of preferred stock acquired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of named products

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

Number of products

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

Summary_of_Fair_Value_of_Consi

Summary of Fair Value of Consideration Transferred and Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2013
In Millions, unless otherwise specified				Gambro AB
Consideration transferred	'	'	'	'
Cash	'	'	'	$3,704
Fair value of consideration transferred	'	'	'	3,704
Assets acquired and liabilities assumed	'	'	'	'
Cash	'	'	'	88
Accounts receivable	'	'	'	490
Inventories	'	'	'	368
Prepaid expenses and other	'	'	'	54
Property, plant, and equipment	'	'	'	726
Other intangible assets	'	'	'	1,290
Other assets	'	'	'	11
Current-maturities of long-term debt and lease obligations	'	'	'	-2
Accounts payable and accrued liabilities	'	'	'	-340
Long-term debt and lease obligations	'	'	'	-261
Other long-term liabilities	'	'	'	-340
Total identifiable net assets	'	'	'	2,084
Goodwill	4,205	2,502	2,317	1,620
Total assets acquired and liabilities assumed	'	'	'	$3,704

Summary_of_Fair_Value_of_Consi1

Summary of Fair Value of Consideration Transferred and Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) (Gambro AB, USD $)	Sep. 30, 2013
In Millions, unless otherwise specified
Gambro AB	'
Business Acquisition [Line Items]	'
Other long-term liabilities, pension obligations	$209

Subsidiary_Information_in_Cons

Subsidiary Information in Consolidated Statement of Income from Acquisition (Detail) (Gambro AB, USD $)	4 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Gambro AB	'
Business Acquisition, Impact on Operating Results [Line Items]	'
Net sales	$513
Net loss	($45)

Supplemental_Pro_Forma_Informa

Supplemental Pro Forma Information (Detail) (Gambro AB, USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Gambro AB	'	'
Business Acquisition, Pro Forma Information [Line Items]	'	'
Net sales	$16,288	$15,767
Net income	$2,138	$2,021
Basic earnings per share	$3.94	$3.67
Diluted earnings per share	$3.89	$3.63

Summary_of_Fair_Value_of_Consi2

Summary of Fair Value of Consideration Transferred and Recognized Amounts of Recognized Amounts of Assets Acquired and Liabilities Assumed (Detail) (USD $)	12 Months Ended			1 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Mar. 31, 2013	Feb. 29, 2012	Nov. 30, 2011	31-May-11
				Inspiration / Ipsen OBI-1 business	Synovis Life Technologies Inc.	Baxa Corporation	Prism Pharmaceuticals
Consideration transferred	'	'	'	'	'	'	'
Cash, net of cash acquired	$3,851	$515	$590	$51	$304	$358	$170
Contingent payments	'	'	'	269	'	'	67
Fair value of consideration transferred	'	'	'	320	304	358	237
Assets acquired and liabilities assumed	'	'	'	'	'	'	'
Other intangible assets	'	'	'	288	115	145	229
Other assets (liabilities), net	'	'	'	25	25	-24	-64
Total identifiable net assets	'	'	'	313	140	121	165
Goodwill	4,205	2,502	2,317	7	164	237	72
Total assets acquired and liabilities assumed	'	'	'	$320	$304	$358	$237

Goodwill_Detail

Goodwill (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Line Items]	'	'
Goodwill,beginning balance	$2,502	$2,317
Additions	1,629	182
Currency translation and other adjustments	74	3
Goodwill,ending balance	4,205	2,502
BioScience	'	'
Goodwill [Line Items]	'	'
Goodwill,beginning balance	975	806
Additions	7	161
Currency translation and other adjustments	9	8
Goodwill,ending balance	991	975
Medical Products	'	'
Goodwill [Line Items]	'	'
Goodwill,beginning balance	1,527	1,511
Additions	1,622	21
Currency translation and other adjustments	65	-5
Goodwill,ending balance	$3,214	$1,527

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets, Net - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill And Other Intangible Asset [Line Items]	'	'	'
Business acquisition purchase price allocation goodwill	$1,629	$182	'
Amortization expense	129	101	81
Anticipated annual amortization expense of other intangible assets for 2014	182	'	'
Anticipated annual amortization expense of other intangible assets for 2015	180	'	'
Anticipated annual amortization expense of other intangible assets for 2016	177	'	'
Anticipated annual amortization expense of other intangible assets for 2017	159	'	'
Anticipated annual amortization expense of other intangible assets for 2018	154	'	'
Laboratoires Fasonut	'	'	'
Goodwill And Other Intangible Asset [Line Items]	'	'	'
Business acquisition purchase price allocation goodwill	$19	'	'
Equity in acquiree	20.00%	'	'

Other_Intangible_Assets_Net_De

Other Intangible Assets, Net (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Intangible Asset Excluding Goodwill [Line Items]	'	'
Gross other intangible assets	$3,103	$1,494
Accumulated amortization	-809	-680
Other intangible assets, net	2,294	814
Developed technology, including patents	'	'
Intangible Asset Excluding Goodwill [Line Items]	'	'
Gross other intangible assets	2,144	1,192
Accumulated amortization	-665	-578
Other intangible assets, net	1,479	614
Other Intangible Assets	'	'
Intangible Asset Excluding Goodwill [Line Items]	'	'
Gross other intangible assets	494	280
Accumulated amortization	-144	-102
Other intangible assets, net	350	178
Indefinite Lived Intangible Assets	'	'
Intangible Asset Excluding Goodwill [Line Items]	'	'
Gross other intangible assets	465	22
Accumulated amortization	'	'
Other intangible assets, net	$465	$22

Infusion_Pump_and_Business_Opt2

Infusion Pump and Business Optimization Charges - Additional Information (Detail) (USD $)	3 Months Ended				12 Months Ended			84 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011
Infusion Pump Charges	'	'	'	'	'	'	'	'	'
Infusion Pump Charges	'	'	'	'	'	'	'	$888	'
Infusion pump charges related to cash	'	'	'	'	'	'	'	742	716
Infusion pump charges related asset impairments	'	'	'	'	'	'	'	146	'
Adjustment to infusion pump reserves	'	'	'	'	'	37	'	'	'
Reclass of infusion pump reserve from non-cash to cash	'	'	'	'	'	63	'	'	'
Increase in cash reserves	'	'	'	'	-17	26	'	'	'
Reclass of infusion pump reserve from cash to non-cash	'	'	'	'	17	'	'	'	'
Business Optimization Charges	'	'	'	'	'	'	'	'	'
Costs associated with optimizing the cost structure	314	'	150	192	'	'	'	'	'
Reserve adjustments	20	2	'	'	-20	'	'	'	'
Cash portion of charges	'	'	'	'	182	98	156	'	'
Other costs, total	'	'	'	'	132	52	36	'	'
Restructuring cost recorded in cost of sales	'	'	'	'	145	62	95	'	'
Restructuring cost recorded in marketing and administrative expense	'	'	'	'	96	60	97	'	'
Restructuring cost recorded in research and development expense	'	'	'	'	$73	$28	'	'	'

Infusion_Pump_Charges_Detail

Infusion Pump Charges (Detail) (USD $)	12 Months Ended		84 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2011
Infusion pump reserves	'	'	'	'
Charges and adjustments in 2005 through 2011	'	'	$742	$716
Utilization	-27	-175	'	-440
Other	-17	26	'	'
Reserves, ending balance	$83	$127	$127	$276

Business_Optimization_Charges_

Business Optimization Charges (Detail) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Optimization Initiatives	'	'	'	'	'
Reserve, beginning balance	'	'	$220	$225	$180
Charge	'	'	182	98	156
Reserve adjustments	20	2	-20	'	'
Utilization	'	'	-98	-99	-110
CTA	'	'	4	-4	-1
Reserve, ending balance	$288	'	$288	$220	$225

Debt_Outstanding_Detail

Debt Outstanding (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Debt Instrument [Line Items]	'	'
Commercial paper	'	'
Other short-term debt	181	27
Short-term debt	$181	$27

Schedule_of_Debt_Outstanding_D

Schedule of Debt Outstanding (Detail) (USD $)	Dec. 31, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	$8,985	[1]	$5,903	[1]
Current portion	-859	[1]	-323	[1]
Long-term portion	8,126	[1]	5,580	[1]
1.8% notes due 2013	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	'		301	[1]
Effective Interest Rate	1.70%	[2]	'
4.0% notes due 2014	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	351	[1]	358	[1]
Effective Interest Rate	4.10%	[2]	'
Floating rate notes due 2014	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	500	[1]	'
Effective Interest Rate	0.70%	[2]	'
Variable Rate Loan due 2015	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	194	[1]	243	[1]
Effective Interest Rate	0.90%	[2]	'
4.625% notes due 2015	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	625	[1]	646	[1]
Effective Interest Rate	4.80%	[2]	'
5.9% notes due 2016	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	622	[1]	631	[1]
Effective Interest Rate	6.00%	[2]	'
0.95% notes due 2016	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	500	[1]	'
Effective Interest Rate	1.10%	[2]	'
1.85% Notes Due 2017	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	500	[1]	500	[1]
Effective Interest Rate	2.00%	[2]	'
Variable-rate loan due 2017	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	136	[1]	170	[1]
Effective Interest Rate	1.10%	[2]	'
5.375% notes due 2018	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	499	[1]	499	[1]
Effective Interest Rate	5.50%	[2]	'
1.85% notes due 2018	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	750	[1]	'
Effective Interest Rate	1.90%	[2]	'
4.5% notes due 2019	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	534	[1]	566	[1]
Effective Interest Rate	4.60%	[2]	'
4.25% notes due 2020	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	299	[1]	299	[1]
Effective Interest Rate	4.40%	[2]	'
2.40% notes due 2022	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	684	[1]	697	[1]
Effective Interest Rate	2.50%	[2]	'
3.2% notes due 2023	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	1,246	[1]	'
Effective Interest Rate	3.20%	[2]	'
6.625% Debentures due 2028	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	133	[1]	133	[1]
Effective Interest Rate	6.70%	[2]	'
6.25% notes due 2037	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	499	[1]	499	[1]
Effective Interest Rate	6.30%	[2]	'
3.65% Notes due 2042	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	298	[1]	298	[1]
Effective Interest Rate	3.70%	[2]	'
4.5% notes due 2043	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	500	[1]	'
Effective Interest Rate	4.40%	[2]	'
Other	'		'
Debt Instrument [Line Items]	'		'
Debt and capital lease obligations	$115	[1]	$63	[1]
[1]	Book values include any discounts, premiums and adjustments related to hedging instruments.
[2]	Excludes the effect of any related interest rate swaps.

Debt_Credit_Facilities_and_Lea2

Debt, Credit Facilities and Lease Commitments - Additional Information (Detail) (USD $)

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Aug. 31, 2012

Aug. 31, 2012

Aug. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jan. 31, 2013

Jun. 30, 2013

Floating rate notes due 2014

Floating rate notes due 2014

Senior Notes maturing June 2016

Senior Notes maturing in June 2018

Senior Notes maturing June 2023

Senior Notes maturing June 2043

Senior Notes Issued August 2012

2.40% notes due 2022

3.65% Notes due 2042

1.85% Notes Due 2017

Domestic Line of Credit

Foreign Line of Credit

Other Line Of Credit

Other Line Of Credit

Gambro AB

Gambro AB

Gambro AB

Bridge Loan Facility

Bridge Loan Facility

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior notes

'

'

'

'

$500,000,000

'

$500,000,000

$750,000,000

$1,250,000,000

$500,000,000

$1,000,000,000

$700,000,000

$300,000,000

$500,000,000

'

'

'

'

'

'

'

Higher rate of debt maturity periods

'

'

'

'

'December 2014

'

'June 2016

'June 2018

'June 2023

'June 2043

'

'August 2022

'August 2042

'January 2017

'

'

'

'

'

'

'

Coupon rates

'

'

'

'

'

'

0.95%

1.85%

3.20%

4.50%

'

2.40%

3.65%

1.85%

'

'

'

'

'

'

'

Senior notes, floating rate

'

'

'

'

'

0.41%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds of debt to be used for acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000,000

'

'

Commercial paper outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

2,733,000,000

3,270,000,000

2,905,000,000

2,685,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility maximum capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000,000

413,000,000

587,000,000

332,000,000

'

3,100,000,000

'

Credit facility expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2015-06

'2014-12

'

'

'

'

'

Line of Credit Facility Amount Outstanding

124,000,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

181,000,000

27,000,000

'

'

'

Bridge loan facility term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'364 days

'

Expense related bridge loan facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13,000,000

Operating lease rent expense

$214,000,000

$202,000,000

$203,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future_Minimum_Lease_Payments_

Future Minimum Lease Payments and Debt Maturities (Detail) (USD $)	Dec. 31, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Leases Future Minimum Payments [Line Items]	'		'
2014	$216		'
2015	180		'
2016	158		'
2017	140		'
2018	120		'
Thereafter	271		'
Total obligations and commitments	1,085		'
Total debt and lease obligations	1,085		'
2014	859		'
2015	813		'
2016	1,111		'
2017	647		'
2018	1,262		'
Thereafter	4,328		'
Total obligations and commitments	9,020		'
Interest on capital leases, discounts and premiums, and adjustments relating to hedging instruments	-35		'
Total debt and lease obligations	$8,985	[1]	$5,903	[1]
[1]	Book values include any discounts, premiums and adjustments related to hedging instruments.

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging Activity - Additional Information (Detail) (USD $)

12 Months Ended

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2013

Mar. 31, 2013

Gambro AB

Gambro AB

Gambro AB

Foreign exchange contract

Foreign exchange contract

Interest rate contract

Interest rate contract

Interest rate contract

Fair value hedges

Fair value hedges

Terminated Fair Value Hedge

Total notional amount of undesignated derivative instruments

Total notional amount of undesignated derivative instruments

Total notional amount of undesignated derivative instruments

Total notional amount of undesignated derivative instruments

Gambro AB

Gambro AB

Derivative Instruments and Hedging Activities Disclosures [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative notional amount

'

'

'

'

'

$2,100

$1,500

$0

$1,000

$250

$1,200

$500

$175

$381

$3,200

$1,500

$3,700

Maximum length of time hedge in cash flow hedge

'24 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain on Cash Flow Hedge

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain on Interest rate contracts designated as cash flow hedge

11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining deferred net loss to be amortized to net interest expense

6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred gain amortized over the remaining term of the hedged item

'

21

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gambro derivative (gain) loss

'

'

-20

55

23

'

'

'

'

'

'

'

'

'

'

'

'

(Gain) loss on hedged item in fair value hedge

-46

11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred, net after-tax gains on derivative instruments

$3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary_of_Gains_and_Losses_on

Summary of Gains and Losses on Derivative Instruments (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) reclassified from AOCI into income	($155)	($113)	($92)
Gain (loss) reclassified from AOCI into income	2,012	2,326	2,256
Cash Flow Hedges	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) recognized in OCI	63	-13	'
Cash Flow Hedges | Interest rate contract	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) recognized in OCI	26	-10	'
Cash Flow Hedges | Foreign Exchange Contracts One	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) recognized in OCI	1	-3	'
Cash Flow Hedges | Foreign Exchange Contracts Two	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) recognized in OCI	36	'	'
Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) reclassified from AOCI into income	41	'	'
Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Interest rate contract	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) reclassified from AOCI into income	10	'	'
Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Foreign Exchange Contracts One	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) reclassified from AOCI into income	-1	-3	'
Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Foreign Exchange Contracts Two	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) reclassified from AOCI into income	32	3	'
Fair value hedges | Interest Expense	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) recognized in income, fair value hedges	-46	11	'
Not Designated as Hedging Instrument | Other (income) expense, net	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) recognized in income, undesignated derivative instruments	$11	($7)	'

Net_of_Tax_Activity_in_Accumul

Net of Tax Activity in Accumulated Other Comprehensive Income Related to Cash Flow Hedges (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2011
Accumulated Other Comprehensive Income (Loss) [Line Items]	'		'	'
Hedging activities, Balance as of December 31, 2012	($5)		$2	($3)
Gain (loss) in fair value of derivatives during the year	41		-7	-31
Amount reclassified to earnings during the year	-26	[1],[2]	'	36
Hedging activities, Balance as of December 31, 2013	$10		($5)	$2
[1]	See table below for details about the reclassifications for the year ended December 31, 2013.
[2]	Amounts in parentheses indicate reductions to net income.

Classification_and_Fair_Value_

Classification and Fair Value Amounts of Derivative Instruments (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value	$72	$142
Derivative liability, fair value	22	37
Designated as Hedging Instrument	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value	72	95
Derivative liability, fair value	21	26
Designated as Hedging Instrument | Interest rate contract | Other Long -Term Assets	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value	35	67
Designated as Hedging Instrument | Interest rate contract | Other Long Term Liabilities	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability, fair value	14	'
Designated as Hedging Instrument | Interest rate contract | Accounts Payable And Accrued Liabilities	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability, fair value	'	21
Designated as Hedging Instrument | Foreign exchange contract | Prepaid Expense And Other	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value	37	28
Designated as Hedging Instrument | Foreign exchange contract | Accounts Payable And Accrued Liabilities	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability, fair value	7	5
Not Designated as Hedging Instrument | Foreign exchange contract | Prepaid Expense And Other	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value	'	47
Not Designated as Hedging Instrument | Foreign exchange contract | Accounts Payable And Accrued Liabilities	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability, fair value	$1	$11

Derivative_Positions_Presented

Derivative Positions Presented On Net Basis (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Derivatives, Fair Value [Line Items]	'	'
Gross amounts recognized in the consolidated balance sheet	$72	$142
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet	-17	-37
Total	55	105
Gross amounts recognized in the consolidated balance sheet	22	37
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet	-17	-37
Total	$5	'

Summary_of_Activity_Relating_t

Summary of Activity Relating to Securitization Arrangement (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounts Receivable Securitization [Line Items]	'	'	'
Sold receivables at beginning of year	$157	$160	$157
Proceeds from sales of receivables	506	630	615
Cash collections (remitted to the owners of the receivables)	-519	-624	-622
Effect of currency exchange rate changes	-30	-9	10
Sold receivables at end of year	$114	$157	$160

Financial_Instruments_and_Rela2

Financial Instruments and Related Fair Value Measurements - Additional Information (Detail) (USD $)

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Share data in Millions, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Jul. 31, 2012

Mar. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

31-May-11

Dec. 31, 2013

Jun. 30, 2012

Dec. 31, 2012

Dec. 31, 2013

Mar. 31, 2013

Jun. 30, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Jul. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Onconova Therapeutics, Inc.

Prism Pharmaceuticals

Prism Pharmaceuticals

Prism Pharmaceuticals

Prism Pharmaceuticals

Prism Pharmaceuticals

Apatech Limited

Apatech Limited

Inspiration / Ipsen OBI-1 business

Inspiration / Ipsen OBI-1 business

Greek Government Bonds and European Financial Stability Facility Bonds

Available-for-sale Securities

Debt Securities

Debt Securities

Preferred Stock

Fair Value, Inputs, Level 2

Fair Value, Inputs, Level 3

Countries With Liquidity Issues

Countries With Liquidity Issues

Countries With Liquidity Issues

Countries With Liquidity Issues

Countries With Liquidity Issues

Maximum

Maximum

Maximum

Onconova Therapeutics, Inc.

Gambro AB

Greece

Greece

Financial Instruments and Fair Value [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total accounts receivable from certain countries with liquidity issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$561,000,000

$385,000,000

'

$29,000,000

$66,000,000

Increase in account receivable from public sector

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

176,000,000

'

'

Cash and equivalents

2,733,000,000

3,270,000,000

2,905,000,000

2,685,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Money market funds, at carrying value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

568,000,000

'

'

'

'

'

'

Weighted average probability

64.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available for sale equity securities amortized cost basis

111,000,000

13,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available for sale equity securities fair value

102,000,000

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available for sale securities cumulative unrealized gain

22,000,000

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available for sale securities net unrealized (loss)

-9,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available for sale securities cumulative unrealized (losses)

-31,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available for sale securities cumulative unrealized gains(losses)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

1,000,000

'

'

'

'

'

'

'

'

Preferred stock, shares acquired

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to acquire stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

'

'

'

'

'

'

'

Losses recognized related to realized an unrealized losses associated with the company's Greek government and European Financial Stability Facility bonds

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,000,000

'

'

'

'

'

'

'

'

'

'

'

Proceed from sale of securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,000,000

45,000,000

'

'

'

'

'

'

'

'

'

'

Securities maturity period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

Business acquisition contingent consideration

340,000,000

86,000,000

'

'

'

'

'

17,000,000

67,000,000

168,000,000

'

'

291,000,000

269,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Gains (loss) related to the reduction (increase) of contingent payment liabilities

-8,000,000

-91,000,000

'

'

'

53,000,000

53,000,000

'

'

'

38,000,000

38,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assets salvage value

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

Financial_Assets_and_Liabiliti

Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Equity securities	$102	$15
Contingent payments related to acquisitions and investments	340	86
Fair Value, Inputs, Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Total assets	0	'
Fair Value, Measurements, Recurring	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Foreign currency hedges, assets at fair value	37	75
Interest rate hedges, assets at fair value	35	67
Equity securities	102	15
Total assets	192	224
Foreign currency hedges, liabilities at fair value	8	16
Interest rate hedges, liabilities at fair value	14	21
Contingent payments related to acquisitions and investments	340	86
Total liabilities	362	123
Fair Value, Measurements, Recurring | Foreign Government Debt Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Debt securities	18	16
Fair Value, Measurements, Recurring | Preferred Stock	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Debt securities	'	51
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Equity securities	102	15
Total assets	102	15
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Foreign currency hedges, assets at fair value	37	75
Interest rate hedges, assets at fair value	35	67
Total assets	90	158
Foreign currency hedges, liabilities at fair value	8	16
Interest rate hedges, liabilities at fair value	14	21
Total liabilities	22	37
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2 | Foreign Government Debt Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Debt securities	18	16
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Total assets	'	51
Contingent payments related to acquisitions and investments	340	86
Total liabilities	340	86
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3 | Preferred Stock	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Debt securities	'	$51

Reconciliation_of_Fair_Value_M

Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Contingent payments, Fair value as of beginning of period	$86	$234
Contingent payments, additions	269	'
Contingent payments, payments	-2	-40
Contingent payments, unrealized gains recognized in earnings	-17	-108
Contingent payments,CTA	4	'
Contingent payments, conversion to a publicly traded equity security	'	'
Contingent payments, Fair value as of end of period	340	86
Preferred stock, Fair value as of beginning of period	51	'
Preferred stock, additions	'	50
Preferred stock, payments	'	'
Preferred stock, unrealized gains recognized in earnings	'	'
Preferred stock,CTA	'	1
Preferred stock, conversion to a publicly traded equity security	-51	'
Preferred stock, Fair value as of end of period	'	$51

Book_Values_and_Fair_Values_of

Book Values and Fair Values of Financial Instruments (Detail) (USD $)	Dec. 31, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]	'		'
Long-Term Debt and Lease Obligations	$8,126	[1]	$5,580	[1]
Long-term litigation liabilities	72		32
Book Values	'		'
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]	'		'
Long-term insurance receivables	2		2
Investments	53		46
Short-term debt	181		27
Current maturities of long-term debt and lease obligations	859		323
Long-Term Debt and Lease Obligations	8,126		5,580
Long-term litigation liabilities	72		32
Approximate Fair Values	'		'
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]	'		'
Long-term insurance receivables	2		2
Investments	53		49
Short-term debt	181		27
Current maturities of long-term debt and lease obligations	862		324
Long-Term Debt and Lease Obligations	8,298		6,201
Long-term litigation liabilities	$70		$31
[1]	Book values include any discounts, premiums and adjustments related to hedging instruments.

Summarization_of_Bases_Used_to

Summarization of Bases Used to Measure Fair Value of Financial Instruments (Detail) (USD $)	Dec. 31, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'		'
Long-Term Debt and Lease Obligations	$8,126	[1]	$5,580	[1]
Long-term litigation liabilities	72		32
Approximate Fair Values	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'		'
Long-term insurance receivables	2		2
Investments	53		49
Total assets	55		51
Short-term debt	181		27
Current maturities of long-term debt and lease obligations	862		324
Long-Term Debt and Lease Obligations	8,298		6,201
Long-term litigation liabilities	70		31
Total liabilities	9,411		6,583
Fair Value, Inputs, Level 2 | Approximate Fair Values	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'		'
Investments	17		19
Total assets	17		19
Short-term debt	181		27
Current maturities of long-term debt and lease obligations	862		324
Long-Term Debt and Lease Obligations	8,298		6,201
Total liabilities	9,341		6,552
Fair Value, Inputs, Level 3	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'		'
Total assets	0		'
Fair Value, Inputs, Level 3 | Approximate Fair Values	'		'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'		'
Long-term insurance receivables	2		2
Investments	36		30
Total assets	38		32
Long-term litigation liabilities	70		31
Total liabilities	$70		$31
[1]	Book values include any discounts, premiums and adjustments related to hedging instruments.

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	Dec. 31, 2013
Contingencies And Commitments [Line Items]	'
Unfunded milestone payments	$2,000,000,000
Unfunded commitment payments	$50,000,000

Shareholders_Equity_Additional

Shareholders' Equity - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

Share data in Millions, except Per Share data, unless otherwise specified

Nov. 30, 2013

31-May-13

Jul. 31, 2012

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Authorized shares available for future awards under the stock-based compensation plans

'

'

'

'

'

'

'

'

'

'

'

'

'

40

Shares available for future awards under the stock-based compensation plans

'

'

'

40

'

'

'

'

'

'

'

40

'

'

Stock compensation expense

'

'

'

'

'

'

'

'

'

'

'

$150,000,000

$130,000,000

$119,000,000

Tax benefit related to stock based compensation

'

'

'

'

'

'

'

'

'

'

'

45,000,000

40,000,000

36,000,000

Stock based compensation in marketing and administrative expenses

'

'

'

'

'

'

'

'

'

'

'

70.00%

70.00%

70.00%

Exercise prices of stock options granted to employees and non employee directors

'

'

'

'

'

'

'

'

'

'

'

'At least equal to 100% of the market value

'

'

Stock options granted contractual term

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

Performance condition to percentage of market basis

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

Employee purchase price

'

'

'

'

'

'

'

'

'

'

'

'85% of the closing market price on the purchase date

'

'

Share issued, ESPP

'

'

'

'

'

'

'

'

'

'

'

0.8

0.9

0.9

Shares under Subscription, ESPP

'

'

'

1

'

'

'

'

'

'

'

1

'

'

Realized excess tax benefits from stock issued under employee benefit plans

'

'

'

'

'

'

'

'

'

'

'

34,000,000

24,000,000

21,000,000

Cash dividends declared per common share

$0.49

$0.49

$0.45

$0.49

$0.49

$0.49

$0.45

$0.45

$0.45

$0.34

$0.34

$1.92

$1.57

$1.26

Cash dividends declared per common share annualized basis

$1.96

$1.96

$1.80

'

'

'

'

'

'

'

'

'

'

'

Percentage of increase in dividend over the previously quarterly rate

'

9.00%

34.00%

'

'

'

'

'

'

'

'

'

'

'

Share repurchases

'

'

'

'

'

'

'

'

'

'

'

13

25

30

Value of share repurchases

'

'

'

'

'

'

'

'

'

'

'

900,000,000

1,500,000,000

1,600,000,000

Stock repurchase program, authorized amount

'

'

2,000,000,000

'

'

'

'

'

'

'

'

'

'

'

Remaining value available under stock repurchase programs

'

'

'

'

'

'

'

'

'

'

'

1,000,000,000

'

'

Minimum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common shares received as a percentage of performance shares

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

Maximum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common shares received as a percentage of performance shares

'

'

'

'

'

'

'

'

'

'

'

200.00%

'

'

Senior Management | Performance Based Awards With Market Conditions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Performance condition to percentage of market basis

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

Employee Stock Option

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total intrinsic value of stock options exercised

'

'

'

'

'

'

'

'

'

'

'

176,000,000

129,000,000

102,000,000

Unrecognized compensation cost related to all unvested

'

'

'

58,000,000

'

'

'

'

'

'

'

58,000,000

'

'

Weighted-average period for all unvested

'

'

'

'

'

'

'

'

'

'

'

'1 year 7 months 6 days

'

'

Stock Options And Restricted Stock Units To Employees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options and RSUs vesting period

'

'

'

'

'

'

'

'

'

'

'

'One-third increments over a three-year period

'

'

Stock Options And Restricted Stock Units To Non Employee Directors

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options and RSUs vesting period

'

'

'

'

'

'

'

'

'

'

'

'100% one year from the grant date

'

'

Employee Stock Purchase Plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Authorized shares available for future awards under the stock-based compensation plans

'

'

'

'

'

'

'

'

'

'

'

'

'

10

Restricted Stock Units

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to all unvested

'

'

'

68,000,000

'

'

'

'

'

'

'

68,000,000

'

'

Weighted-average period for all unvested

'

'

'

'

'

'

'

'

'

'

'

'1 year 8 months 12 days

'

'

Weighted average fair value

'

'

'

'

'

'

'

'

'

'

'

$70.09

$57.03

$53.87

Fair value of RSUs and restricted stock vested

'

'

'

'

'

'

'

'

'

'

'

47,000,000

21,000,000

7,000,000

Performance Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to all unvested

'

'

'

$15,000,000

'

'

'

'

'

'

'

$15,000,000

'

'

Weighted-average period for all unvested

'

'

'

'

'

'

'

'

'

'

'

'1 year 7 months 6 days

'

'

Weighted average fair value

'

'

'

'

'

'

'

'

'

'

'

$68.04

'

'

Stock_Options_Fair_Value_Assum

Stock Options Fair Value Assumptions (Detail) (Employee Stock Option, USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Stock Option	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected volatility	25.00%	25.00%	25.00%
Expected life (in years)	'5 years 6 months	'5 years 6 months	'5 years
Risk-free interest rate	0.90%	1.00%	2.20%
Dividend yield	2.60%	2.30%	2.30%
Fair value per stock option	$12	$10	$10

Summary_of_Stock_Option_Activi

Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013
Number of options	'
Number of options, Outstanding at beginning of year	32,055
Number of options, Granted	6,354
Number of options, Exercised	-8,517
Number of options, Forfeited	-679
Number of options, Expired	-84
Number of options, Outstanding at end of year	29,129
Number of options, Vested or expected to vest at end of year	28,642
Number of options , Exercisable at end of year	17,732
Stock options grant weighted-average exercise price	'
Weighted-average exercise price, Outstanding at beginning of year	$52.62
Weighted-average exercise price, Granted	$70.23
Weighted-average exercise price, Exercised	$50.15
Weighted-average exercise price, Forfeited	$62.26
Weighted-average exercise price, Expired	$40.26
Weighted Average Exercise Price Outstanding at end of year	$57
Weighted Average Exercise Price Vested or expected to vest at end of year	$56.82
Weighted Average Exercise Price Exercisable at end of year	$52.64
Stock options grant Weighted-average remaining contractual life	'
Weighted average remaining contractual life, Outstanding at end of year	'6 years 2 months 12 days
Weighted average remaining contractual life, Vested or expected to vest at end of year	'6 years 1 month 6 days
Weighted average remaining contractual life, Exercisable at end of year	'4 years 8 months 12 days
Aggregate intrinsic value, outstanding, ending balance	$361,468
Aggregate intrinsic value,Vested or expected to vest at end of year	360,329
Aggregate intrinsic value, Exercisable at end of year	$293,590

Summary_of_Nonvested_Restricte

Summary of Nonvested Restricted Stock Units Activity (Detail) (Restricted Stock Units, USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restricted Stock Units	'	'	'
RSUs shares	'	'	'
Nonvested Units at beginning of year	1,979	'	'
Granted	1,043	'	'
Vested	-647	'	'
Forfeited	-157	'	'
Nonvested Units at end of year	2,218	1,979	'
RSUs weighted-average grant date fair value	'	'	'
Weighted-average grant date fair value Nonvested Units at beginning of year	$55.36	'	'
Weighted-average grant date fair value Granted	$70.09	$57.03	$53.87
Weighted-average grant date fair value Vested	$54.96	'	'
Weighted-average grant date fair value Forfeited	$60.55	'	'
Weighted-average grant date fair value Nonvested Units at end of year	$62.06	$55.36	'

Performance_Stock_Units_Fair_V

Performance Stock Units Fair Value Assumptions (Detail) (Performance Shares, USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Performance Shares	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Baxter volatility	21.00%	24.00%	28.00%
Peer group volatility	'	'	'
Peer group volatility minimum	13.00%	14.00%	19.00%
Peer group volatility maximum	38.00%	50.00%	55.00%
Correlation of returns	'	'	'
Correlation of returns minimum	0.37	0.26	0.29
Correlation of returns maximum	0.62	0.54	0.61
Risk-free interest rate	0.30%	0.40%	1.20%
Fair value per PSU	$67	$72	$62

Summary_of_Nonvested_Performan

Summary of Nonvested Performance Stock Unit Activity (Detail) (Performance Shares, USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013
Performance Shares	'
PSUs shares	'
Nonvested Units at beginning of year	804
Granted	251
Vested	-387
Forfeited	-23
Nonvested Units at end of year	645
PSUs weighted-average grant date fair value	'
Weighted-average grant date fair value Nonvested Units at beginning of year	$66.63
Weighted-average grant date fair value Granted	$68.04
Weighted-average grant date fair value Vested	$61.62
Weighted-average grant date fair value Forfeited	$61.20
Weighted-average grant date fair value Nonvested Units at end of year	$70.18

Retirement_and_Other_Benefit_P2

Retirement and Other Benefit Programs - Additional Information (Detail) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Equity Securities

Fixed Income Securities

Us Pension Plan Settlement

Accumulated Benefit Obligation

Accumulated Benefit Obligation

Pension And Other Postretirement Benefits

Pension And Other Postretirement Benefits

Pension Plans, Defined Benefit

Pension Plans, Defined Benefit

Gambro AB

Person

OPEB Plan

Defined Benefit Plan Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Net pension liability

'

'

'

'

'

'

'

'

'

'

($1,425,000,000)

($1,722,000,000)

$212,000,000

Noncurrent liability

'

'

'

'

'

'

'

'

'

'

1,446,000,000

1,741,000,000

209,000,000

Number of eligible terminated-vested participants

'

'

'

'

'

16,000

'

'

'

'

'

'

'

Defined Benefit Plan, Settlements acceptance rate

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

Settlement charge final payout

'

'

'

'

'

377,000,000

'

'

'

'

'

'

'

Settlement charge

'

'

'

'

'

164,000,000

'

'

'

'

-1,000,000

-168,000,000

'

Accumulated benefit obligation of company's pension plan

'

'

'

'

'

'

5,000,000,000

4,950,000,000

'

'

'

'

'

Expected federal subsidies

'

'

'

'

'

'

'

'

'

49,000,000

'

'

'

Expected OPEB benefit payments, net of federal subsidies year 2014

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

Expected OPEB benefit payments, net of federal subsidies year 2015

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

Expected OPEB benefit payments, net of federal subsidies year 2016

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

Expected OPEB benefit payments, net of federal subsidies year 2017

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

Expected OPEB benefit payments, net of federal subsidies year 2018

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

Settlement Charges, before tax

'

'

'

'

'

'

'

'

'

'

'

168,000,000

'

Settlement Charges, Net of tax

'

103,000,000

'

'

'

'

'

'

'

'

'

103,000,000

'

Expected return on plan assets assumption rate for 2014

7.50%

'

'

'

'

'

'

'

'

'

'

'

'

General investment portfolio limits on holdings, description

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

Target allocation for plan assets

'

'

'

'60 percent

'40 percent

'

'

'

'

'

'

'

'

Allowed variance from target allocation of plan assets

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

Minimum expected cash contribution to pension plans in 2014

42,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Expected cash outflow relating to OPEB in 2014

'

'

'

'

'

'

'

'

25,000,000

'

'

'

'

Defined contribution plan, contributions by employer

$45,000,000

$39,000,000

$37,000,000

'

'

'

'

'

'

'

'

'

'

Reconciliation_of_Pension_and_

Reconciliation of Pension and Other Postemployment Benefits (OPEB) Plan Obligations, Assets and Funded Status (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Benefit obligations	'	'	'
End of period	$5,425	'	'
Fair value of plan assets	'	'	'
End of period	4,000	3,642	'
Pension Plans, Defined Benefit	'	'	'
Benefit obligations	'	'	'
Beginning of period	5,364	4,944	'
Service cost	137	110	112
Interest cost	207	235	237
Participant contributions	9	9	'
Actuarial (gain)/loss	-350	652	'
Benefit payments	-203	-196	'
Settlements	-4	-387	'
Acquisition	220	'	'
Foreign exchange and other	45	-3	'
End of period	5,425	5,364	4,944
Fair value of plan assets	'	'	'
Beginning of period	3,642	3,673	'
Actual return on plan assets	464	464	'
Employer contributions	67	78	'
Participant contributions	9	9	'
Benefit payments	-203	-196	'
Settlements	-4	-387	'
Acquisition	8	'	'
Foreign exchange and other	17	1	'
End of period	4,000	3,642	3,673
Funded status at December 31	-1,425	-1,722	'
Amounts recognized in the consolidated balance sheets	'	'	'
Noncurrent asset	50	38	'
Current liability	-29	-19	'
Noncurrent liability	-1,446	-1,741	'
Net liability recognized at December 31	-1,425	-1,722	'
Other Postretirement Benefit Plans, Defined Benefit	'	'	'
Benefit obligations	'	'	'
Beginning of period	650	618	'
Service cost	10	7	6
Interest cost	26	29	28
Participant contributions	11	14	'
Actuarial (gain)/loss	-99	18	'
Benefit payments	-34	-36	'
End of period	564	650	618
Fair value of plan assets	'	'	'
Employer contributions	23	22	'
Participant contributions	11	14	'
Benefit payments	-34	-36	'
Funded status at December 31	-564	-650	'
Amounts recognized in the consolidated balance sheets	'	'	'
Current liability	-24	-25	'
Noncurrent liability	-540	-625	'
Net liability recognized at December 31	($564)	($650)	'

Information_Relating_to_Indivi

Information Relating to Individual Plans in Funded Status Table above that have ABO in Excess of Plan Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Information relating to the individual plans in the funded status table above that have an ABO in excess of plan assets	'	'
ABO	$4,780	$4,816
Fair value of plan assets	$3,710	$3,452

Information_Relating_to_Indivi1

Information Relating to Individual Plans in Funded Status Table that have PBO in Excess of Plan Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Information relating to the individual plans in the funded status table above that have a PBO in excess of plan assets	'	'
PBO	$5,260	$5,211
Fair value of plan assets	$3,785	$3,452

Expected_Net_Pension_and_OPEB_

Expected Net Pension and OPEB Plan Payments for Next 10 Years (Detail) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Pension Plans, Defined Benefit	'
Expected Net Pension and OPEB Plan Payments for the Next 10 Years	'
2014	$219
2015	231
2016	243
2017	261
2018	275
2019 through 2023	1,608
Total expected net benefit payments for next 10 years	2,837
Other Postretirement Benefit Plans, Defined Benefit	'
Expected Net Pension and OPEB Plan Payments for the Next 10 Years	'
2014	24
2015	27
2016	28
2017	30
2018	32
2019 through 2023	172
Total expected net benefit payments for next 10 years	$313

Summary_of_PreTax_losses_Inclu

Summary of Pre-Tax losses Included in AOCI (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Pension Plans, Defined Benefit	'	'
Summary of the pre-tax losses included in AOCI	'	'
Actuarial loss	$1,455	$2,247
Prior service cost (credit) and transition obligation	'	1
Total pre-tax loss recognized in AOCI	1,455	2,248
Other Postretirement Benefit Plans, Defined Benefit	'	'
Summary of the pre-tax losses included in AOCI	'	'
Actuarial loss	55	163
Prior service cost (credit) and transition obligation	-1	-1
Total pre-tax loss recognized in AOCI	$54	$162

Summary_of_NetofTax_Amounts_Re

Summary of Net-of-Tax Amounts Recorded in OCI Relating to Pension and OPEB Plans (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of the net-of-tax amounts recorded in OCI relating to pension and OPEB plans	'	'	'
Gain (charge) arising during the year, net of tax expense (benefit) of $221 in 2013, ($143) in 2012 and ($214) in 2011	$426	($353)	($375)
Settlement charge, net of tax expense of $65 in 2012	'	103	'
Amortization of loss to earnings, net of tax expense of $88 in 2013, $77 in 2012 and $63 in 2011	166	139	112
Pension and other employee benefits gain (charge)	$592	($111)	($263)

Summary_of_NetofTax_Amounts_Re1

Summary of Net-of-Tax Amounts Recorded in OCI Relating to Pension and OPEB Plans (Parenthetical) (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Gain (charge) arising during the year, tax amount	$221	($143)	($214)
Settlement charge, tax expense	'	65	'
Amortization of loss to earnings, tax expense	$88	$77	$63

Amounts_Expected_to_be_Amortiz

Amounts Expected to be Amortized from AOCI to Net Periodic Benefit Cost in 2014 (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Pension Plans, Defined Benefit	'
Defined Benefit Plan Disclosure [Line Items]	'
Actuarial loss	$144
Prior service cost (credit) and transition obligation	'
Total pre-tax amount expected to be amortized from AOCI to net pension and OPEB cost in 2014	144
Other Postretirement Benefit Plans, Defined Benefit	'
Defined Benefit Plan Disclosure [Line Items]	'
Actuarial loss	'
Prior service cost (credit) and transition obligation	'
Total pre-tax amount expected to be amortized from AOCI to net pension and OPEB cost in 2014	'

Net_Periodic_Benefit_Cost_Deta

Net Periodic Benefit Cost (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Pension Plans, Defined Benefit	'	'	'
Net periodic benefit cost	'	'	'
Service cost	$137	$110	$112
Interest cost	207	235	237
Expected return on plan assets	-254	-288	-303
Amortization of net losses and other deferred amounts	245	209	177
Settlement losses	1	168	'
Net periodic benefit cost	336	434	223
Other Postretirement Benefit Plans, Defined Benefit	'	'	'
Net periodic benefit cost	'	'	'
Service cost	10	7	6
Interest cost	26	29	28
Amortization of net loss and prior service credit	9	7	-2
Net periodic benefit cost	$45	$43	$32

WeightedAverage_Assumptions_Us

Weighted-Average Assumptions Used in Determining (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Pension Benefits	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
by the year ended	'	'	'
Pension Benefits | United States And Puerto Rico Nonqualified Plans	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Discount rate	4.85%	3.95%	'
Rate of compensation increase	3.80%	4.50%	'
Discount rate	3.95%	4.80%	5.45%
Expected return on plan assets	7.50%	7.75%	8.25%
Rate of compensation increase	4.50%	4.50%	4.50%
Pension Benefits | International Unfunded Plans	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Discount rate	3.41%	3.19%	'
Rate of compensation increase	3.29%	3.51%	'
Discount rate	3.19%	4.48%	4.57%
Expected return on plan assets	6.33%	6.85%	7.29%
Rate of compensation increase	3.51%	3.54%	3.57%
Other Postretirement Benefit Plans, Defined Benefit	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Annual rate of increase in the per-capita cost	6.25%	6.50%	'
Rate decreased to	5.00%	5.00%	'
by the year ended	'2019	'2019	'
Annual rate of increase in the per-capita cost	6.50%	7.00%	7.50%
Rate decreased to	5.00%	5.00%	5.00%
by the year ended	'2019	'2016	'2016
Other Postretirement Benefit Plans, Defined Benefit | United States And Puerto Rico Nonqualified Plans	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Discount rate	4.90%	4.00%	'
Discount rate	4.00%	4.75%	5.40%

Effect_of_OnePercent_Change_in

Effect of One-Percent Change in Assumed Healthcare Cost Trend Rate on the OPEB Plan (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Effect of a one-percentage change in assumed healthcare cost trend rate on the OPEB plan	'	'
Effect on total of service and interest cost components of OPEB cost,one percent increase	$6	$5
Effect on OPEB obligation,one percent increase	74	92
Effect on total of service and interest cost components of OPEB cost, one point decrease	-5	-4
Effect on OPEB obligation, one point decrease	($61)	($74)

Fair_Value_of_Pension_Plan_Ass

Fair Value of Pension Plan Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Millions, unless otherwise specified
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	$4,000	$3,642	'
Cash and Cash Equivalents	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	267	324	'
U.S Government and Government Agency Issues	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	287	252	'
Corporate Debt Securities	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	637	657	'
Common Stock Large Cap	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	974	807	'
Common Stock Mid Cap	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	442	426	'
Common Stock Small Cap	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	93	121	'
Common Stock	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	1,509	1,354	'
Mutual Funds	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	381	317	'
Common Collective Trust Funds	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	617	467	'
Partnership Investments	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	199	180	'
Other Holdings	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	103	91	'
Collateral Held on Loaned Securities	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	248	168	'
Securities Pledged as Collateral	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Collateral to be paid on loaned securities	-248	-168	'
Fair Value, Inputs, Level 1	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	1,635	1,655	'
Fair Value, Inputs, Level 1 | Cash and Cash Equivalents	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	24	210	'
Fair Value, Inputs, Level 1 | Common Stock Large Cap	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	974	807	'
Fair Value, Inputs, Level 1 | Common Stock Mid Cap	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	442	426	'
Fair Value, Inputs, Level 1 | Common Stock Small Cap	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	93	121	'
Fair Value, Inputs, Level 1 | Common Stock	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	1,509	1,354	'
Fair Value, Inputs, Level 1 | Mutual Funds	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	180	143	'
Fair Value, Inputs, Level 1 | Other Holdings	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	10	8	'
Fair Value, Inputs, Level 1 | Securities Pledged as Collateral	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Collateral to be paid on loaned securities	-88	-60	'
Fair Value, Inputs, Level 2	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	2,159	1,800	'
Fair Value, Inputs, Level 2 | Cash and Cash Equivalents	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	243	114	'
Fair Value, Inputs, Level 2 | U.S Government and Government Agency Issues	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	287	252	'
Fair Value, Inputs, Level 2 | Corporate Debt Securities	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	637	657	'
Fair Value, Inputs, Level 2 | Mutual Funds	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	201	174	'
Fair Value, Inputs, Level 2 | Common Collective Trust Funds	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	612	462	'
Fair Value, Inputs, Level 2 | Other Holdings	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	91	81	'
Fair Value, Inputs, Level 2 | Collateral Held on Loaned Securities	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	248	168	'
Fair Value, Inputs, Level 2 | Securities Pledged as Collateral	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Collateral to be paid on loaned securities	-160	-108	'
Fair Value, Inputs, Level 3	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	206	187	176
Fair Value, Inputs, Level 3 | Common Collective Trust Funds	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	5	5	'
Fair Value, Inputs, Level 3 | Partnership Investments	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	199	180	170
Fair Value, Inputs, Level 3 | Other Holdings	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Fair value of pension plan assets	$2	$2	$2

Changes_in_Fair_Value_Measurem

Changes in Fair Value Measurements that Used Significant Unobservable Inputs (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Defined Benefit Plan Disclosure [Line Items]	'	'
End of period	$4,000	$3,642
Fair Value, Inputs, Level 3	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'
Beginning of period	187	176
Actual return on plan assets still held at year end	8	12
Actual return on plan assets sold during the year	'	'
Purchases, sales and settlements	11	-1
End of period	206	187
Collective Trust Funds | Fair Value, Inputs, Level 3	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'
Beginning of period	5	4
Actual return on plan assets still held at year end	'	1
Actual return on plan assets sold during the year	'	'
End of period	5	5
Partnership Investments	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'
End of period	199	180
Partnership Investments | Fair Value, Inputs, Level 3	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'
Beginning of period	180	170
Actual return on plan assets still held at year end	8	11
Actual return on plan assets sold during the year	'	'
Purchases, sales and settlements	11	-1
End of period	199	180
Other Holdings	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'
End of period	103	91
Other Holdings | Fair Value, Inputs, Level 3	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'
Beginning of period	2	2
Actual return on plan assets sold during the year	'	'
End of period	$2	$2

Funded_Status_Percentage_of_Co

Funded Status Percentage of Company's Pension Plans (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Funded status percentage of the company's pension plans	'	'
Fair value of plan assets	$4,000	$3,642
PBO	5,425	'
Funded status percentage	74.00%	'
United States Pension Plans of US Entity, Defined Benefit | Qualified Pension Plan	'	'
Funded status percentage of the company's pension plans	'	'
Fair value of plan assets	3,253	'
PBO	3,750	'
Funded status percentage	87.00%	'
United States Pension Plans of US Entity, Defined Benefit | Non Qualified Pension Plan	'	'
Funded status percentage of the company's pension plans	'	'
PBO	191	'
Foreign Pension Plans, Defined Benefit | Qualified Pension Plan	'	'
Funded status percentage of the company's pension plans	'	'
Fair value of plan assets	747	'
PBO	1,152	'
Funded status percentage	65.00%	'
Foreign Pension Plans, Defined Benefit | Non Qualified Pension Plan	'	'
Funded status percentage of the company's pension plans	'	'
PBO	$332	'

Summary_of_Changes_in_AOCI_by_

Summary of Changes in AOCI by Component (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2011
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'		'	'
Currency translation adjustment, Balance as of December 31, 2012	($1,227)		'	'
Currency translation adjustment, other comprehensive income (loss) before reclassifications	236		'	'
Currency translation adjustment, amounts reclassified from AOCI	'	[1]	'	'
Currency translation adjustment, net other comprehensive income (loss)	236		-98	-205
Currency translation adjustment, Balance as of December 31, 2013	-991		-1,227	'
Pension and other employee benefit Balance as of December 31, 2012	-1,619		'	'
Pension and other employee benefit, Other comprehensive income (loss) before reclassifications	426		'	'
Pension and other employee benefit, Amounts reclassified from AOCI	166	[1],[2]	'	'
Pension and other employee benefit, Net other comprehensive income (loss)	592		-111	-263
Pension and other employee benefit Balance as of Balance as of December 31, 2013	-1,027		-1,619	'
Hedging activities, Balance as of December 31, 2012	-5		2	-3
Hedging activities, Other comprehensive income (loss) before reclassifications	41		-7	-31
Hedging activities, Amounts reclassified from AOCI	-26	[1],[2]	'	36
Hedging activities, Net other comprehensive income (loss)	15		-7	5
Hedging activities, Balance as of December 31, 2013	10		-5	2
Other, Balance as of December 31, 2012	41		'	'
Other, Other comprehensive income (loss) before reclassifications	-13		'	'
Other, Amounts reclassified from AOCI	4	[1],[2]	'	'
Other, Net other comprehensive income (loss)	-9		'	'
Other, Balance as of December 31, 2013	32		41	'
Total, Balance as of December 31, 2012	-2,810		'	'
Total, Other comprehensive income (loss) before reclassifications	690		'	'
Total, Amounts reclassified from AOCI	144	[1],[2]	'	'
Total other comprehensive income (loss), net of tax	834		-219	-462
Total, Balance as of December 31, 2013	($1,976)		($2,810)	'
[1]	See table below for details about the reclassifications for the year ended December 31, 2013.
[2]	Amounts in parentheses indicate reductions to net income.

Summary_of_Amounts_Reclassific

Summary of Amounts Reclassification from AOCI to Net Income (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2011
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, before tax	($254)	[1]	'
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, tax benefit	88	[1]	'
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, net of tax	-166	[1],[2]	'
Gain (loss) on hedging activities reclassified from AOCI to net income, before tax	41	[1]	'
Gain (loss) on hedging activities reclassified from AOCI to net income, tax expense	-15	[1]	'
Gain (loss) on hedging activities reclassified from AOCI to net income, net of tax	26	[1],[2]	-36
Other Impairment charge reclassified from AOCI to net income, before tax	-6	[1]	'
Other Impairment charge reclassified from AOCI to net income, tax expense	2	[1]	'
Other Impairment charge reclassified from AOCI to net income, net of tax	-4	[1],[2]	'
Total reclassification for the period	-144	[1],[2]	'
Interest rate contract | Interest Expense	'		'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'
Gain (loss) on hedging activities reclassified from AOCI to net income, before tax	10	[1]	'
Foreign exchange contract | Net Sales	'		'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'
Gain (loss) on hedging activities reclassified from AOCI to net income, before tax	-1	[1]	'
Foreign exchange contract | Cost of Sales	'		'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'
Gain (loss) on hedging activities reclassified from AOCI to net income, before tax	32	[1]	'
Asset Impairment and Other Charges | Other (income) expense, net	'		'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'
Other Impairment charge reclassified from AOCI to net income, before tax	-6	[1]	'
Actuarial losses and other	'		'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, before tax	($254)	[1],[3]	'
[1]	Amounts in parentheses indicate reductions to net income.
[2]	See table below for details about the reclassifications for the year ended December 31, 2013.
[3]	These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 12.

Income_Before_Income_Tax_Expen

Income Before Income Tax Expense by Category (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Before Income Taxes [Line Items]	'	'	'
United States	$446	$386	$399
International	2,103	2,503	2,410
Income before income taxes	$2,549	$2,889	$2,809

Income_Tax_Expense_Detail

Income Tax Expense (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current	'	'	'
Federal	$296	$122	$75
State and local	28	55	32
International	437	403	274
Current income tax expense	761	580	381
Deferred	'	'	'
Federal	-147	112	155
State and local	-5	-81	-6
International	-72	-48	23
Deferred income tax (benefit) expense	-224	-17	172
Income tax expense	$537	$563	$553

Deferred_Tax_Assets_and_Liabil

Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Deferred tax assets	'	'
Accrued expenses	$426	$171
Retirement benefits	669	804
Tax credits and net operating losses	426	169
Valuation allowances	-137	-104
Total deferred tax assets	1,384	1,040
Deferred tax liabilities	'	'
Subsidiaries' unremitted earnings	265	222
Asset basis differences	849	294
Total deferred tax liabilities	1,114	516
Net deferred tax asset	$270	$524

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 31, 2012

Dec. 31, 2012

Jun. 30, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Prism Pharmaceuticals

Prism Pharmaceuticals

Apatech Limited

Apatech Limited

Apatech Limited

Colleague

Investments in Foreign Subsidiaries and Foreign Corporate Joint Ventures that are Essentially Permanent in Duration

Investments in Foreign Subsidiaries and Foreign Corporate Joint Ventures that are Essentially Permanent in Duration

Domestic Tax Authority

Domestic Tax Authority

Domestic Tax Authority

Domestic Tax Authority

Foreign Tax Authority

Foreign Tax Authority

SWITZERLAND

SWITZERLAND

SWITZERLAND

Operating Loss Carryforward Expiring Year One

Operating Loss Carryforward Expiring Year Two

Operating Loss Carryforward Expiring Year Three

Operating Loss Carryforward Expiring Year Four

Operating Loss Carryforward Expiring Year Five

Operating Loss Carryforward Expiring Year Six

Operating Loss Carryforward Expiring After 2018

Operating Loss Carryforward No Expiration

BioScience

Gambro AB

Minimum

Maximum

Gambro AB

Forecast

Maximum

Foreign Tax Authority

Foreign Tax Authority

Foreign Tax Authority

Foreign Tax Authority

Foreign Tax Authority

Foreign Tax Authority

Foreign Tax Authority

Foreign Tax Authority

Income Taxes [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating loss carryforwards

'

'

'

'

'

'

'

'

'

'

'

$142,000,000

$125,000,000

'

'

$1,300,000,000

$992,000,000

'

'

'

$8,000,000

$4,000,000

$31,000,000

$49,000,000

$37,000,000

$2,000,000

$100,000,000

$1,100,000,000

Operating loss carryforwards, expiration dates

'

'

'

'

'

'

'

'

'

'

'

'

'

'2014

'2032

'

'

'

'

'

'2014

'2015

'2016

'2017

'2018

'2019

'

'

Foreign tax credit carryforwards

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

65,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Operating loss carryforwards, expiration dates

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'After 2019

'No expiration date

Valuation allowance

137,000,000

104,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Foreign earnings for prior years not indefinitely reinvested

47,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Foreign unremitted earnings

'

'

'

'

'

'

'

'

'

12,200,000,000

10,600,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated federal and state income tax amounts net of applicable credits on foreign unremitted earnings

'

'

'

'

'

'

'

'

'

3,800,000,000

3,400,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective income tax rate

21.00%

20.00%

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

Unrecognized tax benefits arising from research and development credit

16,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gains (loss) related to the reduction (increase) of contingent payment liabilities

-8,000,000

-91,000,000

'

53,000,000

53,000,000

38,000,000

38,000,000

38,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Infusion pump reserve adjustment

'

37,000,000

'

'

'

'

'

'

37,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income expense(benefit)

537,000,000

563,000,000

553,000,000

'

0

'

0

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized interest and penalties expense

1,000,000

12,000,000

18,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net interest and penalties

124,000,000

103,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross unrecognized tax benefit liability

393,000,000

517,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impact on earnings per diluted share

$0.44

$0.50

$0.56

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Manufacturing Operation will be partially exempt from local tax rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

Income tax holiday termination date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'End of 2013

'

'

'

'

'

'

'

'

'

'

Expected reduction in uncertain tax positions

$75,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income tax examination expected months for settlement proceedings

'Within the next 12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income_Tax_Expense_Reconciliat

Income Tax Expense Reconciliation (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Expense Reconciliation	'	'	'
Income tax expense at U.S. statutory rate	$892	$1,011	$983
Tax incentives	-240	-277	-360
State and local taxes	22	-11	25
Foreign tax benefit	-122	-177	-118
Contingent tax matters	26	30	39
Other factors	-41	-13	-16
Income tax expense	$537	$563	$553

Reconciliation_of_Companys_Unr

Reconciliation of Company's Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns	'	'	'
Balance at beginning of the year	$437	$443	$423
Increase associated with tax positions taken during the current year	31	25	37
Increase (decrease) associated with tax positions taken during a prior year	38	-9	15
Settlements	-216	-21	-18
Decrease associated with lapses in statutes of limitations	-3	-1	-14
Balance at end of the year	$287	$437	$443

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail) (USD $)	Dec. 31, 2013	Sep. 30, 2013	Jan. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
In Millions, unless otherwise specified	DerivativeAction		Subsequent Event	Illinois State	Delaware	Heparin Litigation
				DerivativeAction	DerivativeAction	Case
Loss Contingencies [Line Items]	'	'	'	'	'	'
Total legal liabilities	$160	$83	'	'	'	'
Litigation related receivables	7	'	'	'	'	'
Number of derivative actions filed in state court	2	'	'	1	1	'
Settlement amount	'	'	$64	'	'	'
Lawsuits pending	'	'	'	'	'	30

Segment_Information_Additional

Segment Information - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2011
	Segment	Total Assets	Capital Expenditures
Segment Information [Line Items]	'	'	'
Number of segments	2	'	'
Impact of re-allocation on segment measures, shift from MP to BioScience	'	$988	$25

Segment_Information_Detail

Segment Information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	$4,368	$3,774	$3,669	$3,448	$3,753	$3,477	$3,572	$3,388	$15,259	$14,190	$13,893
Depreciation and amortization	'	'	'	'	'	'	'	'	823	712	670
Pre-tax income (loss)	'	'	'	'	'	'	'	'	2,549	2,889	2,809
Assets	25,869	'	'	'	20,390	'	'	'	25,869	20,390	19,073
Capital expenditures	'	'	'	'	'	'	'	'	1,525	1,161	960
BioScience	'	'	'	'	'	'	'	'	'	'	'
Segment Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	6,564	6,237	6,053
Depreciation and amortization	'	'	'	'	'	'	'	'	263	243	209
Pre-tax income (loss)	'	'	'	'	'	'	'	'	2,435	2,309	2,416
Assets	8,967	'	'	'	7,380	'	'	'	8,967	7,380	6,533
Capital expenditures	'	'	'	'	'	'	'	'	868	570	370
Medical Products	'	'	'	'	'	'	'	'	'	'	'
Segment Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	8,695	7,953	7,840
Depreciation and amortization	'	'	'	'	'	'	'	'	472	385	341
Pre-tax income (loss)	'	'	'	'	'	'	'	'	1,398	1,592	1,522
Assets	12,269	'	'	'	7,568	'	'	'	12,269	7,568	7,495
Capital expenditures	'	'	'	'	'	'	'	'	530	495	467
Other	'	'	'	'	'	'	'	'	'	'	'
Segment Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Depreciation and amortization	'	'	'	'	'	'	'	'	88	84	120
Pre-tax income (loss)	'	'	'	'	'	'	'	'	-1,284	-1,012	-1,129
Assets	4,633	'	'	'	5,442	'	'	'	4,633	5,442	5,045
Capital expenditures	'	'	'	'	'	'	'	'	$127	$96	$123

Pre_Tax_Income_Reconciliation_

Pre- Tax Income Reconciliation (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'
Consolidated income before income taxes	$2,549	$2,889	$2,809
Operating Segments	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'
Consolidated income before income taxes	3,833	3,901	3,938
Unallocated Amount To Segment Net Interest Expense	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'
Consolidated income before income taxes	-128	-87	-54
Unallocated Amount To Segment Certain Foreign Exchange Fluctuations and Hedging Activities	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'
Consolidated income before income taxes	83	53	-16
Unallocated Amount To Segment Stock Compensation	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'
Consolidated income before income taxes	-150	-130	-119
Unallocated Amount To Segment Business Optimization Charges	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'
Consolidated income before income taxes	-280	-150	-192
Unallocated Amount to Segment Average Wholesale Prices Litigation and Historical Price Reporting Charge	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'
Consolidated income before income taxes	'	'	-79
Unallocated Amount To Segment Asset Impairment And Other Charges	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'
Consolidated income before income taxes	'	'	-103
Unallocated Amount To Pension Settlement Charges	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'
Consolidated income before income taxes	'	-168	'
Unallocated Amount to Segment Certain Tax and Legal Reserves	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'
Consolidated income before income taxes	-104	'	'
Unallocated Amount to Segment Other Corporate Items	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'
Consolidated income before income taxes	($705)	($530)	($566)

Assets_Reconciliation_Detail

Assets Reconciliation (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Millions, unless otherwise specified
Segment Reporting, Asset Reconciling Item [Line Items]	'	'	'
Consolidated total assets	$25,869	$20,390	$19,073
Operating Segments	'	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'	'
Consolidated total assets	21,236	14,948	'
Unallocated Amount To Segment Cash And Cash Equivalents	'	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'	'
Consolidated total assets	2,733	3,270	'
Unallocated Amount To Segment Deferred Income Taxes	'	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'	'
Consolidated total assets	1,269	1,500	'
Unallocated Amount to Segment Property, Plant and Equipment	'	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'	'
Consolidated total assets	437	461	'
Unallocated Amount To Segment Other Corporate Assets	'	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'	'
Consolidated total assets	$194	$211	'

Geographic_Information_Detail

Geographic Information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Geographic Information	'	'	'	'	'	'	'	'	'	'	'
Consolidated net sales	$4,368	$3,774	$3,669	$3,448	$3,753	$3,477	$3,572	$3,388	$15,259	$14,190	$13,893
Consolidated total assets	25,869	'	'	'	20,390	'	'	'	25,869	20,390	19,073
Consolidated PP&E, net	7,832	'	'	'	6,098	'	'	'	7,832	6,098	5,525
US	'	'	'	'	'	'	'	'	'	'	'
Geographic Information	'	'	'	'	'	'	'	'	'	'	'
Consolidated net sales	'	'	'	'	'	'	'	'	6,451	6,056	5,709
Consolidated total assets	7,141	'	'	'	8,034	'	'	'	7,141	8,034	7,524
Consolidated PP&E, net	3,091	'	'	'	2,333	'	'	'	3,091	2,333	2,091
Europe	'	'	'	'	'	'	'	'	'	'	'
Geographic Information	'	'	'	'	'	'	'	'	'	'	'
Consolidated net sales	'	'	'	'	'	'	'	'	4,597	4,196	4,392
Consolidated total assets	14,541	'	'	'	8,597	'	'	'	14,541	8,597	8,096
Asia Pacific	'	'	'	'	'	'	'	'	'	'	'
Geographic Information	'	'	'	'	'	'	'	'	'	'	'
Consolidated net sales	'	'	'	'	'	'	'	'	2,378	2,229	2,107
Consolidated total assets	2,347	'	'	'	1,943	'	'	'	2,347	1,943	1,807
Latin America And Canada	'	'	'	'	'	'	'	'	'	'	'
Geographic Information	'	'	'	'	'	'	'	'	'	'	'
Consolidated net sales	'	'	'	'	'	'	'	'	1,833	1,709	1,685
Consolidated total assets	1,840	'	'	'	1,816	'	'	'	1,840	1,816	1,646
Austria	'	'	'	'	'	'	'	'	'	'	'
Geographic Information	'	'	'	'	'	'	'	'	'	'	'
Consolidated PP&E, net	914	'	'	'	802	'	'	'	914	802	786
Other Countries	'	'	'	'	'	'	'	'	'	'	'
Geographic Information	'	'	'	'	'	'	'	'	'	'	'
Consolidated PP&E, net	$3,827	'	'	'	$2,963	'	'	'	$3,827	$2,963	$2,648

Significant_Product_Sales_Deta

Significant Product Sales (Detail)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Hemophilia	'		'		'
Revenue from External Customer [Line Items]	'		'		'
Net sales as percentage of consolidated net sales for principal product categories	23.00%	[1]	23.00%	[1]	23.00%	[1]
Fluid Systems	'		'		'
Revenue from External Customer [Line Items]	'		'		'
Net sales as percentage of consolidated net sales for principal product categories	20.00%	[2]	21.00%	[2]	21.00%	[2]
Renal	'		'		'
Revenue from External Customer [Line Items]	'		'		'
Net sales as percentage of consolidated net sales for principal product categories	20.00%	[3]	18.00%	[3]	18.00%	[3]
Bio Therapeutics	'		'		'
Revenue from External Customer [Line Items]	'		'		'
Net sales as percentage of consolidated net sales for principal product categories	14.00%	[4]	15.00%	[4]	14.00%	[4]
Specialty Pharmaceuticals	'		'		'
Revenue from External Customer [Line Items]	'		'		'
Net sales as percentage of consolidated net sales for principal product categories	10.00%	[5]	10.00%	[5]	10.00%	[5]
[1]	Includes sales of recombinant FVIII products (ADVATE and RECOMBINATE) and plasma-derived hemophilia products (primarily FVII, FVIII and FEIBA).
[2]	Principally includes IV therapies, infusion pumps, administration sets, and premixed drug platforms.
[3]	Consists of PD and HD therapies.
[4]	Includes sales of the company's liquid formulation of the antibody-replacement therapy immunoglobulin product (GAMMAGARD LIQUID) and other plasma-based therapies such as albumin and alpha-1 antitrypsin products.
[5]	Principally includes nutrition and anesthesia products.

Quarterly_Financial_Results_an2

Quarterly Financial Results and Market for Company's Stock (Detail) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

In Millions, except Per Share data, unless otherwise specified

Nov. 30, 2013

31-May-13

Jul. 31, 2012

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Quarterly Financial Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net sales

'

'

'

$4,368

$3,774

$3,669

$3,448

$3,753

$3,477

$3,572

$3,388

$15,259

$14,190

$13,893

Gross margin

'

'

'

1,954

[1]

1,946

[1]

1,939

[1]

1,756

[1]

1,905

[2]

1,810

[2]

1,872

[2]

1,714

[2]

7,595

[1]

7,301

[2]

7,046

Net income attributable to Baxter

'

'

'

$326

[1]

$544

[1]

$590

[1]

$552

[1]

$494

[2]

$583

[2]

$661

[2]

$588

[2]

$2,012

[1]

$2,326

[2]

$2,224

Earnings per common share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Basic

'

'

'

$0.60

[1]

$1

[1]

$1.09

[1]

$1.01

[1]

$0.90

[2]

$1.07

[2]

$1.20

[2]

$1.05

[2]

$3.70

[1]

$4.22

[2]

$3.91

Diluted

'

'

'

$0.59

[1]

$0.99

[1]

$1.07

[1]

$1

[1]

$0.89

[2]

$1.06

[2]

$1.19

[2]

$1.04

[2]

$3.66

[1]

$4.18

[2]

$3.88

Cash dividends declared per common share

$0.49

$0.49

$0.45

$0.49

$0.49

$0.49

$0.45

$0.45

$0.45

$0.34

$0.34

$1.92

$1.57

$1.26

Market price per common share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

High

'

'

'

$69.55

$74.43

$73.04

$72.64

$68.81

$61.15

$60.27

$60.26

$74.43

$68.81

'

Low

'

'

'

$63.89

$65.69

$68.10

$66.42

$60.09

$53.58

$49.03

$49.66

$63.89

$49.03

'

[1]

The first quarter of 2013 included currency-related charges of $28 million related to the Venezuelan currency devaluation in February 2013 and derivative instruments entered into to hedge anticipated foreign currency cash outflows for the planned acquisition of Gambro (Gambro-related derivatives), in addition to charges of $17 million associated with Gambro pre-acquisition costs. The second quarter of 2013 included losses of $55 million for Gambro-related derivatives, charges of $23 million related to Gambro pre-acquisition costs and a net benefit of $2 million related to business optimization activity. The third quarter of 2013 included Gambro acquisition and integration charges of $58 million, tax and legal reserves of $83 million, business development charges of $25 million related to upfront payments for collaboration agreements, and a net gain of $20 million principally associated with Gambro-related derivatives. The fourth quarter of 2013 included business development charges of $78 million related to upfront and milestone payments for collaboration agreements, business optimization charges of $282 million, Gambro acquisition and integration charges of $94 million and product-related charges of $17 million, principally related to remediation efforts for modifications to the SIGMA Spectrum Infusion Pump.

[2]

The first quarter of 2012 included a $53 million gain related to the reduction of a contingent payment liability for certain milestones associated with the 2011 acquisition of Prism and business development charges of $48 million which primarily related to an R&D charge associated with the company's collaboration with Momenta. The second quarter of 2012 included a $38 million gain related to the reduction of a contingent payment liability for certain milestones associated with the 2010 acquisition of ApaTech, business development charges of $30 million which related to an R&D charge associated with the company's collaboration with Chatham and a $23 million net benefit from reserve adjustments which primarily related to an adjustment to the COLLEAGUE infusion pump reserves. The third quarter of 2012 included an R&D charge of $50 million related to the company's agreement with Onconova. The fourth quarter of 2012 included charges of $170 million primarily related to the settlement of certain pension obligations and $150 million related to business optimization initiatives (of which $62 million was recorded in cost of sales).

Quarterly_Financial_Results_an3

Quarterly Financial Results and Market for Company's Stock (Parenthetical) (Detail) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Dec. 31, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Feb. 28, 2013

Feb. 28, 2013

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2012

Dec. 31, 2012

Mar. 31, 2012

Dec. 31, 2012

Jun. 30, 2012

Sep. 30, 2012

Dec. 31, 2012

Venezuelan Currency Devaluation

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Apatech Limited

Apatech Limited

Prism Pharmaceuticals

Prism Pharmaceuticals

Chatham Therapeutics

Onconova Therapeutics, Inc.

Cost of Sales

Quarterly Financial Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Charges related to foreign currency devaluation

'

'

'

'

'

'

'

'

'

'

$28

'

'

'

'

'

'

'

'

'

'

'

Business development related charges

78

25

'

'

'

48

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition, pre acquisition

'

'

23

'

'

'

'

'

'

17

'

'

'

'

'

'

'

'

'

'

'

'

Reserve adjustment primarily related to infusion pump reserve

'

'

'

'

23

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gambro derivative (gain) loss

'

'

'

'

'

'

'

'

'

'

'

'

-20

55

23

'

'

'

'

'

'

'

Settlement of certain pension obligations and other

'

'

'

170

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business optimization benefit

20

'

2

'

'

'

-20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition and integration charges

'

'

'

'

'

'

'

'

'

'

'

94

58

'

'

'

'

'

'

'

'

'

Tax and legal reserves

160

83

'

'

'

'

160

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business optimization charges

282

'

'

150

'

'

282

150

192

'

'

'

'

'

'

'

'

'

'

'

'

62

Product-related charges

17

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gains (loss) related to the reduction (increase) of contingent payment liabilities

'

'

'

'

'

'

-8

-91

'

'

'

'

'

'

'

38

38

53

53

'

'

'

R&D charge related to company Collaboration

'

'

'

'

'

'

$1,246

$1,156

$946

'

'

'

'

'

'

'

'

'

'

$30

$50

'

Quarterly_Financial_Results_an4

Quarterly Financial Results and Market for Company's Stock - Additional Information (Detail) (Subsequent Event)	Jan. 31, 2014
	Person
Subsequent Event	'
Quarterly Financial Results and Market For The Company's Stock	'
Number of holders of common stock	36,629

Valuation_and_Qualifying_Accou1

Valuation and Qualifying Accounts (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Allowance for Doubtful Accounts	'		'		'
Valuation and Qualifying Accounts Disclosure [Line Items]	'		'		'
Valuation Allowances and Reserves, Beginning Balance	$127		$128		$139
Valuation Allowances and Reserves, Charged to Cost and Expense	26		12		32
Valuation Allowances and Reserves, Charged (credited) to Other Accounts	27	[1]	-2	[1]	-6	[1]
Valuation Allowances and Reserves, Deductions	-11	[2]	-11	[2]	-37	[2]
Valuation Allowances and Reserves, Ending Balance	169		127		128
Inventory Valuation Reserve	'		'		'
Valuation and Qualifying Accounts Disclosure [Line Items]	'		'		'
Valuation Allowances and Reserves, Beginning Balance	284		302		359
Valuation Allowances and Reserves, Charged to Cost and Expense	217		199		144
Valuation Allowances and Reserves, Charged (credited) to Other Accounts	1	[1]	4	[1]	-10	[1]
Valuation Allowances and Reserves, Deductions	-241	[2]	-221	[2]	-191	[2]
Valuation Allowances and Reserves, Ending Balance	261		284		302
Deferred tax asset valuation allowance	'		'		'
Valuation and Qualifying Accounts Disclosure [Line Items]	'		'		'
Valuation Allowances and Reserves, Beginning Balance	104		116		118
Valuation Allowances and Reserves, Charged to Cost and Expense	13		10		11
Valuation Allowances and Reserves, Charged (credited) to Other Accounts	25	[1]	-4	[1]	-4	[1]
Valuation Allowances and Reserves, Deductions	-5	[2]	-18	[2]	-9	[2]
Valuation Allowances and Reserves, Ending Balance	$137		$104		$116
[1]	Valuation accounts of acquired or divested companies and foreign currency translation adjustments.
[2]	Deductions from reserves includes the write-off of previously reserved inventory that was used in research and development (R&D) and recorded in R&D expenses in the year reserved.